Home The Word Brain My Amedeo FAQ Privacy About   


C49 + CC Journal Club

For more information, please refer to our special emails from April 13 and May 19.


  Influenza

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 1128 articles:
HTML format



Single Articles


    May 2025
  1. GIANNINI F, Hogan AB, Cameron E, Le H, et al
    Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study.
    Vaccine. 2025;56:127155.
    PubMed     Abstract available


  2. MANDVIWALA AS, Munje AK, Huckriede ALW, Arankalle VA, et al
    Immunogenicity evaluation of respiratory syncytial virus prefusogenic-F based virus-like-particles consisting of G and M proteins in mice.
    Vaccine. 2025;56:127203.
    PubMed     Abstract available


  3. KISLAYA I, Caserta M, Faye SLB, Dia OK, et al
    Evaluating the effects of a multisectoral dialogue-based COVID-19 awareness-raising intervention in a limited-resource setting: A quasi-experimental study in Senegal.
    Vaccine. 2025;56:127168.
    PubMed     Abstract available


  4. TIAN X, Zhou Y, Deng P, Xu N, et al
    Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial.
    Vaccine. 2025;59:127268.
    PubMed     Abstract available


  5. MYBURGH L, van Loon K, Huijbers EJM, van Beijnum JR, et al
    Guided design for the development of an evolution-proof influenza vaccine.
    Vaccine. 2025;59:127281.
    PubMed     Abstract available


  6. LIAW K, Konrath KM, Trachtman AR, Tursi NJ, et al
    DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo.
    Vaccine. 2025;59:127231.
    PubMed     Abstract available


  7. SOBLE A, Malhame M, Malvolti S, Mantel C, et al
    Identification and sizing of the current use cases for seasonal influenza vaccines.
    Vaccine. 2025 May 15:127233. doi: 10.1016/j.vaccine.2025.127233.
    PubMed     Abstract available


  8. MOU J, LaSalle G, Pflugeisen C, Sherls-Jones J, et al
    Practice, beliefs and intent in influenza vaccination among Hispanic patients during the pandemic: An interventional study.
    Vaccine. 2025;58:127207.
    PubMed     Abstract available


  9. CARTER DM, Bloom CE, Kirchenbaum GA, Tsvetnitsky V, et al
    Corrigendum to "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine (2015) 33(1) 108-16].
    Vaccine. 2025;57:127174.
    PubMed    


  10. TILMANNE A, Pirson M, Leclercq P, Van Den Bulcke J, et al
    Evaluation of the costs of care for pediatric patients hospitalized for RSV: A retrospective cohort study in Belgium.
    Vaccine. 2025;55:127065.
    PubMed     Abstract available


  11. GAGNON D, Gubany C, Ouakki M, Malo B, et al
    Factors influencing acceptance of RSV immunization for newborns among pregnant individuals: A mixed-methods study.
    Vaccine. 2025;55:127062.
    PubMed     Abstract available


  12. HAO T, Ryan GE, Lydeamore MJ, Cromer D, et al
    Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19.
    Vaccine. 2025;55:126987.
    PubMed     Abstract available


  13. MASHAMBA M, Msibi T, Tshabalala G, Tsotetsi L, et al
    Factors influencing influenza vaccine uptake among adults in Johannesburg, South Africa: A qualitative study.
    Vaccine. 2025;57:127133.
    PubMed     Abstract available


  14. RAHA JR, Kim KH, Le CTT, Bhatnagar N, et al
    Intranasal vaccination with multi-neuraminidase and M2e virus-like particle vaccine results in greater mucosal immunity and protection against influenza than intramuscular injection.
    Vaccine. 2025;57:127206.
    PubMed     Abstract available


  15. PADRON-REGALADO E, Escudero Gonzalez NA, Del Carmen Selvera HN
    Morbidity of viral vaccine preventable diseases in the Mexican states bordering the U.S., 2014-2023.
    Vaccine. 2025;56:127192.
    PubMed     Abstract available


  16. ASHRAF U, Lee A, Gao Q, Gonzalez JC, et al
    Impact of age and prior COVID-19 on the response to influenza a components in the 2020-2021 Fluzone vaccine.
    Vaccine. 2025;56:127171.
    PubMed     Abstract available


  17. BOUADDI O, Khalis M, Abdellatifi M, Seedat F, et al
    Behavioural and social drivers of vaccination among child and adult migrants in Morocco: A qualitative interview study.
    Vaccine. 2025;56:127166.
    PubMed     Abstract available


  18. PITTER JG, Mihajlovic J, Nagy D, van der Schans J, et al
    Underreported influenza mortality in Central and Eastern Europe hinders the extension of seasonal influenza vaccination programs in older adults.
    Vaccine. 2025;56:127184.
    PubMed     Abstract available


  19. AKMATOVA R, Otorbaeva D, Ebama MS
    Impact of the COVID-19 pandemic on influenza knowledge, attitudes, and vaccination practices in at-risk groups in the Kyrgyz Republic: A comparative study.
    Vaccine. 2025;56:127159.
    PubMed     Abstract available


  20. SEFAT KMSR, Kulkarni R, Trinh J, Leekha A, et al
    Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats.
    Vaccine. 2025;56:127183.
    PubMed     Abstract available


  21. OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al
    Corrigendum to "Post-introduction evaluation (PIE) of the seasonal influenza vaccination program in Kyrgyzstan in 2023" Vaccine 55 (2025) 127052.
    Vaccine. 2025;56:127123.
    PubMed    


  22. KANESHITA S, Chambers CD, Johnson D, Kavanaugh A, et al
    Short-term side effects following COVID-19 vaccination in pregnancies complicated by autoimmune inflammatory rheumatic diseases: A prospective cohort study.
    Vaccine. 2025;56:127194.
    PubMed     Abstract available


    April 2025
  23. FUJI N, Gonzalez E, Salamone FN, Bajorski P, et al
    Comparison of Streptococcus pneumoniae nasopharyngeal colonization, serotype-specific and protein-specific antibody and cytokine levels in young children prior to, during and post COVID-19 pandemic.
    Vaccine. 2025;54:126954.
    PubMed     Abstract available


  24. MOTTA M, Callaghan T, Ross JC, Gargano L, et al
    Promoting RSV vaccine confidence through reversal narrative (RN) messaging.
    Vaccine. 2025;56:127178.
    PubMed     Abstract available


  25. PAUL MJ, Hudda MT, Pallett S, Groppelli E, et al
    Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination.
    Vaccine. 2025;56:127175.
    PubMed     Abstract available


  26. SHANKER A, Vlaev I
    The social influence of the corrections of vaccine misinformation on social media.
    Vaccine. 2025;56:127177.
    PubMed     Abstract available


  27. BAYSAC DJ, Guay M, Chen R, Dube E, et al
    Did inequalities in COVID-19 vaccination resolve over time? Insights from the Canadian Community Health Survey.
    Vaccine. 2025;56:127153.
    PubMed     Abstract available


  28. HANSEN BT, Kristoffersen AB, Stecher M
    Vaccination readiness among adults in Norway: A cross-sectional survey using the 7C model.
    Vaccine. 2025;56:127169.
    PubMed     Abstract available


  29. SINGLETON KL, Post DJ, Augustine AD, Ison MG, et al
    Collaborative influenza vaccine innovation centers (CIVICs) program.
    Vaccine. 2025;54:127118.
    PubMed     Abstract available


  30. ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al
    Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791.
    Vaccine. 2025;56:127127.
    PubMed    


  31. FATIMAH MNN, Thian BYZ, Wong CL, Ong HK, et al
    Chimeric virus-like particles of nodavirus displaying M2e of human and avian influenza A viruses as a potential dual-use vaccine: Inducing a broader immune response and protecting mice against viral infections.
    Vaccine. 2025;56:127165.
    PubMed     Abstract available


  32. BUSTAMANTE Q, Sparkes D, Findlater L, Munro K, et al
    Understanding occupational and attitudinal factors influencing UK healthcare worker decisions for COVID-19 and influenza vaccination: A cross-sectional survey within SIREN.
    Vaccine. 2025;56:127160.
    PubMed     Abstract available


  33. OHNO M, Sekiya T, Obeng-Kyeremeh R, Handabile C, et al
    Optimization of the preparation method of inactivated intact virus particle vaccine for COVID-19.
    Vaccine. 2025;56:127173.
    PubMed     Abstract available


  34. LANATA CF, Ochoa TJ, Bancalari EM, Baylor NW, et al
    Testing an experimental vaccine during a public health emergency: Lessons from a Peruvian case.
    Vaccine. 2025;56:127176.
    PubMed     Abstract available


  35. HONDA-OKUBO Y, Sakala IG, Li L, Bielefeldt-Ohmann H, et al
    Advax(R)-adjuvanted inactivated influenza vaccine provides accelerated protection of mice via early induction of an influenza-specific IgM response.
    Vaccine. 2025;56:127144.
    PubMed     Abstract available


  36. MCGRATH LJ, Khan FL, Lopez SMC, Brouillette MA, et al
    2023-2024 COVID-19 vaccine uptake among immunocompromised individuals in two US states.
    Vaccine. 2025;56:127120.
    PubMed     Abstract available


  37. ZHANG X, Shi H, Ross TM
    Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in a pre-immune elderly ferret model.
    Vaccine. 2025;56:127156.
    PubMed     Abstract available


  38. FINNEY J, Kuraoka M, Song S, Watanabe A, et al
    Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases.
    Vaccine. 2025;56:127157.
    PubMed     Abstract available


  39. OLESEN SW, Holmdahl I, Ortega-Sanchez IR, Biggerstaff M, et al
    Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season.
    Vaccine. 2025;53:127109.
    PubMed     Abstract available


  40. KADOI K, Toba J, Uehara A, Isoda N, et al
    Enhanced sulfate pseudo-affinity chromatography using monolith-like particle architecture for purifying SARS-CoV-2.
    Vaccine. 2025;53:126951.
    PubMed     Abstract available


  41. EYAL N, Wendler D
    Assessing the risks of current COVID-19 challenge trials systematically.
    Vaccine. 2025;53:126877.
    PubMed     Abstract available


  42. TAKEUCHI N, Chang B, Ishiwada N, Cho Y, et al
    Nationwide population-based surveillance of invasive pneumococcal disease in children in Japan (2014-2022): Impact of 13-valent pneumococcal conjugate vaccine and COVID-19 pandemic.
    Vaccine. 2025;54:127138.
    PubMed     Abstract available


  43. STONER MCD, Michaels J, Stocks JB, Mancuso N, et al
    Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination.
    Vaccine. 2025;54:127136.
    PubMed     Abstract available


  44. TONG F, Zhou T, Tang L, Wu X, et al
    Evaluating the impact of influenza vaccine on preventing stroke hospitalization and death in Chinese elderly hypertensive patients: A retrospective cohort study.
    Vaccine. 2025;54:127004.
    PubMed     Abstract available


  45. WEETS CM, Wilson R, Swadley H, Katz R, et al
    Strengthening health security through routine vaccination policy: A comprehensive analysis of childhood vaccination laws across 194 countries.
    Vaccine. 2025;54:127121.
    PubMed     Abstract available


  46. ENTRICAN G, Bredell H, Charlier J, Cunningham AF, et al
    Opportunities and challenges for the adoption of novel platform technologies to develop veterinary bacterial vaccines.
    Vaccine. 2025;54:127117.
    PubMed     Abstract available


  47. LEYNS C, McClenaghan E, Rodriguez P, Nguipdop-Djomo P, et al
    Hybrid, vaccine-induced and natural immunity against SARS-CoV-2 in traditional food markets in Bolivia (2020-2022): A cross-sectional analysis of a serological survey.
    Vaccine. 2025;54:127104.
    PubMed     Abstract available


  48. ZHANG L, Xia Y, Chu L, Sundaram ME, et al
    Differences in seasonal influenza vaccine hesitancy profiles between clinicians practicing traditional Chinese medicine and modern Western medicine: A national cross-sectional survey.
    Vaccine. 2025;53:127106.
    PubMed     Abstract available


  49. CHAN MXJ, Wouters OJ, Chan HY, Terblanche P, et al
    Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective.
    Vaccine. 2025 Apr 10:127107. doi: 10.1016/j.vaccine.2025.127107.
    PubMed     Abstract available


  50. BRUXVOORT KJ, Sy LS, Contreras R, Lewin B, et al
    Development and validation of a clinical prediction tool for non-receipt of updated COVID-19 vaccines.
    Vaccine. 2025;53:127074.
    PubMed     Abstract available


  51. ZASZTOWT-STERNICKA M, Jagielska A, Rzad M, Szymusik I, et al
    Immunogenicity of inactivated quadrivalent influenza vaccine in pregnant women, including the level of postvaccination antibodies in umbilical cord blood.
    Vaccine. 2025;53:127047.
    PubMed     Abstract available


  52. LLOYD PC, Acharya G, Zhao H, Shah N, et al
    Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older.
    Vaccine. 2025;53:127069.
    PubMed     Abstract available


  53. SASANKAN S, Gathers D, Bellerose A, Pankratz VS, et al
    Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on oncology patients in New Mexico with substantial representation of racial minorities and rural residents.
    Vaccine. 2025;53:127091.
    PubMed     Abstract available


  54. LA EM, Sweeney C, Davenport E, Bunniran S, et al
    Pharmacy and healthcare provider offices as convenient adult vaccination settings in the US: Patient experiences from a survey of recently-vaccinated adults.
    Vaccine. 2025;54:127057.
    PubMed     Abstract available


  55. PRALL S, Lopes A
    "Better to die trying": Vaccine perceptions and COVID-19 experiences in rural Namibian pastoralists.
    Vaccine. 2025;55:127061.
    PubMed     Abstract available


  56. SHEARN C, Postavaru GI, Hylton L, Morris H, et al
    COVID-19 vaccine decision-making and the role of institutions across the pandemic in UK Black African and Black Caribbean communities.
    Vaccine. 2025;53:127071.
    PubMed     Abstract available


  57. CHEN PL, Richardson RA, Rovito S, Yang G, et al
    Live-attenuated pandemic H1N1 influenza vaccines expressing computationally optimized broadly reactive antigens (COBRAs) are immunogenic and protective in mice and ferrets.
    Vaccine. 2025;53:127090.
    PubMed     Abstract available


  58. BERNARD C, Drouin J, Le Vu S, Botton J, et al
    COVID-19 vaccination rates among pregnant women in France: A nationwide cohort study.
    Vaccine. 2025;53:127070.
    PubMed     Abstract available


  59. FISHER KA, Goldthwait L, Desrochers O, Zemel M, et al
    Reasons for COVID-19 vaccination late in the pandemic: A qualitative study.
    Vaccine. 2025;53:127084.
    PubMed     Abstract available


  60. FLYNN PM, Stull C, Jain VM, Evans MD, et al
    A national cross-sectional study of dentists' vaccine hesitancy and intention to provide HPV vaccines following emergency COVID-19 vaccination authorization.
    Vaccine. 2025;53:127035.
    PubMed     Abstract available


  61. FELIX P, Melo AA, Costa JP, Colaco M, et al
    Exploring TLR agonists as adjuvants for COVID-19 oral vaccines.
    Vaccine. 2025;53:127078.
    PubMed     Abstract available


  62. MCCOSKER LK, Dyer B, Sudarmana T, Seale H, et al
    COVID-19 vaccination uptake in people experiencing homelessness during the first three years of the global COVID-19 vaccination effort: A systematic review and meta-analysis.
    Vaccine. 2025;53:127050.
    PubMed     Abstract available


  63. PAYNE AB, Novosad S, Sung HM, Zhang Y, et al
    Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged >/=18 years with end stage kidney disease - United States, September 2023-April 2024.
    Vaccine. 2025;55:127010.
    PubMed     Abstract available


  64. OLIVIERI G, Amodio D, Manno EC, Santilli V, et al
    Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies.
    Vaccine. 2025;51:126853.
    PubMed     Abstract available


  65. PATRICK R, Mahale P, Ackerson BK, Hong V, et al
    Respiratory syncytial virus vaccine uptake among adults aged >/=60 years in a large, integrated healthcare system in Southern California 2023-2024.
    Vaccine. 2025;53:127033.
    PubMed     Abstract available


  66. FORAN AM, Jetten J, Muldoon OT
    Religious group membership and conspiracy beliefs influence vaccine uptake: Insights from 20 European countries.
    Vaccine. 2025;53:127086.
    PubMed     Abstract available


  67. ALVES K, Kouassi A, Plested JS, Kalkeri R, et al
    Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study.
    Vaccine. 2025;55:127046.
    PubMed     Abstract available


  68. PEREZ MARC G, Coria LM, Ceballos A, Rodriguez JM, et al
    Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial.
    Vaccine. 2025;54:127045.
    PubMed     Abstract available


  69. OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al
    Post-introduction evaluation (PIE) of the seasonal influenza vaccination program in Kyrgyzstan in 2023.
    Vaccine. 2025;55:127052.
    PubMed     Abstract available


    March 2025
  70. KARAN S, Opdensteinen P, Ma Y, De Oliveira JFA, et al
    A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic virus-like particles.
    Vaccine. 2025;53:127063.
    PubMed     Abstract available


  71. JIANG J, Lam KF, Lau EHY, Yin G, et al
    Estimation of trajectory of COVID-19 vaccines effectiveness against infection.
    Vaccine. 2025;55:127067.
    PubMed     Abstract available


  72. NEWBERN EC, Shoaibi A, Haynes K, Blacketer C, et al
    A rapid cycle analytics framework for vaccine safety surveillance within a real-world data network: Experience with enhanced surveillance of the Janssen COVID-19 vaccine.
    Vaccine. 2025;55:127044.
    PubMed     Abstract available


  73. CENAT JM, Moshirian Farahi SMM, Dalexis RD, Xu Y, et al
    Vaccine hesitancy among racially diverse parents in Canada: The important role of health literacy, conspiracy beliefs and racial discrimination.
    Vaccine. 2025;55:127049.
    PubMed     Abstract available


  74. TIRUNEH YM, Choi J, Cuccaro PM, Martinez J, et al
    Sociodemographic and health-related predictors of COVID-19 booster uptake among fully vaccinated adults.
    Vaccine. 2025;54:127048.
    PubMed     Abstract available


  75. FRIVOLD C, Giersing B, Amorij JP, Mvundura M, et al
    Identification of potential vaccines for use with microarray patches in low- and middle-income countries: An assessment from the Vaccine Innovation Prioritisation Strategy Alliance.
    Vaccine. 2025;55:126996.
    PubMed     Abstract available


  76. BLACKWELL CK, Bekelman T, Bakre S, Jacobson LP, et al
    Sociodemographic differences in parental hesitancy to the COVID-19 vaccine.
    Vaccine. 2025;55:127041.
    PubMed     Abstract available


  77. HARALAMBIEVA IH, Ratishvili T, Goergen KM, Grill DE, et al
    Effect of lymphocyte miRNA expression on influenza vaccine-induced immunity.
    Vaccine. 2025;55:127023.
    PubMed     Abstract available


  78. FRANCIS MJ
    A rapid human vaccine process development map outlining lessons learnt from ChAdOx1 nCoV-19 vaccine during the COVID-19 pandemic.
    Vaccine. 2025;55:127040.
    PubMed     Abstract available


  79. GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
    Adverse events among early caregivers' COVID-19 vaccination correlated inversely with intention to vaccinate their children.
    Vaccine. 2025;55:127001.
    PubMed     Abstract available


  80. VACHON A, Keeshan A, Galipeau Y, Crawley AM, et al
    Alcohol consumption does not influence SARS-CoV-2 vaccine immunogenicity: A stop the spread Ottawa cohort analysis.
    Vaccine. 2025;55:127034.
    PubMed     Abstract available


  81. KAISER S, Kaiser S, Reis J, Marschalek R, et al
    Quantification of objective concentrations of DNA impurities in mRNA vaccines.
    Vaccine. 2025;55:127022.
    PubMed     Abstract available


  82. HAMID S, Simeone RM, Newhams MM, Halasa N, et al
    Concordance between parent-reported and documented COVID-19 vaccination status among hospitalized children and adolescents: Implications for vaccine effectiveness estimates, May 2021-October 2023.
    Vaccine. 2025;54:126891.
    PubMed     Abstract available


  83. SHINO MY, Ibarrondo FJ, Yang OO
    SARS-CoV-2 spike antibody levels in lung transplantation recipients versus the spectrum in non-immunocompromised persons.
    Vaccine. 2025;50:126851.
    PubMed     Abstract available


  84. THORS V, Vias RD, Bjornsdottir K, Palsdottir EB, et al
    Influenza vaccine effectiveness in Iceland 2014-2022: A test-negative design.
    Vaccine. 2025;55:126981.
    PubMed     Abstract available


  85. RASKIN N, Hiligsmann M, Luyten J, Tubeuf S, et al
    Socio-demographic differences in citizen' preferences for distributing a scarce, lifesaving resource: A case study using COVID-19 vaccine distribution in Belgium.
    Vaccine. 2025;55:126997.
    PubMed     Abstract available


  86. CHOI J, Feelemyer J, Choe K, Lynch K, et al
    Anti-vaccine attitudes and COVID-19 vaccine status at the end of the U.S. public health emergency.
    Vaccine. 2025;55:127003.
    PubMed     Abstract available


  87. HEGMANN TE, Walter EB, Smith MJ, Campbell J, et al
    A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone(R) or Flublok(R)) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age.
    Vaccine. 2025;54:126991.
    PubMed     Abstract available


  88. PATTHAMMAVONG C, Wodniak N, Phounphenghack K, Tengbriacheu C, et al
    Factors associated with influenza and COVID-19 vaccination among health workers in Lao PDR, 2023.
    Vaccine. 2025;54:127006.
    PubMed     Abstract available


  89. XU J, Davoudpour S, Phillips G 2nd
    Applying the health belief model (HBM) to understand COVID-19 vaccine uptake among youth and young adults: Findings from a 6-month follow-up study in the United States.
    Vaccine. 2025;54:127002.
    PubMed     Abstract available


  90. RICCI L, Fery C, Tubach F, Agrinier N, et al
    Health care institutions and their physicians are the greatest promoters of COVID-19 vaccine acceptance among health care workers.
    Vaccine. 2025;54:127005.
    PubMed     Abstract available


  91. MYBURGH L, Karsjens H, Blanas A, de Ligt A, et al
    Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine.
    Vaccine. 2025;54:126989.
    PubMed     Abstract available


  92. SKOCZYNSKA A, Golebiewska A, Wrobel-Pawelczyk I, Ronkiewicz P, et al
    The direct impact of mandatory PCV10 vaccination on invasive pneumococcal disease in Polish children.
    Vaccine. 2025;54:126999.
    PubMed     Abstract available


  93. VEDEL JO, Furtado O, Almeida LL, Nehal KR, et al
    Childhood vaccination coverages in rural Guinea-Bissau before and during the early COVID-19 pandemic, a cohort study.
    Vaccine. 2025;54:127011.
    PubMed     Abstract available


  94. BOLU O, Alo OD, Iwara E, Longley AT, et al
    Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021.
    Vaccine. 2025;52:126907.
    PubMed     Abstract available


  95. MEERAUS W, Postema A, Gray CM, Lee A, et al
    Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.
    Vaccine. 2025;53:126955.
    PubMed     Abstract available


  96. DI CHIARA C, Karimi-Shahrbabak E, Peresin J, Farrar DS, et al
    A review of Canadian online resources providing information on COVID-19 vaccination for caregivers of children aged 5-11 years.
    Vaccine. 2025;54:126990.
    PubMed     Abstract available


  97. KRAMMER F
    Next-generation seasonal influenza virus vaccines need a neuraminidase component.
    Vaccine. 2025;54:126994.
    PubMed    


  98. OTIENO NA, Kalani R, Ayugi J, Nyawanda BO, et al
    Seasonal influenza vaccination in Kenya: What determines healthcare Workers' willingness to accept and recommend vaccination?
    Vaccine. 2025;54:126963.
    PubMed     Abstract available


  99. DE SOUZA RA, Barreto FR, de Jesus Lima CCO, da Natividade MS, et al
    Efficacy of BCG vaccination on incidence, severity and clinical progression of COVID-19: A BCG-REVAC population analysis.
    Vaccine. 2025;54:126911.
    PubMed     Abstract available


  100. JI C, Senthinathan A, Apajee J, Dubey V, et al
    Impact of the COVID-19 pandemic on routine immunization coverage of children and teenagers in Ontario, Canada.
    Vaccine. 2025;49:126811.
    PubMed     Abstract available


  101. DESILVA MB, Vazquez-Benitez G, Seburg EM, Henderson MSG, et al
    Pregnant persons perceptions and uptake of prenatal RSV vaccine - Minnesota, 2023-2024.
    Vaccine. 2025;54:126958.
    PubMed     Abstract available


  102. DOWGIER G, Hobbs A, Greenwood D, Shawe-Taylor M, et al
    Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics.
    Vaccine. 2025;54:126960.
    PubMed     Abstract available


  103. LEE DW, Nasir A, Elbashir S, Jani H, et al
    mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice.
    Vaccine. 2025;54:126961.
    PubMed     Abstract available


  104. CARROLL M, Fox HB, Tran A, Chellappan G, et al
    SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.
    Vaccine. 2025;54:126988.
    PubMed     Abstract available


  105. MOORE M, Anderson L, Schiffer JT, Matrajt L, et al
    Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis.
    Vaccine. 2025;54:126966.
    PubMed     Abstract available


  106. RAJA AI, Connor RI, Ashare A, Weiner JA, et al
    Binding and neutralising antibodies to respiratory syncytial virus and influenza A virus in serum and bronchoalveolar lavage fluid of healthy adults in the United States: A cross-sectional study.
    Vaccine. 2025;53:126936.
    PubMed     Abstract available


  107. PEIXOTO DE MIRANDA EJF, Calado RT, Boulos FC, de Sousa Moreira JA, et al
    Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil.
    Vaccine. 2025;52:126680.
    PubMed     Abstract available


  108. CHU CF, Chang TH, Ho JJ
    Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates.
    Vaccine. 2025;52:126830.
    PubMed     Abstract available


  109. ZHAO T, Xu Q, Cai X, Wang M, et al
    Global spatio-temporal distribution of coronavirus disease 2019 vaccine hesitancy between 2020 and 2022: A meta-analysis.
    Vaccine. 2025;53:126933.
    PubMed     Abstract available


  110. COTTER LM, Hopkins-Sheets M, Yang S, Passmore SR, et al
    Increasing confidence for pediatric COVID-19 and influenza vaccines using messages affirming parental autonomy: A randomized online experiment.
    Vaccine. 2025;53:126947.
    PubMed     Abstract available


  111. TENGATTINI S, Bavaro T, Rinaldi F, Temporini C, et al
    Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices.
    Vaccine. 2025;53:126932.
    PubMed     Abstract available


  112. NIU Y, Yan Y, Hu Y, Yang X, et al
    A novel tetravalent influenza vaccine based on one chimpanzee adenoviral vector.
    Vaccine. 2025;53:126959.
    PubMed     Abstract available


  113. KEELING MJ, Hill EM, Petrou S, Tran PB, et al
    Cost-effectiveness of routine COVID-19 adult vaccination programmes in England.
    Vaccine. 2025;53:126948.
    PubMed     Abstract available


    February 2025
  114. RIGAMONTI V, Torri V, Morris SK, Ieva F, et al
    Real-world effectiveness of influenza vaccination in preventing influenza and influenza-like illness in children.
    Vaccine. 2025;53:126946.
    PubMed     Abstract available


  115. WANG B, Lassi Z, Andraweera P, Chen G, et al
    Pregnant women's choices for preventing respiratory syncytial virus (RSV).
    Vaccine. 2025;48:126790.
    PubMed     Abstract available


  116. ADU P, Popoola T, Iqbal N, Roemer A, et al
    A cross-country network analysis of disease infodemics: Looking through the lens of the COVID-19 pandemic.
    Vaccine. 2025;48:126733.
    PubMed     Abstract available


  117. SHEERAH HA, Al-Jedai AH, Al-Jerian NA, Al-Otaiby MA, et al
    COVID-19 and influenza hospitalizations and the role of COVID-19 vaccination in the post-pandemic period: A cross-sectional study from Saudi Arabia.
    Vaccine. 2025;52:126937.
    PubMed     Abstract available


  118. MATHUR I, Ruisch A, Conlin M, Oyatoye I, et al
    COVID-19 vaccination integration, innovations and key populations: Results from a global survey.
    Vaccine. 2025;52:126863.
    PubMed     Abstract available


  119. DIYA O, Gayed J, Lowry FS, Ma H, et al
    A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults >/=18 years old.
    Vaccine. 2025;52:126869.
    PubMed     Abstract available


  120. LEBLANG D, Smith MD, Wesselbaum D
    Global perspectives on COVID-19 vaccination: Impacts on well-being and inequality.
    Vaccine. 2025;52:126906.
    PubMed     Abstract available


  121. ANDERSEN KM, Allen KE, Nepal RM, Mateus JS, et al
    Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.
    Vaccine. 2025;52:126881.
    PubMed     Abstract available


  122. FARAH Z, Bazant ES, Basha I, Saleh N, et al
    Determinants of seasonal influenza vaccination uptake, intention and recommendations among Lebanese physicians.
    Vaccine. 2025;52:126890.
    PubMed     Abstract available


  123. YE Q, Xiao Z, Bai C, Yao H, et al
    Unveiling the multi-characteristic potential of hyper-productive suspension MDCK cells for advanced influenza A virus propagation.
    Vaccine. 2025;52:126900.
    PubMed     Abstract available


  124. DUDLEY MZ, Zapf AJ, Delamater P, Proveaux TM, et al
    Attitudes of California school personnel on potential COVID-19 vaccine mandates and state law SB277 to remove nonmedical vaccine exemptions.
    Vaccine. 2025;52:126888.
    PubMed     Abstract available


  125. MACKENZIE LJ, Bousie JA, Newman P, Cunningham J, et al
    What three years of COVID-19 vaccine administration reveals about the incidence of shoulder injury related to vaccine administration (SIRVA).
    Vaccine. 2025;51:126892.
    PubMed     Abstract available


  126. ATTI A, England A, Sung J, Foulkes S, et al
    Estimating neutralising antibody responses against emerging SARS-CoV-2 variants utilising convalescent sera before the roll-out of XBB-lineage vaccines.
    Vaccine. 2025;51:126898.
    PubMed     Abstract available


  127. MEYERS E, De Rop L, Deschepper E, Duysburgh E, et al
    SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and staff post-primary course vaccination in Belgium between February and December 2021.
    Vaccine. 2025;51:126865.
    PubMed     Abstract available


  128. BERGSTROM F, Gunther F, Britton T
    A counterfactual analysis quantifying the COVID-19 vaccination impact in Sweden.
    Vaccine. 2025;52:126870.
    PubMed     Abstract available


  129. ZHAO T, Liu X, Huang X, Wang L, et al
    Development and evaluation of mosaic VLPs vaccine for enhanced broad-Spectrum immunity against influenza B virus lineages in mice.
    Vaccine. 2025;51:126882.
    PubMed     Abstract available


  130. TAAFFE J, Goldin S, Lambach P, Sparrow E, et al
    Global production capacity of seasonal and pandemic influenza vaccines in 2023.
    Vaccine. 2025;51:126839.
    PubMed     Abstract available


  131. HALL C, Lanning J, Romano CJ, Bukowinski AT, et al
    COVID-19 vaccine initiation in pregnancy and risk for adverse neonatal outcomes among United States military service members, January-December 2021.
    Vaccine. 2025;51:126894.
    PubMed     Abstract available


  132. DARWAR R, Huang X, Abayeneh A, Alemayehu Beshah S, et al
    Costing approaches for vaccine-preventable disease surveillance: Lessons from Ethiopia and Nepal.
    Vaccine. 2025;50:126776.
    PubMed     Abstract available


  133. APPEL AM, Janbek J, Laursen TM, Gasse C, et al
    Dementia and influenza vaccination: Time trends and predictors of vaccine uptake among older adults.
    Vaccine. 2025;51:126864.
    PubMed     Abstract available


  134. KEMP M, Capriola A, Schauer S
    RSV immunization uptake among infants and pregnant persons - Wisconsin, October 1, 2023-March 31, 2024.
    Vaccine. 2025;47:126674.
    PubMed     Abstract available


  135. CHANG C, Patel H, Ferrari A, Scalzo T, et al
    sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models.
    Vaccine. 2025;51:126883.
    PubMed     Abstract available


  136. SMITH DS, Postma M, Fisman D, Mould-Quevedo J, et al
    Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs.
    Vaccine. 2025;51:126879.
    PubMed     Abstract available


  137. VAN DIEMEN PM, Lean FZX, Ramsay A, Mollett BC, et al
    Evaluation of a nanoparticle influenza vaccine in the pig model.
    Vaccine. 2025;49:126844.
    PubMed     Abstract available


  138. KIM SY, Song M, Kwon SL
    Impact of caregiver vaccination status on child influenza vaccination hesitancy: A time-to-vaccination analysis for 2023-2024 season in the Republic of Korea.
    Vaccine. 2025;49:126852.
    PubMed     Abstract available


  139. ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al
    A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older.
    Vaccine. 2025;51:126791.
    PubMed     Abstract available


  140. WILLIAMS JTB, Johnson D, Weinshenker D, O'Leary ST, et al
    Co-creation of pediatric influenza digital stories via rapid community translation.
    Vaccine. 2025;51:126866.
    PubMed     Abstract available


  141. COTUGNO N, Sanna M, Amodio D, Morrocchi E, et al
    Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in vulnerable groups - The CONVERS project, report from a pediatric tertiary hospital.
    Vaccine. 2025;49:126778.
    PubMed     Abstract available


  142. O'KENNEDY MM, Reedy SE, Abolnik C, Khan A, et al
    Protective efficacy of a bivalent equine influenza H3N8 virus-like particle vaccine in horses.
    Vaccine. 2025;50:126861.
    PubMed     Abstract available


  143. CAPAO A, Araujo MF, Tort LFL, Toledo TS, et al
    Impact in the humoral and cellular immune response to SARS-CoV-2 variants after primary vaccination with AZD1222/COVISHIELD protocol in healthy adults.
    Vaccine. 2025;50:126785.
    PubMed     Abstract available


  144. SHARMA A, Kerkhoff AD, Haambokoma M, Shamoya B, et al
    Intention to receive new vaccines post-COVID-19 pandemic among adults and health workers in Lusaka, Zambia.
    Vaccine. 2025;50:126846.
    PubMed     Abstract available


  145. FAUSTINI SE, Backhouse C, Duggal NA, Toellner KM, et al
    Time of day of vaccination does not influence antibody responses to pneumococcal and annual influenza vaccination in a cohort of healthy older adults.
    Vaccine. 2025;49:126770.
    PubMed     Abstract available


  146. FU Y, Xu Z, Wang Q, Zhang J, et al
    Effectiveness and coverage of COVID-19 vaccination among the infection-naive population: A community-based retrospective cohort study in China.
    Vaccine. 2025;50:126836.
    PubMed     Abstract available


  147. ABBAD A, Yueh J, Yellin T, Singh G, et al
    Co-administration of seasonal quadrivalent influenza and COVID-19 vaccines leads to enhanced immune responses to influenza virus and reduced immune responses to SARS-CoV-2 in naive mice.
    Vaccine. 2025;50:126825.
    PubMed     Abstract available


  148. SOENS M, Ananworanich J, Hicks B, Lucas KJ, et al
    A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults.
    Vaccine. 2025;50:126847.
    PubMed     Abstract available


  149. VAHORA MS, Leao O, da Silveira MF, Domingues MR, et al
    Impacts of vaccination, school attendance, and nutrition on SARS-CoV-2 antibody titer in a prospective birth cohort in Brazil.
    Vaccine. 2025;49:126838.
    PubMed     Abstract available


  150. MCCLYMONT E, Wong JMH, Forward L, Blitz S, et al
    Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.
    Vaccine. 2025;50:126818.
    PubMed     Abstract available


  151. KANG HS, Kim SY, De Gagne JC, Chae SM, et al
    Pregnant women's experiences of and attitudes toward COVID-19 vaccination: A qualitative descriptive study.
    Vaccine. 2025;50:126835.
    PubMed     Abstract available


  152. HONDA-OKUBO Y, Sajkov D, Wauchope B, Turner JV, et al
    Immunogenicity and safety study of a single dose of SpikoGen(R) vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.
    Vaccine. 2025;49:126744.
    PubMed     Abstract available


  153. DOUA J, Ndembi N, Auerbach J, Kaseya J, et al
    Advancing local manufacturing capacities for vaccines within Africa - Opportunities, priorities and challenges.
    Vaccine. 2025;50:126829.
    PubMed     Abstract available


  154. KAN AKC, Mak HWF, Chiang V, Yim JSH, et al
    Leveraging COVID-19 vaccine allergy evaluations with coincident drug allergy delabelling: Effectiveness and impact on quality of life.
    Vaccine. 2025;50:126849.
    PubMed     Abstract available


  155. POWELL A, Jones A, Van Hout MC, Montgomery C, et al
    Influenza vaccine uptake in socially deprived areas: A multilevel retrospective population-based cross-sectional study using electronic health records in Liverpool, United Kingdom.
    Vaccine. 2025;50:126837.
    PubMed     Abstract available


  156. GE Y, Handel A, Giabbanelli PJ, Lemacks J, et al
    Exploring bias due to below-limit-of-detection values in influenza vaccine antibody modeling: A case study and instructional guide for the CIVIC study.
    Vaccine. 2025;49:126802.
    PubMed     Abstract available


    January 2025
  157. MCGOLDRICK M, Truong TBQ, Campa C, Ali M, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part III: Reflections after the pandemic.
    Vaccine. 2025;49:126782.
    PubMed     Abstract available


  158. GSCHWEND MH, Marchese AM, Poelaert D, Warren B, et al
    Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review.
    Vaccine. 2025;49:126777.
    PubMed     Abstract available


  159. GRAILEY K, Crespo RF, Woldmann L, Chisambi M, et al
    Implementing behavioural science-informed letter interventions to increase COVID-19 vaccination uptake in London residents. A difference-in-difference study in London, United Kingdom.
    Vaccine. 2025;49:126781.
    PubMed     Abstract available


  160. YILMAZ IC, Ipekoglu EM, Golcuklu BS, Bildik T, et al
    A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen carrying virus-like particle COVID-19 vaccine.
    Vaccine. 2025;49:126787.
    PubMed     Abstract available


  161. HASHIMOTO M, Tsujii K, Nakajima-Yoshida H, Akiyama N, et al
    A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets.
    Vaccine. 2025;49:126780.
    PubMed     Abstract available


  162. MWENDA JM, Mandomando I, Worwui AK, Gacic-Dobo M, et al
    A decade of rotavirus vaccination in the World Health Organization African Region: An in-depth analysis of vaccine coverage from 2012 to 2023.
    Vaccine. 2025 Jan 30:126768. doi: 10.1016/j.vaccine.2025.126768.
    PubMed     Abstract available


  163. WIEGAND RE, Devine O, Wallace M, Ortega-Sanchez IR, et al
    Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023-2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach.
    Vaccine. 2025;49:126808.
    PubMed     Abstract available


  164. KHAN A, Zhu Y, Babcock HM, Busse LW, et al
    COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United States, 2019-2022.
    Vaccine. 2025 Jan 29:126806. doi: 10.1016/j.vaccine.2025.126806.
    PubMed     Abstract available


  165. ITO S, Tsuchida N, Kusunoki S, Kaneko Y, et al
    Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan.
    Vaccine. 2025;49:126754.
    PubMed     Abstract available


  166. LAO G, Feng J, Wu L, Su W, et al
    Development of a genetically modified full-length human respiratory syncytial virus preF protein vaccine.
    Vaccine. 2025;49:126799.
    PubMed     Abstract available


  167. ROPER LE, Link-Gelles R, Surie D, DeCuir J, et al
    A framework for monitoring RSV prevention product effectiveness in the United States.
    Vaccine. 2025;45:126633.
    PubMed     Abstract available


  168. GEBRECHERKOS Y, Hodgson D
    Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom.
    Vaccine. 2025;45:126647.
    PubMed     Abstract available


  169. MYEMBA DT, Smets L, Sunguya BF, Vandaele N, et al
    Challenges and strategies for sustainable and resilient immunization systems in sub-Saharan Africa: A comprehensive scoping review.
    Vaccine. 2025;45:126639.
    PubMed     Abstract available


  170. EURICH DT, Weaver O, McDermott C, Soprovich A, et al
    Describing COVID-19 immunizations for First Nations people on-reserve in Alberta using real-time integration of point of care and provincial data.
    Vaccine. 2025;45:126614.
    PubMed     Abstract available


  171. CONLIN K, Jenkin D, de Whalley P, Weckx LY, et al
    Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
    Vaccine. 2025;45:126582.
    PubMed     Abstract available


  172. OKA E, Ueda Y, Yagi A, Machida M, et al
    Challenges to promoting maternal respiratory syncytial virus vaccination in Japan.
    Vaccine. 2025;48:126767.
    PubMed     Abstract available


  173. PROSSER LA, Perroud J, Chung GS, Gebremariam A, et al
    The cost-effectiveness of vaccination against COVID-19 illness during the initial year of vaccination.
    Vaccine. 2025;48:126725.
    PubMed     Abstract available


  174. LIAO Z, Deng L, Luo J, Shi M, et al
    Association between adults' vaccine literacy and their intention to recommend older family members for influenza vaccine.
    Vaccine. 2025;48:126757.
    PubMed     Abstract available


  175. CLAESSENS T, Eagan RL, Hendrickx G, Van Damme P, et al
    Navigating vaccine confidence: A mixed methods study investigating healthcare providers' perspectives across four non-EU European regions.
    Vaccine. 2025;47:126694.
    PubMed     Abstract available


  176. RAINERI D, Mazzucca CB, Moia R, Bruna R, et al
    Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination.
    Vaccine. 2025;48:126723.
    PubMed     Abstract available


  177. TRANTER I, Judd D, Stickley M, Vasant B, et al
    Promoting aged care COVID-19 and influenza vaccination through education of Australian residential aged care staff: A mixed methods project evaluation.
    Vaccine. 2025;48:126742.
    PubMed     Abstract available


  178. SHAH RM, Parzen-Johnson S, Sun S, Patel SJ, et al
    Childhood opportunity index and vaccine uptake in pediatric COVID-19 hospitalizations.
    Vaccine. 2025;48:126734.
    PubMed     Abstract available


  179. DOS SANTOS CVB, Coelho LE, de Noronha TG, Goedert GT, et al
    The impact of vaccination on the length of stay of hospitalized COVID-19 patients in Brazil.
    Vaccine. 2025;48:126735.
    PubMed     Abstract available


  180. DE OLIVEIRA PMN, Hartmann K, Bhamare C, Lucchesi MBB, et al
    Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries.
    Vaccine. 2025;48:126727.
    PubMed     Abstract available


  181. ZHANG Y, Li X, Yang Y, Yin Y, et al
    Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant breakthrough infection.
    Vaccine. 2025;48:126722.
    PubMed     Abstract available


  182. COROMINAS J, Garriga C, Prenafeta A, Moros A, et al
    Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
    Vaccine. 2025;47:126685.
    PubMed     Abstract available


  183. MARCHESE AM, Beyhaghi H, Rousculp MD, Huang V, et al
    Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).
    Vaccine. 2025;44:126569.
    PubMed     Abstract available


  184. FILIMONOVIC J, Stosic M, Gazibara T, Dotlic J, et al
    The trend in national childhood immunization program coverage throughout Serbian communities in Kosovo and Metohija from 2003 to 2022: pre-COVID-19 period vs. COVID-19 pandemic.
    Vaccine. 2025;44:126576.
    PubMed     Abstract available


  185. HARTEVELD LM, van Leeuwen LM, Euser SM, Smit LJ, et al
    Respiratory syncytial virus (RSV) prevention: Perception and willingness of expectant parents in the Netherlands.
    Vaccine. 2025;44:126541.
    PubMed     Abstract available


  186. DE LIMA EDS, Antunes MOB, de Souza JS, Jones MH, et al
    Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study.
    Vaccine. 2025;44:126550.
    PubMed     Abstract available


  187. FREY SE, Brady R, Jackson L, Goepfert P, et al
    Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59(R).
    Vaccine. 2025;47:126702.
    PubMed     Abstract available


  188. HONDA-OKUBO Y, Vaghasiya U, Petrovsky N
    Immunogenicity in mice and non-human primates of an Advax-CpG55.2-adjuvanted recombinant hemagglutinin seasonal quadrivalent influenza vaccine.
    Vaccine. 2025;47:126707.
    PubMed     Abstract available


  189. SHIELDS T, King KD, Cripps S, Edwards SA, et al
    Perspectives on vaccination among unvaccinated members of a Canadian indigenous population.
    Vaccine. 2025;47:126665.
    PubMed     Abstract available


  190. CASPERSEN IH, Skodvin SN, Blix K, Robertson AH, et al
    Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster vaccination: A population-based cohort study.
    Vaccine. 2025;47:126664.
    PubMed     Abstract available


  191. LE N, McMann TJ, Wenzel C, Li Z, et al
    COVID-19 pediatric vaccine Hesitancy: Themes and interactions with verified twitter accounts.
    Vaccine. 2025;47:126688.
    PubMed     Abstract available


  192. EL SAHLY HM, Anderson EJ, Jackson LA, Neuzil KM, et al
    Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.
    Vaccine. 2025;47:126689.
    PubMed     Abstract available


  193. DUAN Y, Suo L, Li X, Bai C, et al
    Association between underlying conditions, multimorbidity, and COVID-19 vaccination status of adults aged >/=80 years old in Beijing, China.
    Vaccine. 2025;47:126677.
    PubMed     Abstract available


  194. ALVARADO-FACUNDO E, Herrup R, Wang W, Colombo RE, et al
    Comparison of neuraminidase inhibiting antibody responses elicited by egg- and cell-derived influenza vaccines.
    Vaccine. 2025;46:126669.
    PubMed     Abstract available


  195. ANSELEM O, Charlier C, Viaud M, Lelong N, et al
    Barriers to influenza vaccination during pregnancy in France: A national population-based study.
    Vaccine. 2025;47:126671.
    PubMed     Abstract available


  196. GIERSING B, Mo AX, Hwang A, Baqar S, et al
    Meeting summary: Global vaccine and immunization research forum, 2023.
    Vaccine. 2025;46:126686.
    PubMed     Abstract available


  197. HAEBERER M, Lopez-Ibanez de Aldecoa A, Seabroke S, Ramirez Agudelo JL, et al
    Economic burden of children hospitalized with respiratory syncytial virus infection in Spain, 2016-2019.
    Vaccine. 2025;43.
    PubMed     Abstract available


  198. DERMENCHYAN A, Choi KR, Bokhoor PR, Cho DJ, et al
    Receipt of respiratory vaccines among patients with heart failure in a multicenter health system registry.
    Vaccine. 2025;46:126682.
    PubMed     Abstract available


    December 2024
  199. PILAPITIYA D, Lee WS, Vu MN, Kelly A, et al
    Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles.
    Vaccine. 2024;46:126668.
    PubMed     Abstract available


  200. CHOI YJ, Jung J, Kang M, Choi MJ, et al
    Corrigendum to The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: propensity score-matched analysis with influenza vaccination.
    Vaccine. 2024;46:126676.
    PubMed    


  201. NAZARENO AL, Wood JG, Muscatello DJ, Homaira N, et al
    Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: A dynamic and economic modelling analysis.
    Vaccine. 2024;46:126651.
    PubMed     Abstract available


  202. MALTEZOU HC, Poland GA, de Lejarazu RO
    Influenza vaccination for children in Europe: The health of every child matters.
    Vaccine. 2024 Dec 27:126675. doi: 10.1016/j.vaccine.2024.126675.
    PubMed    


  203. ZHANG J, Zhang L, Li J, Ma J, et al
    Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season.
    Vaccine. 2024;46:126662.
    PubMed     Abstract available


  204. MA Y, Dong C, Kim JK, Zhu W, et al
    Impact of influenza immune imprinting on immune responses to subsequent vaccinations in mice.
    Vaccine. 2024;46:126670.
    PubMed     Abstract available


  205. HAEBERER M, Lopez-Ibanez de Aldecoa A, Seabroke S, Ramirez Agudelo JL, et al
    Hospitalization cost estimates of respiratory syncytial virus and influenza infections in adults in Spain, 2016-2019.
    Vaccine. 2024;46:126683.
    PubMed     Abstract available


  206. AI L, Gao Z, Lv H, Zhang J, et al
    Immunogenicity and safety of live attenuated influenza vaccine in children aged 3-17 years in China.
    Vaccine. 2024;46:126653.
    PubMed     Abstract available


  207. GRIMES DR
    Tortured confessions? Potentially erroneous statistical inferences may underpin misleading claims of harms in reanalyses of COVID-19 and HPV vaccines.
    Vaccine. 2024 Dec 25:126657. doi: 10.1016/j.vaccine.2024.126657.
    PubMed     Abstract available


  208. SAVULESCU C, Prats-Uribe A, Brolin K, Uuskula A, et al
    Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023).
    Vaccine. 2024;45:126615.
    PubMed     Abstract available


  209. SHELDENKAR A, Ling TP, Schulz PJ, Chen MI, et al
    Trust in government vaccine recommendations during the Covid-19 pandemic in Singapore: A longitudinal survey study.
    Vaccine. 2024;45:126643.
    PubMed     Abstract available


  210. CAMPANELLA S, Volpe T, Safar Y, Lunsky Y, et al
    "They need to speak a language everyone can understand": Accessibility of COVID-19 vaccine information for Canadian adults with intellectual and developmental disabilities.
    Vaccine. 2024;45:126618.
    PubMed     Abstract available


  211. WERTHNER Q, Faehrmann L, Och K, Bragazzi NL, et al
    Client satisfaction, safety, and insights from a three-season survey on influenza vaccinations delivered at community pharmacies in Germany.
    Vaccine. 2024;45:126650.
    PubMed     Abstract available


  212. FRAIHA ALS, da Silva Santos BSA, Aguilar NR, Gallinari GC, et al
    Immunization and challenge trials in a murine model using different inactivated recombinant vaccines against H1N1 swine influenza virus circulating in Brazil.
    Vaccine. 2024;45:126638.
    PubMed     Abstract available


  213. WANG J, Tonnies T, Brinks R
    Seasonal influenza vaccination coverage and the social determinants of influenza vaccination among people over 50 with diabetes in Europe: Analyzing population-based SHARE data for the 2019-2020 and 2021-2022 influenza seasons.
    Vaccine. 2024;45:126646.
    PubMed     Abstract available


  214. YANG J, Yao YL, Lv XY, Geng LH, et al
    The Safety and Efficacy of inactivated COVID-19 vaccination in couples undergoing assisted reproductive technology: A prospective cohort study.
    Vaccine. 2024;45:126635.
    PubMed     Abstract available


  215. SUN JW, Dodge LE, Kim EJ, Zhou L, et al
    Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States.
    Vaccine. 2024;45:126629.
    PubMed     Abstract available


  216. PERRIER Q, Noble J, Bonadona A, Augier C, et al
    Timing of rejection events preceded by Covid-19 mRNA vaccination in recipients of solid organ transplants.
    Vaccine. 2024;45:126617.
    PubMed     Abstract available


  217. MOGHTADERI A, Callaghan T, Luo Q, Motta M, et al
    Evidence on trends in uptake of childhood vaccines and association with COVID-19 vaccination rates.
    Vaccine. 2024;45:126631.
    PubMed     Abstract available


  218. WILLIAMS JTB, Ritger C, Holliman BD, Huebschmann AG, et al
    Staff and caregivers' perceptions of digital storytelling to increase influenza vaccine confidence in an urban safety-net healthcare system.
    Vaccine. 2024;45:126572.
    PubMed     Abstract available


  219. KARACHALIOU M, Espinosa A, Farre X, Blay N, et al
    Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia.
    Vaccine. 2024;45:126591.
    PubMed     Abstract available


  220. SLAMANIG S, Lemus N, Lai TY, Singh G, et al
    A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge.
    Vaccine. 2024;45:126586.
    PubMed     Abstract available


  221. XIA M, Huang P, Vago FS, Jiang W, et al
    Pseudovirus nanoparticles targeting the receptor binding HA1 domains of influenza viruses elicited high HA1-specific antibody responses and protected mice against mortality caused by influenza virus challenges.
    Vaccine. 2024 Dec 7:126585. doi: 10.1016/j.vaccine.2024.126585.
    PubMed     Abstract available


  222. BODY A, Lal L, Srihari S, MacIntyre CR, et al
    Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer.
    Vaccine. 2024 Dec 7:126547. doi: 10.1016/j.vaccine.2024.126547.
    PubMed     Abstract available


  223. CUNNINGHAM-ERVES J, Sanderson M, Jin SW, Davis J, et al
    Predictors of HPV vaccination coverage among adolescents in Tennessee during the COVID-19 pandemic: A cross-sectional study.
    Vaccine. 2024 Dec 7:126581. doi: 10.1016/j.vaccine.2024.126581.
    PubMed     Abstract available


  224. KAPLAN BS, Souza CK, Kimble JB, Brand MW, et al
    A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine.
    Vaccine. 2024 Dec 6:126574. doi: 10.1016/j.vaccine.2024.126574.
    PubMed     Abstract available


  225. SANKAR C, Meyer JC, Schonfeldt M, Gunter H, et al
    Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening.
    Vaccine. 2024 Dec 6:126535. doi: 10.1016/j.vaccine.2024.126535.
    PubMed     Abstract available


  226. HODGSON D, Sanchez-Ovando S, Carolan L, Liu Y, et al
    Quantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity.
    Vaccine. 2024 Dec 4:126579. doi: 10.1016/j.vaccine.2024.126579.
    PubMed     Abstract available


  227. VYSE A, Wright H, Begier E
    Estimating adult accident and emergency attendances in English hospitals attributed to respiratory syncytial virus.
    Vaccine. 2024;42:126412.
    PubMed     Abstract available


  228. AVERIN A, Sato R, Begier E, Gessner BD, et al
    Annual public health and economic burden of medically attended respiratory syncytial virus illnesses among US adults.
    Vaccine. 2024;42:126323.
    PubMed     Abstract available


  229. FOTAKIS EA, Picasso E, Sacco C, Petrone D, et al
    Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023-March 2024).
    Vaccine. 2024;42:126375.
    PubMed     Abstract available


  230. PRY JM, McCullough K, Lai KW, Lim E, et al
    Defining long COVID using a population-based SARS-CoV-2 survey in California.
    Vaccine. 2024;42:126358.
    PubMed     Abstract available


  231. CHUN J, Yoon D, Nowakowska A, Lee HD, et al
    Delivery of SARS-CoV-2 spike and membrane genes in a single Baculoviral vector enhance the immune breadth against SARS-CoV-2 variants of concern.
    Vaccine. 2024;42:126355.
    PubMed     Abstract available


  232. CANETTI M, Barda N, Lustig Y, Weiss-Ottolenghi Y, et al
    Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers.
    Vaccine. 2024;42:126308.
    PubMed     Abstract available


    November 2024
  233. GONG S, Beukema M, De Vries-Idema J, Huckriede A, et al
    Assessing human B cell responses to influenza virus vaccines and adjuvants in a PBMC-derived in vitro culture system.
    Vaccine. 2024;44:126563.
    PubMed     Abstract available


  234. PICHE-RENAUD PP, Drover SSM, Austin PC, Morris SK, et al
    COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: A Canadian immunization research network (CIRN) study.
    Vaccine. 2024 Nov 30:126539. doi: 10.1016/j.vaccine.2024.126539.
    PubMed     Abstract available


  235. COSMA C, Radi A, Cattano R, Zanobini P, et al
    Exploring Chatbot contributions to enhancing vaccine literacy and uptake: A scoping review of the literature.
    Vaccine. 2024;44:126559.
    PubMed     Abstract available


  236. FLORES D, Luna EM
    The effectiveness of vaccines against COVID-19 in Mexico: A time series approach.
    Vaccine. 2024;44:126565.
    PubMed     Abstract available


  237. THIEM VD, Anh DD, Ha VH, Van Thom N, et al
    Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.
    Vaccine. 2024;44:126542.
    PubMed     Abstract available


  238. WANG Q, Yang L, Li L, Xiu S, et al
    Investigating parental perceptions of respiratory syncytial virus (RSV) and attitudes to RSV vaccine in Jiangsu, China: Insights from a cross-section study.
    Vaccine. 2024;44:126570.
    PubMed     Abstract available


  239. GEMANDER N, Kemlin D, Depickere S, Kelkar NS, et al
    COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients.
    Vaccine. 2024;44:126544.
    PubMed     Abstract available


  240. BLUKACZ A, Obach A, Vasquez P, Campana C, et al
    Determinants of COVID-19 and non-COVID-19 vaccine confidence in low- and middle-income countries: A systematic review of qualitative evidence and thematic synthesis.
    Vaccine. 2024;44:126546.
    PubMed     Abstract available


  241. AMODIO D, Angelidou A, Cotugno N, Sherman AC, et al
    Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference.
    Vaccine. 2024;43.
    PubMed     Abstract available


  242. CHOI YJ, Jung J, Kang M, Choi MJ, et al
    The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination.
    Vaccine. 2024;44:126506.
    PubMed     Abstract available


  243. DEAN NE, Halloran ME, Zarnitsyna VI
    Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease.
    Vaccine. 2024;43.
    PubMed     Abstract available


  244. LEE M, Qin C, Lee Y, Deng J, et al
    COVID-19 vaccine acceptance and 5C psychological antecedents amid the omicron surge in South Korea and China.
    Vaccine. 2024;43.
    PubMed     Abstract available


  245. DE OLIVEIRA LA, de Morais IRB, Marchioro SB, de Almeida GB, et al
    Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents.
    Vaccine. 2024;43.
    PubMed     Abstract available


  246. MEELDIJK A, Vandeberg L, Akkermans R, Hautvast J, et al
    How text message reminders increase COVID-19 booster vaccine uptake: Two randomized controlled trials.
    Vaccine. 2024;43.
    PubMed     Abstract available


  247. MAO J, Kang HJ, Eom GD, Yoon KW, et al
    Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2.
    Vaccine. 2024;43.
    PubMed     Abstract available


  248. VASQUEZ WF, Trudeau JM
    Americans' willingness to give to global immunization programs: Political heterogeneity in preferences for program management and response to priming communications.
    Vaccine. 2024;42:126126.
    PubMed     Abstract available


  249. KIRK B, Bush C, Toyip A, Mues KE, et al
    Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged >/= 65 years in the United States.
    Vaccine. 2024;42:126113.
    PubMed     Abstract available


  250. BONNIN FA, Talarico LB, Ferolla FM, Acosta PL, et al
    Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants.
    Vaccine. 2024;42:126119.
    PubMed     Abstract available


  251. LOCKMAN A, Callaghan T, Blackburn CC, Colwell B, et al
    Vaccine spillover effects in Africa: A cross-national study of vaccine spillover and confidence in Kenya, Nigeria, and South Africa.
    Vaccine. 2024;43.
    PubMed     Abstract available


  252. JASTORFF A, Gymnopoulou E, Salas J, Merrall E, et al
    Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.
    Vaccine. 2024;43.
    PubMed     Abstract available


  253. REGAN AK, Couture MC, Callaghan T, Agnew B, et al
    Modification and validation of a vaccine hesitancy scale for adolescent COVID-19 vaccination.
    Vaccine. 2024;43.
    PubMed     Abstract available


  254. LOPEZ-MACIAS C, Torres M, Armenta-Copca B, Wacher NH, et al
    Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico.
    Vaccine. 2024;43.
    PubMed     Abstract available


  255. GWAK E, Choe SA, Bolormaa E, Choe YJ, et al
    Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea.
    Vaccine. 2024;43.
    PubMed     Abstract available


  256. MATTES F, Dratva J, Schmelzer S, Wagner A, et al
    The association between service experience in vaccination centers and expectation confirmation as a driver of future vaccination intentions: Results from a survey among users of a Swiss mass COVID-19 vaccination center.
    Vaccine. 2024;43.
    PubMed     Abstract available


  257. AGUIRRE-CAMACHO A, Hidalgo B, Rash JA
    Exposure to objective/sensationalist information moderates associations between psychological factors and COVID-19 anti-vaccination attitudes: An experimental study.
    Vaccine. 2024;43.
    PubMed     Abstract available


  258. LEWIS NM, Harker EJ, Leis A, Zhu Y, et al
    Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023.
    Vaccine. 2024;43.
    PubMed     Abstract available


  259. WILLIAMS E, Echeverri Tribin F, Carreno JM, Krammer F, et al
    Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2.
    Vaccine. 2024;43.
    PubMed     Abstract available


  260. DENG Y, Hayes KN, Zhao Y, Chachlani P, et al
    Variation in the time to complete the primary COVID-19 vaccine series by race, ethnicity, and geography among older US adults.
    Vaccine. 2024;43.
    PubMed     Abstract available


  261. STEFFENS MS, Bolsewicz KT, King C, Bullivant B, et al
    Australian parents' experiences with adolescent age-based vaccinations during the COVID-19 pandemic.
    Vaccine. 2024;43.
    PubMed     Abstract available


  262. LE MARCHAND C, Singson JRC, Clark A, Shah D, et al
    Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California.
    Vaccine. 2024;43.
    PubMed     Abstract available


  263. DELARUELLE K, Lermytte E, Bockstal M, Vuolanto P, et al
    Unraveling COVID-19 vaccine hesitancy in Europeans 50 and older through a lens of preventive practices.
    Vaccine. 2024;43.
    PubMed     Abstract available


  264. KIM SA, Maeda M, Murata F, Fukuda H, et al
    Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: The VENUS study.
    Vaccine. 2024;43.
    PubMed     Abstract available


  265. CHARLAND K, Quach C, Papenburg J, Pierce L, et al
    Parental decisions regarding the vaccination of children and adolescents against SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and children in Montreal, Canada.
    Vaccine. 2024;43.
    PubMed     Abstract available


    October 2024
  266. KASAMATSU A, Yahata Y, Fukushima W, Sakamoto H, et al
    Estimating influenza vaccine effectiveness among older adults using an integrated administrative database and the implications of potential bias: A population-based cohort study in Japan.
    Vaccine. 2024;42:126488.
    PubMed     Abstract available


  267. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Akache B, et al
    SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice.
    Vaccine. 2024;42:126463.
    PubMed     Abstract available


  268. HOFSTETTER AM, Klein EJ, Strelitz B, Selvarangan R, et al
    On-time childhood vaccination before and during the COVID-19 pandemic in seven communities: Findings from the New Vaccine Surveillance Network.
    Vaccine. 2024;42:126455.
    PubMed     Abstract available


  269. MACINTYRE CR, Akhtar Z, Moa A
    Corrigendum to "Influenza B/Yamagata - extinct, eradicated or hiding? [Vaccine 42/26 (2024) 126450]".
    Vaccine. 2024 Oct 29:126486. doi: 10.1016/j.vaccine.2024.126486.
    PubMed    


  270. LEIS AM, Wagner A, Flannery B, Chung JR, et al
    Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses.
    Vaccine. 2024;42:126493.
    PubMed     Abstract available


  271. WHITE TM, Lazarus JV, Rabin KH, Ratzan SC, et al
    Emerging global patterns of COVID-19 vaccine information fatigue in 23 countries in 2023.
    Vaccine. 2024;42:126475.
    PubMed     Abstract available


  272. EBERHARDT J, Al-Qerem W, Ling J
    Comparing COVID-19 booster vaccine acceptance in the United Kingdom, Germany, Austria, and Jordan: The role of protection motivation theory, conspiracy beliefs, social media use and religiosity.
    Vaccine. 2024;42:126474.
    PubMed     Abstract available


  273. MCGREGOR R, Paterson A, Lavender B, Hooker C, et al
    The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.
    Vaccine. 2024;42:126482.
    PubMed     Abstract available


  274. LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al
    Exploring the delivery of adult vaccination outside of primary care settings: A mixed methods scoping review.
    Vaccine. 2024;42:126458.
    PubMed     Abstract available


  275. HO TC, Chuang SC, Hung KC, Chang CC, et al
    Exploring risk factors for Raynaud's phenomenon post COVID-19 vaccination.
    Vaccine. 2024;42:126470.
    PubMed     Abstract available


  276. LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al
    Exploring the attitudes and practices of adult service users and providers towards vaccination in non-primary care settings: A mixed methods scoping review.
    Vaccine. 2024;42:126472.
    PubMed     Abstract available


  277. MOHD HISHAM AA, Mat Yassim AS, Suppian R, Azlan M, et al
    Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia.
    Vaccine. 2024;42:126471.
    PubMed     Abstract available


  278. JORDAN E, Jenkins V, Silbernagl G, Chavez MPV, et al
    A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.
    Vaccine. 2024;42:126427.
    PubMed     Abstract available


  279. TUFFY KM, Ahani B, Domachowske JB, Furuno K, et al
    Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).
    Vaccine. 2024;42:126276.
    PubMed     Abstract available


  280. ROWE M, Collier AY, Barouch DH
    Insights from an observational translational research program during the COVID-19 pandemic: Four years of experience.
    Vaccine. 2024;42:126306.
    PubMed     Abstract available


  281. PHAM-HUY A, Bowes J, Russell K, Amira A, et al
    Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center.
    Vaccine. 2024;42:126090.
    PubMed     Abstract available


  282. SINTAYEHU K, Shaum A, Bonger ZT, Dagnachew Zeleke E, et al
    Applicability of selected Brighton Collaboration case definitions in low-resource settings: A prospective hospital-based active surveillance in Addis Ababa, Ethiopia.
    Vaccine. 2024;42:126079.
    PubMed     Abstract available


  283. GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al
    The 2020 immunization programme landscape: Piloting an assessment metric to evaluate the maturity of national immunization programmes across the life course.
    Vaccine. 2024;42 Suppl 4:125541.
    PubMed     Abstract available


  284. NG AJJ, Teo DCH, Dorajoo SR, Yap AJY, et al
    Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore.
    Vaccine. 2024;42:126462.
    PubMed     Abstract available


  285. DARKO DM, Seaneke SK, Karikari-Boateng E, Nkansah E, et al
    Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study.
    Vaccine. 2024;42:126460.
    PubMed     Abstract available


  286. AB RAHMAN N, King TL, Peariasamy KM, Sivasampu S, et al
    Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study.
    Vaccine. 2024;42:126465.
    PubMed     Abstract available


  287. SHARFF KA, Tandy TK, Lewis PF, Johnson ES, et al
    Incidence of ischemic stroke after COVID-19 bivalent booster vaccination in an integrated health system.
    Vaccine. 2024;42:126440.
    PubMed     Abstract available


  288. WICKLINE MM, Carpenter PA, Harris JR, Iribarren SJ, et al
    Vaccine hesitancy and routine revaccination among adult HCT survivors in the United States: A convergent mixed methods analysis.
    Vaccine. 2024;42:126374.
    PubMed     Abstract available


  289. HARRACHE A, Saker K, Mokdad B, Generenaz L, et al
    Anti-RBD IgG dynamics following infection or vaccination.
    Vaccine. 2024;42:126464.
    PubMed     Abstract available


  290. MACINTYRE CR, Akhtar Z, Moa A
    Influenza B/Yamagata cannot currently be declared extinct.
    Vaccine. 2024 Oct 18:126450. doi: 10.1016/j.vaccine.2024.126450.
    PubMed    


  291. MA SH, Chen TL, Ou WF, Chao WC, et al
    The risk of postherpetic neuralgia in COVID-19 vaccination-associated herpes zoster: A retrospective cohort study using TriNetX.
    Vaccine. 2024;42:126451.
    PubMed     Abstract available


  292. EVIATAR T, Ziv A, Oved A, Miller-Barmak A, et al
    Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study.
    Vaccine. 2024;42:126426.
    PubMed     Abstract available


  293. NAZARENO AL, Newall AT, Muscatello DJ, Hogan AB, et al
    Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia.
    Vaccine. 2024;42:126418.
    PubMed     Abstract available


  294. SANO K, Kurosawa T, Horikawa K, Kimura Y, et al
    Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5 monovalent vaccination in Japan.
    Vaccine. 2024;42:126452.
    PubMed     Abstract available


  295. NUZHATH T, Colwell B, Callaghan T, Hotez P, et al
    Pediatric COVID-19 vaccine hesitancy among pregnant and post-partum women: A mixed-method study.
    Vaccine. 2024;42:126420.
    PubMed     Abstract available


  296. EIDEN AL, Drakeley S, Modi K, Mackie D, et al
    Attitudes and beliefs of healthcare providers toward vaccination in the United States: A cross-sectional online survey.
    Vaccine. 2024;42:126437.
    PubMed     Abstract available


  297. COCKERILL R, Horney JA, Penta SC, Silver A, et al
    Factors associated with COVID-19 vaccination or intent to be vaccinated across three U.S. states.
    Vaccine. 2024;42:126457.
    PubMed     Abstract available


  298. TOP KA, Shulha HP, Muller MP, Valiquette L, et al
    Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study.
    Vaccine. 2024;42:126445.
    PubMed     Abstract available


  299. HSIEH HC, Chen CC, Liu WC, Wu SC, et al
    Intranasal booster with SARS-CoV-2 RBD protein fused to E. coli enterotoxin a subunit after primary mRNA vaccination in mice.
    Vaccine. 2024;42:126448.
    PubMed     Abstract available


  300. SEDAGHAT M, Karami B, Najafi F, Shadmani FK, et al
    Gender differences in adverse effects following the second dose of AstraZeneca COVID-19 vaccine: a cross-sectional study among healthcare workers.
    Vaccine. 2024;42:126424.
    PubMed     Abstract available


  301. LITAO L, Feng C, Hongyu Z, Wenbin C, et al
    Field production efficiency investigation of broilers immunized with a turkey herpesvirus vector vaccine expressing hemagglutinin from H9N2 subtype avian influenza virus.
    Vaccine. 2024;42:126436.
    PubMed     Abstract available


  302. DOYON-PLOURDE P, Farley R, Krishnan R, Tunis M, et al
    Direct quantitative comparison of benefits and risks of COVID-19 vaccines used in National Immunization Technical Advisory Groups Guidance during the first two years of the pandemic.
    Vaccine. 2024;42:126406.
    PubMed     Abstract available


  303. TAAFFE J, Ostrowsky JT, Mott J, Goldin S, et al
    Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact.
    Vaccine. 2024;42:126408.
    PubMed     Abstract available


  304. MWAMBA G, Gibson EM, Toko C, Tunda C, et al
    Effective integration of COVID-19 vaccination with routine immunization: A case study from Kinshasa, DRC.
    Vaccine. 2024 Oct 4:126392. doi: 10.1016/j.vaccine.2024.126392.
    PubMed     Abstract available


  305. PASCOE KM, Bishop S, Ci X, Ramirez M, et al
    Factors that shape COVID-19 pediatric vaccine decision-making in rural agricultural communities: A qualitative study.
    Vaccine. 2024;42:126389.
    PubMed     Abstract available


  306. HOJO-SOUZA NS, de Castro JT, Rivelli GG, Azevedo PO, et al
    SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern.
    Vaccine. 2024;42:126394.
    PubMed     Abstract available


  307. ALANSARI KDH, Buhl C, Thabit AK, Badr AF, et al
    Validation of the Arabic translation of the vaccination attitudes examination (VAX) scale.
    Vaccine. 2024;42:126411.
    PubMed     Abstract available


  308. EARP M, Meng L, Black CL, Carter RJ, et al
    Using regression tree analysis to examine demographic and geographic characteristics of COVID-19 vaccination trends over time, United States, May 2021-April 2022, National Immunization Survey Adult COVID Module.
    Vaccine. 2024;42:126372.
    PubMed     Abstract available


  309. REN J, Gao Q, Zhou X, Chen L, et al
    Identification of gene and protein signatures associated with long-term effects of COVID-19 on the immune system after patient recovery by analyzing single-cell multi-omics data using a machine learning approach.
    Vaccine. 2024;42:126253.
    PubMed     Abstract available


  310. RAMIREZ MA, Loaiza RA, Martinez-Balboa Y, Bruneau N, et al
    Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity.
    Vaccine. 2024;42:126203.
    PubMed     Abstract available


  311. GALLANT AJ, Steenbeek A, Halperin SA, Parsons Leigh J, et al
    Operationalizing the Behaviour Change Wheel and APEASE criteria to co-develop recommendations with stakeholders to address barriers to school-based immunization programs.
    Vaccine. 2024;42:126226.
    PubMed     Abstract available


  312. MENG Q, Wang B, Du Q, Zhang X, et al
    Seroprevalence of B. pertussis infection and the changes of specific antibody levels in health care workers during the first two years of COVID-19 in Wuhu, China.
    Vaccine. 2024;42:126239.
    PubMed     Abstract available


  313. GUINAZU G, Dvorkin J, Mahmud S, Baral R, et al
    Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina.
    Vaccine. 2024;42:126234.
    PubMed     Abstract available


  314. LANGER S, Holzapfel S, August L, Badura A, et al
    Parental knowledge and attitudes to infant immunization in the context of RSV: All about confidence?
    Vaccine. 2024;42:126050.
    PubMed     Abstract available


  315. CHOI YJ, Song JY, Wie SH, Choi WS, et al
    Real-world effectiveness of influenza vaccine over a decade during the 2011-2021 seasons-Implications of vaccine mismatch.
    Vaccine. 2024;42:126381.
    PubMed     Abstract available


  316. PATRICK-SMITH M, Emary K, Hodgson SH, Thomas TM, et al
    Roles and responsibilities of participants, researchers, and the media in the communication of vaccine trials: Experience from the United Kingdom's first COVID-19 vaccine trial.
    Vaccine. 2024;42:126391.
    PubMed     Abstract available


    September 2024
  317. LYU X, Liu X, Hong H
    Validation of the Chinese version of the vaccine conspiracy beliefs scale during COVID-19 pandemic and its correlates.
    Vaccine. 2024;42:126395.
    PubMed     Abstract available


  318. SOTOODEH A, Hedberg P, Granath F, Alfven T, et al
    Sociodemographic determinants of COVID-19 vaccination in adolescents in Stockholm, Sweden.
    Vaccine. 2024;42:126388.
    PubMed     Abstract available


  319. ENGLAND A, Sung J, Deulofeu M, Soler LF, et al
    Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2 vaccine (Bimervax(R)) by HIPRA.
    Vaccine. 2024;42:126386.
    PubMed     Abstract available


  320. LAZARUS R, Harris R, Thirard R, Baos S, et al
    Comparison of assays used to detect antibody response in COVID-19 vaccine trials: Results from of a UK multi-Centre randomised controlled trial to determine the immunogenicity responses of COVID-19 vaccines administered concomitantly with seasonal inf
    Vaccine. 2024;42:126369.
    PubMed     Abstract available


  321. AL-DAHIR S, Hassan TAL, Moss W, Khalil A, et al
    The impact of coronavirus pandemic shutdowns on immunization completion in Hadeetha, Anbar, Iraq: A case-study of vaccine completion in a recovering healthcare system.
    Vaccine. 2024 Sep 21:126383. doi: 10.1016/j.vaccine.2024.126383.
    PubMed     Abstract available


  322. BERNADIN O, Cochin M, Driouich JS, Laprie C, et al
    Preclinical evaluation in hamster model of the mRNA COVID-19 vaccine candidate AfriVac 2121 (Wuhan) produced under the WHO/MPP mRNA Technology Transfer Programme.
    Vaccine. 2024;42:126378.
    PubMed     Abstract available


  323. LAEMMLE-RUFF I, Fryk JJ, Shenton P, Clothier HJ, et al
    Detailed review of mortality reported following COVID-19 vaccination in Victoria, Australia: 2021-2023.
    Vaccine. 2024;42:126368.
    PubMed     Abstract available


  324. GOLDIN S, Brooks D, Jorgensen P, Wijesinghe P, et al
    Seasonal influenza vaccination: A global review of national policies in 194 WHO member states in 2022.
    Vaccine. 2024;42:126274.
    PubMed     Abstract available


  325. IMRAN M, Mills C, McDermott KW, Dean A, et al
    Relative effectiveness of adjuvanted versus non-adjuvanted influenza vaccines in older adults with risk factors for influenza complications during the 2019-2020 U.S. influenza season.
    Vaccine. 2024;42:126316.
    PubMed     Abstract available


  326. WEE LE, Malek MIBA, Tan J, Chiew C, et al
    Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission.
    Vaccine. 2024;42:126356.
    PubMed     Abstract available


  327. ROELS S, Bruckner M, Sadoff J, Cardenas V, et al
    Pre- and post-Ad26.COV2.S booster dose antibody levels predict COVID-19 disease risk.
    Vaccine. 2024;42:126159.
    PubMed     Abstract available


  328. ESTRELLA-PORTER P, Blanco-Calvo C, Lameiras-Azevedo AS, Juaneda J, et al
    Effectiveness of nirsevimab introduction against respiratory syncytial virus in the Valencian Community: A preliminary assessment.
    Vaccine. 2024;42:126030.
    PubMed     Abstract available


  329. REICHERZ F, Li S, Watts AA, Goldfarb DM, et al
    Bordetella pertussis infection following relaxation of COVID-19 non-pharmaceutical interventions in 2021-2023 in Vancouver metropolitan area, British Columbia, Canada.
    Vaccine. 2024;42:126004.
    PubMed     Abstract available


  330. SHEN AK, Gutu V, Druc A, Ebama M, et al
    An evaluation of the National Influenza Vaccination Program in the Republic of Moldova, 2023-2024.
    Vaccine. 2024;42:126322.
    PubMed     Abstract available


  331. MEANEY-DELMAN D, Carroll S, Polen K, Jatlaoui TC, et al
    Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic.
    Vaccine. 2024;42 Suppl 3.
    PubMed     Abstract available


  332. JONES-JACK N, El Kalach R, Yassanye D, Link-Gelles R, et al
    Advancing public health informatics during the COVID-19 pandemic: Lessons learned from a public-private partnership with pharmacies.
    Vaccine. 2024;42 Suppl 3:125667.
    PubMed     Abstract available


  333. HEINS MJ, Spreeuwenberg P, Caini S, Hooiveld M, et al
    Measuring the impact of influenza vaccination in the Netherlands using retrospective observational primary care, hospitalisation and mortality data.
    Vaccine. 2024;42:126244.
    PubMed     Abstract available


  334. KRAUSE KD, D'Avanzo PA, Karr AG, Rhem C, et al
    Vaccination uptake in LGBTQ adults in two US states: Findings from the QVax study.
    Vaccine. 2024;42:126320.
    PubMed     Abstract available


  335. SHIU EYC, Cheng SMS, Martin-Sanchez M, Au NYM, et al
    Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine.
    Vaccine. 2024;42:126317.
    PubMed     Abstract available


  336. VAN HEESBEEN R, Bastian AR, Omoruyi E, Rosen J, et al
    Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study.
    Vaccine. 2024;42:126273.
    PubMed     Abstract available


  337. BAFFOUR AWUAH G, Tanaka LF, Eberl M, Donnachie E, et al
    Analysis of health claims data on vaccination coverage in older adults in Bavaria, Germany: Influenza, pneumococcus and herpes zoster.
    Vaccine. 2024;42:126354.
    PubMed     Abstract available


  338. CHANG JY, Chang M, Huang S, Bosco J, et al
    COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City.
    Vaccine. 2024;42:126260.
    PubMed     Abstract available


  339. GAUDOUEN H, Tattevin P, Thibault V, Menard G, et al
    Determinants of influenza and COVID vaccine uptake in healthcare workers: A cross-sectional survey during the post-pandemic era in a network of academic hospitals in France.
    Vaccine. 2024;42:126272.
    PubMed     Abstract available


  340. REGAN AK, Sullivan SG, Arah OA
    Maternal influenza vaccination and associated risk of fetal loss: A claims-based prospective cohort study.
    Vaccine. 2024;42:126256.
    PubMed     Abstract available


  341. BLASCO A, Royuela A, Garcia-Gomez S, Gomez-Lozano N, et al
    Association of SARS-CoV-2 immunoserology and vaccination status with myocardial infarction severity and outcome.
    Vaccine. 2024;42:126305.
    PubMed     Abstract available


  342. WOO EJ, Miller ER, Stroud E
    Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024).
    Vaccine. 2024;42:126290.
    PubMed     Abstract available


  343. HOXIE I, Vasilev K, Clark JJ, Bushfield K, et al
    A recombinant N2 neuraminidase-based CpG 1018(R) adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters.
    Vaccine. 2024;42:126269.
    PubMed     Abstract available


  344. GROOM HC, Biel FM, Crane B, Sun E, et al
    Disparities in COVID-19 vaccination receipt by race, ethnicity, and social determinants of health among a large patient population in a network of community-based healthcare centers.
    Vaccine. 2024;42:126288.
    PubMed     Abstract available


  345. HUTTON DW, Prosser LA, Rose AM, Mercon K, et al
    Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus.
    Vaccine. 2024;42:126294.
    PubMed     Abstract available


  346. POH XY, Torres-Ruesta A, Yoong T, Wong N, et al
    Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
    Vaccine. 2024;42:126275.
    PubMed     Abstract available


  347. KIM C, Dunphy C, Duggar C, Pike J, et al
    Jurisdiction-level costs of the initial phase of the COVID-19 vaccination program in the United States, December 20, 2020-May 31, 2021.
    Vaccine. 2024;42:126287.
    PubMed     Abstract available


  348. BONNER C, Taba M, Fajardo MA, Batcup C, et al
    Using health literacy principles to improve understanding of evolving evidence in health emergencies: Optimisation and evaluation of a COVID-19 vaccination risk-benefit calculator.
    Vaccine. 2024;42:126296.
    PubMed     Abstract available


  349. LIU S, van Dijk LLA, den Hartog Y, Hoek R, et al
    mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.
    Vaccine. 2024;42:126250.
    PubMed     Abstract available


  350. BOTTON J, Bertrand M, Jabagi MJ, Duranteau L, et al
    Risk of heavy menstrual bleeding following COVID-19 vaccination: A nationwide case-control study.
    Vaccine. 2024;42:126252.
    PubMed     Abstract available


  351. COLEMAN BL, Gutmanis I, Bondy SJ, Harrison R, et al
    Canadian health care providers' and education workers' hesitance to receive original and bivalent COVID-19 vaccines.
    Vaccine. 2024;42:126271.
    PubMed     Abstract available


    August 2024
  352. MACKAY H, Gretton JD, Chyderiotis S, Elliott S, et al
    Confidence and barriers: Analysis of factors associated with timely routine childhood vaccination in Canada during the COVID-19 pandemic.
    Vaccine. 2024;42:126236.
    PubMed     Abstract available


  353. GUARNIERI V, Macucci C, Mollo A, Trapani S, et al
    Impact of respiratory syncytial virus on older children: Exploring the potential for preventive strategies beyond the age of 2 years.
    Vaccine. 2024;42:126170.
    PubMed     Abstract available


  354. AIZAWA Y, Sato I, Abe Y, Sasagawa F, et al
    Impact of the emergence of severe acute respiratory syndrome coronavirus 2 omicron variants on routine childhood immunization in Japan.
    Vaccine. 2024;42:126137.
    PubMed     Abstract available


  355. MAI W, Shen J, Ma F, Zhu J, et al
    Specific humoral immune response and XBB variants re-infection risk of hemodialysis patients after Omicron BA.5 infection in China.
    Vaccine. 2024;42:126108.
    PubMed     Abstract available


  356. EYAWO O, Ugoji UC, Pan S, Oyibo P, et al
    Predictors of the willingness to accept a free COVID-19 vaccine among households in Nigeria.
    Vaccine. 2024;42:126225.
    PubMed     Abstract available


  357. BRESEE JS, Lafond KE
    The partnership for international vaccine initiatives: The importance and opportunity to develop influenza vaccination programs in low- and middle-income countries.
    Vaccine. 2024 Aug 29:126255. doi: 10.1016/j.vaccine.2024.126255.
    PubMed    


  358. HARADA Y, Takahashi H, Fujimoto T, Horikoshi F, et al
    Evaluation of a qualified MDCK cell line for virus isolation to develop cell-based influenza vaccine viruses with appropriate antigenicity.
    Vaccine. 2024;42:126242.
    PubMed     Abstract available


  359. LLABRE MM, Timpano KR, Broos HC, Leite RO, et al
    Lessons from a longitudinal community-based investigation of adherence to guidelines and intent to vaccinate during the COVID-19 pandemic.
    Vaccine. 2024;42:126265.
    PubMed     Abstract available


  360. PATHER S, Charpentier N, van den Ouweland F, Rizzi R, et al
    A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.
    Vaccine. 2024;42:126165.
    PubMed     Abstract available


  361. FERREIRA-SILVA SN, Soares MEM, Vasconcelos R, Barbieri C, et al
    COVID-19 vaccine hesitancy: Meaning relations between responses in an epidemiological study and twitter messages.
    Vaccine. 2024;42:126247.
    PubMed     Abstract available


  362. SINGH D, Damasevicius R, Kumar V, Bagnoli F, et al
    Editorial: ML-driven vaccine against COVID-19: Developmental challenges and foresight.
    Vaccine. 2024;42:126267.
    PubMed    


  363. VIELOT NA, Kelly NK, Ludema C, Rosenberg M, et al
    Patterns and predictors of COVID-19 vaccination among young adults at 44 US sites: Secondary analysis of a randomized, controlled, open-label trial, March - December 2021.
    Vaccine. 2024;42:126237.
    PubMed     Abstract available


  364. UNAGAMI K, Yoshikawa M, Egawa H, Ohfuji S, et al
    Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study.
    Vaccine. 2024;42:126221.
    PubMed     Abstract available


  365. SHINJOH M, Yaginuma M, Yamaguchi Y, Tamura K, et al
    Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures.
    Vaccine. 2024;42:126241.
    PubMed     Abstract available


  366. ADAMS L, Prasinou AK, Hadley L, Ramsay M, et al
    Estimating the potential number of cases prevented by infant/ toddler immunisation with a MenACWY vaccine.
    Vaccine. 2024;42:126240.
    PubMed     Abstract available


  367. OGAR CK, Gilbert HN, Bloem LT, Leopold C, et al
    Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study.
    Vaccine. 2024;42:126196.
    PubMed     Abstract available


  368. ESPOSITO GL, Fassio F, Girardi D, Picasso E, et al
    "REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE).
    Vaccine. 2024;42:126208.
    PubMed     Abstract available


  369. SANFTENBERG L, Bader F, Rottenkolber M, Sebastiao M, et al
    Associations of mental health with vaccination readiness in informal caregivers and the vaccination status of their care recipients during the Covid-19 pandemic - A cross sectional analysis.
    Vaccine. 2024;42:126218.
    PubMed     Abstract available


  370. HERNANDEZ-BERNAL F, Noa-Romero E, Quintana-Guerra J, Chavez-Chong CO, et al
    Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MENIQUE).
    Vaccine. 2024;42:126223.
    PubMed     Abstract available


  371. IHENETU G, Aylin P, Novov V, Skirrow H, et al
    Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19 in pregnancy: Retrospective cohort study.
    Vaccine. 2024 Aug 13:126214. doi: 10.1016/j.vaccine.2024.126214.
    PubMed     Abstract available


  372. WALDEN J, Stanek JR, Young J, Griffith MM, et al
    Influenza vaccine uptake among youth with sickle cell disease who are seen in clinic before and after the COVID-19 pandemic.
    Vaccine. 2024;42:126212.
    PubMed     Abstract available


  373. GRAF DD, Westphal L, Hallgreen CE
    The life cycle of vaccines evaluated by the European Medicines Agency.
    Vaccine. 2024;42:126186.
    PubMed     Abstract available


  374. GOMEZ-ACEBO I, Barquin-Ruiz A, Llorente S, Alonso-Molero J, et al
    The impact of the COVID-19 pandemic on childhood vaccination rates and the role of sociodemographic factors: A cohort study.
    Vaccine. 2024;42:126207.
    PubMed     Abstract available


  375. BAJPAI D, Bose S, Saxena N, Kulkarni B, et al
    Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients.
    Vaccine. 2024 Aug 8:126206. doi: 10.1016/j.vaccine.2024.126206.
    PubMed     Abstract available


  376. GAO Y, Yang X, Li X, Chen H, et al
    Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial.
    Vaccine. 2024;42:126182.
    PubMed     Abstract available


  377. D'SOUZA S, Ghatole B, Raghuram H, Sukhija S, et al
    Understanding structural inequities in Covid-19 vaccine access and uptake among disability, transgender and gender-diverse communities in India.
    Vaccine. 2024 Aug 7:126174. doi: 10.1016/j.vaccine.2024.126174.
    PubMed     Abstract available


  378. GEORGE G, Strauss M, Lansdell E, Nota P, et al
    Factors associated with COVID-19 vaccine uptake among south African health care workers.
    Vaccine. 2024;42:126181.
    PubMed     Abstract available


  379. BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al
    Identifying psychological predictors of SARS-CoV-2 vaccination: A machine learning study.
    Vaccine. 2024;42:126198.
    PubMed     Abstract available


  380. BOKEL J, Martins-Goncalves R, Grinsztejn E, Mendes-de-Almeida DP, et al
    Anti-PF4 positivity and platelet activation after Ad26.COV2.S vaccination in Brazil.
    Vaccine. 2024 Aug 5:126175. doi: 10.1016/j.vaccine.2024.126175.
    PubMed     Abstract available


  381. MCCARRON M, Marcenac P, Yau TS, Lafond KE, et al
    Healthcare personnel acceptance and recommendations for influenza vaccine in twelve low- and middle-income countries: A pooled analysis from 2018 to 2020.
    Vaccine. 2024 Aug 2:125670. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  382. AUGELLO M, Wagenhauser I, Krone M, Dauby N, et al
    Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment.
    Vaccine. 2024 Aug 2:126184. doi: 10.1016/j.vaccine.2024.126184.
    PubMed     Abstract available


  383. JIANG M, Zhang H, Yao X, Wang Y, et al
    Immunization-related stress and stress-related responses of mucosal versus intramuscular COVID-19 vaccination among adults in China.
    Vaccine. 2024 Aug 1:126150. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  384. WOOLFORK MN, Haire K, Farinu O, Ruffin J, et al
    A health equity science approach to assessing drivers of COVID-19 vaccination coverage disparities over the course of the COVID-19 pandemic, United States, December 2020-December 2022.
    Vaccine. 2024 Aug 1:126158. doi: 10.1016/j.vaccine.2024.126158.
    PubMed     Abstract available


    July 2024
  385. MATSUMOTO N, Sasaki A, Kadowaki T, Mitsuhashi T, et al
    Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan.
    Vaccine. 2024;42:126156.
    PubMed     Abstract available


  386. ASUPOTO O, Li X, Hemberg JL, Emerson A, et al
    COVID-19 and influenza vaccine uptake in women with criminal-legal system involvement.
    Vaccine. 2024 Jul 30:126176. doi: 10.1016/j.vaccine.2024.126176.
    PubMed     Abstract available


  387. GE Y, Lu Y, Allen JD, Einav T, et al
    Pre-existing immunity to influenza aids ferrets in developing stronger and broader H3 vaccine-induced antibody responses.
    Vaccine. 2024 Jul 29:126149. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  388. ELYASS J, Desalegn A, Trinh NTH, Orangzeb S, et al
    Individual and familial factors associated with mRNA COVID-19 vaccine uptake in pregnancy: A large-scale registry-based linkage study.
    Vaccine. 2024 Jul 29:126171. doi: 10.1016/j.vaccine.2024.126171.
    PubMed     Abstract available


  389. TAHSIN A, Bhattacharjee P, Al Saba A, Yasmin T, et al
    Genetic and epigenetic analyses of IFN-gamma gene proximal promoter region underlying positive correlation between persistently high anti-SARS-CoV-2 IgG and IFN-gamma among COVID-19 vaccinated Bangladeshi adults.
    Vaccine. 2024 Jul 29:126157. doi: 10.1016/j.vaccine.2024.126157.
    PubMed     Abstract available


  390. GEBRETEKLE GB, Yeung MW, Ximenes R, Cernat A, et al
    Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
    Vaccine. 2024 Jul 29:126164. doi: 10.1016/j.vaccine.2024.126164.
    PubMed     Abstract available


  391. MOTAGHI S, Pullenayegum E, Morgan RL, Loeb M, et al
    The role of influenza Hemagglutination-Inhibition antibody as a vaccine mediator in children.
    Vaccine. 2024 Jul 28:126122. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  392. SULEMAN A, Vicente P
    COVID-19 vaccination reluctance across Europe: Lessons for the future.
    Vaccine. 2024 Jul 27:126168. doi: 10.1016/j.vaccine.2024.126168.
    PubMed     Abstract available


  393. KHANAFER N, Oudot S, Maligeay M, Planckaert C, et al
    A quick access to information on influenza burden and prevention in Lyon university hospital: A prospective QR code-based information campaign in 2022-2023.
    Vaccine. 2024 Jul 26:126160. doi: 10.1016/j.vaccine.2024.126160.
    PubMed     Abstract available


  394. JENA D, Ghosh A, Jha A, Prasad P, et al
    Impact of vaccination on SARS-CoV-2 evolution and immune escape variants.
    Vaccine. 2024 Jul 26:126153. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  395. WILLIAMS LR, Emary KRW, Phillips DJ, Hay J, et al
    Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial.
    Vaccine. 2024 Jul 26:126167. doi: 10.1016/j.vaccine.2024.126167.
    PubMed     Abstract available


  396. BILGIN GM, Munira SL, Lokuge K, Glass K, et al
    Mathematical modelling of the 100-day target for vaccine availability after the detection of a novel pathogen: A case study in Indonesia.
    Vaccine. 2024 Jul 26:126163. doi: 10.1016/j.vaccine.2024.126163.
    PubMed     Abstract available


  397. ATAULLAHJAN A, Piche-Renaud PP, Shahrbabak EK, Fadaleh SA, et al
    Weighing the risks and benefits: Parental perspectives on COVID-19 vaccines for 5- to 11-year-old children.
    Vaccine. 2024 Jul 26:126154. doi: 10.1016/j.vaccine.2024.126154.
    PubMed     Abstract available


  398. JIMENEZ-SEPULVEDA N, Gras-Valenti P, Chico-Sanchez P, Castro-Garcia JM, et al
    Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.
    Vaccine. 2024;42:4011-4021.
    PubMed     Abstract available


  399. WAGENHAUSER I, Almanzar G, Forg FB, Stein A, et al
    Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.
    Vaccine. 2024 Jul 20:126132. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  400. ZOU GQ, Li K, Yan C, Li YQ, et al
    Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for enhanced COVID-19 subunit vaccine immunogenicity.
    Vaccine. 2024 Jul 20:126145. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  401. SANADA T, Honda T, Kohara M
    Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination.
    Vaccine. 2024 Jul 19:126146. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  402. ANDERSON S, Kuter BJ, Brien K, Bauerle Bass S, et al
    Perceptions of vaccine requirements among students at four Pennsylvania universities.
    Vaccine. 2024 Jul 17:S0264-410X(24)00801-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  403. JIN CHOI S, Lee W, Cheol Kim S, Jo HY, et al
    Longitudinal multiomic profiling and corticosteroid modulation of the immediate innate immune response to an adenovirus-vector vaccine.
    Vaccine. 2024 Jul 17:S0264-410X(24)00774-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  404. SANTIBANEZ TA, Black CL, Zhou T, Srivastav A, et al
    Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines.
    Vaccine. 2024 Jul 16:S0264-410X(24)00802-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  405. LIU G, Pang Y, Lv M, Lu M, et al
    Effectiveness of influenza vaccination on hospitalization outcomes among older patients with diabetes.
    Vaccine. 2024 Jul 16:S0264-410X(24)00806-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  406. ERIKSSON M, Nylen S, Gronvik KO
    Passive immunization of mice with IgY anti-H5N1 protects against experimental influenza virus infection and allows development of protective immunity.
    Vaccine. 2024 Jul 16:S0264-410X(24)00796-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  407. STEENACKERS K, Hanning N, Bruckers L, Desombere I, et al
    Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.
    Vaccine. 2024 Jul 16:S0264-410X(24)00773-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  408. LUNA-MUSCHI A, Carmo Borges I, Dos Santos Barboza A, de Faria E, et al
    Duration of vaccine protection against breakthrough infections during five COVID-19 waves among healthcare workers primarily vaccinated with CoronaVac.
    Vaccine. 2024 Jul 16:S0264-410X(24)00752-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  409. TAKAHASHI Y, Tanaka H, Taniguchi C, Ogata T, et al
    Efficiency of indirect protection of COVID-19 vaccination and interactions between indirect and direct protection on household transmission.
    Vaccine. 2024 Jul 16:S0264-410X(24)00749-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  410. HATFIELD K, Wiegand R, Reddy S, Patel A, et al
    Effectiveness of COVID-19 bivalent vaccination against SARS-CoV-2 infection among residents of US nursing homes, November 2022 - March 2023.
    Vaccine. 2024 Jul 16:S0264-410X(24)00754-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  411. STEFANIZZI P, Di Lorenzo A, Capodiferro L, Moscara L, et al
    Increasing vaccination coverage among healthcare workers: Active call and mandatory laws. Data from a large general hospital in Southern Italy.
    Vaccine. 2024 Jul 15:S0264-410X(24)00739-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  412. FISMAN DN, Simmons AE, Tuite AR
    Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval.
    Vaccine. 2024 Jul 13:S0264-410X(24)00797-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  413. JAJOU R, Lieber T, van Puijenbroek EP, Mulder E, et al
    GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands.
    Vaccine. 2024 Jul 13:S0264-410X(24)00793-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  414. LE BAGOUSSE-BERNARD A, Dussart C, Pin P, Tazarourte K, et al
    Mass COVID-19 vaccination center: Optimizing the vaccination pathway during a 12 month timeframe.
    Vaccine. 2024 Jul 12:S0264-410X(24)00742-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  415. HUANG WT, Law B, Tran H, Schonborn L, et al
    Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.
    Vaccine. 2024 Jul 12:S0264-410X(24)00794-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  416. LI J, Gong L, Li J, Gong Z, et al
    Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
    Vaccine. 2024;42:3751-3755.
    PubMed     Abstract available


  417. HOEVE CE, Huiberts AJ, de Gier B, Andeweg SP, et al
    COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study.
    Vaccine. 2024 Jul 11:S0264-410X(24)00783-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  418. GARCIA S, Shin M, Gill M, He Z, et al
    Identifying the intersection of parental HPV and COVID-19 vaccine hesitancy to inform health messaging interventions in community-based settings.
    Vaccine. 2024 Jul 11:S0264-410X(24)00792-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  419. SARTORI AL, Buffarini R, Machado da Silva A, Amaral de Andrade Leao O, et al
    Child COVID-19 vaccine uptake among participants of the 2015 Pelotas (Brazil) Birth Cohort Study.
    Vaccine. 2024 Jul 11:S0264-410X(24)00746-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  420. KOUASSI KS, Chisupa E, Clarke A, Massenon I, et al
    Pandemic-related resilience in HPV vaccination programmes - Perspectives from selected countries in Africa on what it will take to vaccinate 90 % of girls by 2030.
    Vaccine. 2024;42 Suppl 2:S33-S36.
    PubMed     Abstract available


  421. BANG JY, Kim YJ, Seo YJ, Hong SH, et al
    Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination.
    Vaccine. 2024 Jul 8:S0264-410X(24)00757-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  422. JITENDER, Vikram Kumar B, Singh S, Verma G, et al
    Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.
    Vaccine. 2024 Jul 8:S0264-410X(24)00740-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  423. KORCHINSKI I, Marquez C, McClymont E, Av-Gay G, et al
    Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: A prospective cohort study.
    Vaccine. 2024 Jul 8:S0264-410X(24)00785-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  424. WACHINGER J, Renosa MDC, Endoma V, Landicho-Guevarra J, et al
    Routines, disruptions, revised decisions: A biographical analysis of vaccination trajectories among Filipino caregivers.
    Vaccine. 2024 Jul 6:S0264-410X(24)00736-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  425. ARAUJO-CHAVERON L, Olivier C, Pellissier G, Bouvet E, et al
    Analyzing the 7C psychological antecedents of vaccine acceptance throughout the COVID-19 pandemic among healthcare sector workers in France: A repeated cross-sectional study (CappVac-Cov).
    Vaccine. 2024 Jul 6:S0264-410X(24)00744-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  426. NOWALK MP, Smith KJ, Raviotta JM, Wateska A, et al
    Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age.
    Vaccine. 2024 Jul 5:S0264-410X(24)00748-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  427. KAFADAR AH, Sabatini S, Jones KA, Dening T, et al
    Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy in the United Kingdom: A systematic review and meta-analysis.
    Vaccine. 2024 Jul 2:S0264-410X(24)00733-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  428. HOULE SKD, Waite NM, Vernon-Wilson E, Dolovich L, et al
    Uptake and outcomes of VaxCheck, an adult life-course vaccination service: A study among community pharmacists.
    Vaccine. 2024 Jul 1:S0264-410X(24)00737-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    June 2024
  429. PLEY C, Kampmann B
    Opportunities and challenges to the development and deployment of vaccines for pregnant women in Germany.
    Vaccine. 2024 Jun 28:S0264-410X(24)00735-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  430. ROOZEN GVT, Granger A, van Binnendijk RS, den Hartog G, et al
    Intradermal fractional dose vaccination as a method to vaccinate individuals with suspected allergy to mRNA COVID-19 vaccines.
    Vaccine. 2024 Jun 28:S0264-410X(24)00734-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  431. BHELLA S, Wilkin AM, Hueniken K, Vijenthira A, et al
    COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.
    Vaccine. 2024 Jun 28:S0264-410X(24)00715-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  432. KELLY JA, Walsh JL, Quinn K, Amirkhanian YA, et al
    Factors predicting primary and booster COVID-19 vaccination in a community sample of African American men and women in the United States Midwest.
    Vaccine. 2024 Jun 27:S0264-410X(24)00729-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  433. COULIBALY D, Douba A, N'Guessan K, N'Gattia AK, et al
    Intent to receive flu vaccine and influenza vaccination coverage among health professionals during 2019, 2020 and 2021 campaigns in Cote d'Ivoire.
    Vaccine. 2024 Jun 25:S0264-410X(24)00717-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  434. YOO YM, Katz MA, Greenberg D, Marcenac P, et al
    Knowledge, attitudes, and practices associated with influenza vaccine uptake among healthcare personnel in Israel during three influenza seasons, 2016-2019.
    Vaccine. 2024 Jun 25:S0264-410X(24)00705-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  435. CHATZILENA A, Hyams C, Challen R, Marlow R, et al
    Winter 2022-23 influenza vaccine effectiveness against influenza-related hospitalised aLRTD: A test-negative, case-control study.
    Vaccine. 2024 Jun 24:S0264-410X(24)00713-8. doi: 10.1016/j.vaccine.2024.
    PubMed    


  436. LE GARS M, Sadoff J, Cardenas V, Heerwegh D, et al
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
    Vaccine. 2024 Jun 24:S0264-410X(24)00401-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  437. HELARY A, Botelho-Nevers E, Bonneton M, Khennouf L, et al
    Factors, motivations and barriers associated with eagerness to volunteer in COVID-19 vaccine clinical trials in France: A mixed-method study.
    Vaccine. 2024 Jun 22:S0264-410X(24)00662-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  438. FITZPATRICK T, Yamoah P, Lacuesta G, Sadarangani M, et al
    Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study.
    Vaccine. 2024 Jun 22:S0264-410X(24)00719-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  439. RIMAL RN, Ganjoo R, Jamison A, Parida M, et al
    Social norms, vaccine confidence, and interpersonal communication as predictors of vaccination intentions: Findings from slum areas in Varanasi, India.
    Vaccine. 2024 Jun 21:S0264-410X(24)00666-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  440. MCDERMID P, Abdi I, Mustafa K, Blazek K, et al
    Examining the influence of community leaders and other community actors on immunisation practices in Australia: A national cross-sectional study.
    Vaccine. 2024;42:3647-3654.
    PubMed     Abstract available


  441. ZHANG X, Monnat SM
    Watchful, skeptics, and system distrusters: Characteristics associated with different types of COVID-19 vaccine hesitancy among U.S. working-age adults.
    Vaccine. 2024 Jun 19:S0264-410X(24)00721-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  442. CHENG TM, Chen YS, Wei KC, Chang YC, et al
    Assessment of the herpes zoster risk among renal transplant recipients administered the influenza vaccine.
    Vaccine. 2024 Jun 18:S0264-410X(24)00716-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  443. YAZDAN PANAH M, Vaheb S, Mokary Y, Afshari-Safavi A, et al
    Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders.
    Vaccine. 2024 Jun 16:S0264-410X(24)00702-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  444. DESLAURIERS F, Hoq M, Kaufman J, Enticott J, et al
    Comparison of parent-reported motivators of non-vaccination for children 5-11 years old in Australia and Canada: Results of the iCARE study.
    Vaccine. 2024 Jun 15:S0264-410X(24)00698-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  445. JIANG X, Wang J, Li C, Yeoh EK, et al
    Relationship between parental acceptance of the COVID-19 vaccine and attitudes towards measles vaccination for children: A cross-sectional study.
    Vaccine. 2024 Jun 15:S0264-410X(24)00708-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  446. TING DK, Rosychuk RJ, Hau JP, Righolt CH, et al
    Leveraging a clinical emergency department dataset to estimate two-dose COVID-19 vaccine effectiveness and duration of protection in Canada.
    Vaccine. 2024 Jun 14:S0264-410X(24)00699-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  447. DAVEY SA, Hampson C, Christodoulaki ME, Gaffiero D, et al
    Investigating the predictors of COVID-19 vaccine decision-making among parents of children aged 5-11 in the UK.
    Vaccine. 2024 Jun 13:S0264-410X(24)00646-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  448. QUIROGA R, Gastellu S, Fernandez B, Ottaviani R, et al
    The impact of COVID-19 childhood and adolescent vaccination on mortality in Argentina.
    Vaccine. 2024 Jun 12:S0264-410X(24)00665-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  449. CARDENAS V, Le Gars M, Truyers C, Ruiz-Guinazu J, et al
    Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
    Vaccine. 2024;42:3536-3546.
    PubMed     Abstract available


  450. SHERMAN AC, van Haren SD, Borberg E, Swank Z, et al
    Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series.
    Vaccine. 2024 Jun 10:S0264-410X(24)00695-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  451. MANANDHAR P, Katz J, Lama TP, Khatry SK, et al
    COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.
    Vaccine. 2024 Jun 10:S0264-410X(24)00661-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  452. OTSUKI T, Akada S, Anami A, Kosaka K, et al
    Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
    Vaccine. 2024 Jun 8:S0264-410X(24)00668-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  453. BADLIS S, Yu H, Klusaritz H, S L Tan A, et al
    Engaging Trusted Messengers to Increase COVID-19 Pediatric Vaccine Uptake in Philadelphia: Lessons from the VaxUpPhillyFamilies program.
    Vaccine. 2024 Jun 8:S0264-410X(24)00664-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  454. BRADY K, Lee A, Bassler J, Young Pierce J, et al
    Human papillomavirus vaccine beliefs and intentions Post-COVID-19 vaccine release among mothers in Alabama.
    Vaccine. 2024 Jun 8:S0264-410X(24)00673-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  455. SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al
    Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received.
    Vaccine. 2024 Jun 7:S0264-410X(24)00652-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  456. VILLENA R, Izquierdo G, Wilhelm J, Garcia C, et al
    Dynamics of multisystem inflammatory syndrome in children associated to COVID-19 in Chile: Epidemiologic trends during pandemic, before and after children vaccination.
    Vaccine. 2024 Jun 7:S0264-410X(24)00640-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  457. JAYAWARDANA S, Esquivel M, Oreskovic T, Mossialos E, et al
    Gender differences in COVID-19 preventative measures and vaccination rates in the United States: A longitudinal survey analysis.
    Vaccine. 2024 Jun 7:S0264-410X(24)00671-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  458. R MUGALI R, Ip H, Zikusooka A, Vong L, et al
    Striving for equitable vaccination coverage: Leveraging rapid coverage and community assessments during the COVID-19 pandemic to reach missed populations in Cambodia.
    Vaccine. 2024 Jun 7:S0264-410X(24)00642-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  459. YOUNES S, Nicolai E, Younes N, Pieri M, et al
    Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
    Vaccine. 2024 Jun 5:S0264-410X(24)00669-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  460. GOBIN S, Sahakyan G, Kusi Appiah M, Manukyan A, et al
    Costs of in- and outpatient respiratory disease and the seasonal influenza vaccination program in Armenia - 2020-2021.
    Vaccine. 2024 Jun 4:S0264-410X(24)00623-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  461. LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
    Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
    Vaccine. 2024 Jun 4:S0264-410X(24)00644-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  462. KAWASUJI H, Morinaga Y, Tani H, Yamada H, et al
    Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots.
    Vaccine. 2024 Jun 4:S0264-410X(24)00656-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  463. FENG J, Du Y, Chen L, Su W, et al
    A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models.
    Vaccine. 2024 Jun 3:S0264-410X(24)00624-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  464. FABIANI M, Mateo-Urdiales A, Sacco C, Fotakis EA, et al
    Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged >/=60 years: Estimates over calendar time and by time since administration during prevalent circulation of different O
    Vaccine. 2024 Jun 3:S0264-410X(24)00653-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  465. BEJKO D, Ernst C, Vergison A, Stranges S, et al
    High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis.
    Vaccine. 2024 Jun 1:S0264-410X(24)00636-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    May 2024
  466. KUPEK E
    Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020-2023.
    Vaccine. 2024;42:3437-3444.
    PubMed     Abstract available


  467. EDOKA I, Silal S, Jamieson L, Meyer-Rath G, et al
    A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.
    Vaccine. 2024 May 31:S0264-410X(24)00595-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  468. VASHIST K, Yankey D, Elam-Evans LD, Mu Y, et al
    Changes in vaccine hesitancy among parents of children aged 6 months - 17 Years, National Immunization Surveys, 2019-2022.
    Vaccine. 2024 May 27:S0264-410X(24)00596-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  469. BEGUM T, Efstathiou N, Bailey C, Guo P, et al
    Cultural and social attitudes towards COVID-19 vaccination and factors associated with vaccine acceptance in adults across the globe: A systematic review.
    Vaccine. 2024 May 27:S0264-410X(24)00600-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  470. LUSTIG Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, et al
    Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
    Vaccine. 2024 May 27:S0264-410X(24)00635-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  471. TREHARNE A, Patel Murthy B, Zell ER, Jones-Jack N, et al
    Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions.
    Vaccine. 2024 May 25:S0264-410X(24)00603-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  472. MARANTOS T, Kyriazopoulou E, Angelakis E, Kitsos D, et al
    Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study.
    Vaccine. 2024 May 24:S0264-410X(24)00617-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  473. BAK J, Hasan Q, Kissa J, Mere MO, et al
    Deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region 2021-23: How do we switch to a life course approach?
    Vaccine. 2024 May 24:S0264-410X(24)00560-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  474. LYNETTE EJEZIE C, Cuccaro P, Savas LS, Shegog R, et al
    Regional differences in provider recommendation of HPV vaccines among 13-to-17 year old adolescents from 2019 to 2021.
    Vaccine. 2024 May 24:S0264-410X(24)00581-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  475. BENEDICT KPOZEHOUEN E, Raina Macintyre C, Tan TC
    Coverage of influenza, pneumococcal and zoster vaccination and determinants of influenza and pneumococcal vaccination among adults with cardiovascular diseases in community.
    Vaccine. 2024 May 23:S0264-410X(24)00619-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  476. EIBERG MF, Rezahosseini O, Bukan KB, Charlotte Arp B, et al
    Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis.
    Vaccine. 2024 May 23:S0264-410X(24)00566-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  477. TSAMPALIEROS A, Zemek R, Barrowman N, Langlois MA, et al
    Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years.
    Vaccine. 2024 May 23:S0264-410X(24)00588-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  478. CARNALLA M, Stern D, Arantxa Colchero M, Rangel-Moreno K, et al
    Who is getting COVID-19 boosters? A latent class analysis in a nationally representative sample of Mexican adults 60 years and over.
    Vaccine. 2024;42:3273-3276.
    PubMed     Abstract available


  479. RAMOS-DUARTE VA, Orlowski A, Jaquenod de Giusti C, Corigliano MG, et al
    Safe plant Hsp90 adjuvants elicit an effective immune response against SARS-CoV2-derived RBD antigen.
    Vaccine. 2024;42:3355-3364.
    PubMed     Abstract available


  480. ZHANG WX, Zhang Y, Du J, Shi W, et al
    Effectiveness of momentary intervention on influenza vaccination among the elderly in China: From willingness to action.
    Vaccine. 2024 May 22:S0264-410X(24)00591-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  481. PROSPER P, Rodriguez Puertas R, Guerin DMA, Branda MM, et al
    Computational method for designing vaccines applied to virus-like particles (VLPs) as epitope carriers.
    Vaccine. 2024 May 22:S0264-410X(24)00584-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  482. ZHOU H, Zhao W, Ma R, Zheng Y, et al
    Mixed methods examination of risk perception on vaccination intentions: The perspective of doctor-patient communication.
    Vaccine. 2024 May 22:S0264-410X(24)00565-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  483. VAN DER PLAS JL, Haijema BJ, Leenhouts K, Paul Zoeteweij J, et al
    Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly.
    Vaccine. 2024 May 20:S0264-410X(24)00370-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  484. KARIMI-SHAHRBABAK E, Di Chiara C, Farrar DS, Abu Fadaleh SM, et al
    COVID-19 vaccine acceptance and uptake among caregivers of children aged 5-11?years in Ontario, Canada: A cross-sectional survey.
    Vaccine. 2024 May 20:S0264-410X(24)00553-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  485. MACHIDA M, Fukushima S, Saitoh A, Inoue S, et al
    Uptake among four indicated vaccines by adults aged 65 years and older in Japan, 2023.
    Vaccine. 2024 May 20:S0264-410X(24)00592-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  486. GARG R, Liu Q, Van Kessel J, Asavajaru A, et al
    Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern.
    Vaccine. 2024 May 19:S0264-410X(24)00586-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  487. YANG T, Tong F, Tang L, Li P, et al
    Repeated vaccination does not appear to significantly weaken the protective effect of influenza vaccine in the elderly: A test-negative case-control study in China.
    Vaccine. 2024 May 17:S0264-410X(24)00593-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  488. ANN COSTA CLEMENS S, Weckx L, Milan EP, Smolenov I, et al
    Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.
    Vaccine. 2024 May 17:S0264-410X(24)00555-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  489. URQUIDI C, Sepulveda-Penaloza A, Valenzuela MT, Ponce A, et al
    Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs.
    Vaccine. 2024 May 14:S0264-410X(24)00538-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  490. MUANGNOICHAROEN S, Wiangcharoen R, Lawpoolsri S, Nanthapisal S, et al
    Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
    Vaccine. 2024 May 13:S0264-410X(24)00556-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  491. EJNAR HANSEN M, David Pickering S
    The role of religion and COVID-19 vaccine uptake in England.
    Vaccine. 2024;42:3215-3219.
    PubMed     Abstract available


  492. DINH THIEM V, Van Anh PT, Van Men C, Hung DT, et al
    A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
    Vaccine. 2024 May 10:S0264-410X(24)00523-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  493. MALTEZOU HC, Gamaletsou MN, Giannouchos TV, Koukou DM, et al
    Effectiveness of COVID-19 booster vaccination, morbidity and absenteeism among healthcare personnel during the 2022-2023 season dominated by Omicron BA.5 and BA.2 subvariants.
    Vaccine. 2024 May 9:S0264-410X(24)00522-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  494. SHANI M, Hermesh I, Feldhamer I, Reges O, et al
    The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities.
    Vaccine. 2024 May 9:S0264-410X(24)00536-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  495. LEE KY, Song KH, Lee KH, Baek JY, et al
    Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection.
    Vaccine. 2024 May 9:S0264-410X(24)00539-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  496. KIM DH, Lee SH, Kim J, Lee J, et al
    Efficacy of live and inactivated recombinant Newcastle disease virus vaccines expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza in SPF chickens, Broilers, and domestic ducks.
    Vaccine. 2024 May 8:S0264-410X(24)00527-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  497. TIPPINS A, Acevedo JC, Palomeque FS, Coy KC, et al
    Strategies to strengthen COVID-19 vaccine uptake and improve vaccine equity in U.S. Territories and Freely Associated States during the first six months of vaccine rollout.
    Vaccine. 2024 May 7:S0264-410X(24)00541-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  498. KIM J, Chang J
    Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2.
    Vaccine. 2024 May 6:S0264-410X(24)00481-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  499. CAO A, Ueta M, Uchibori M, Murakami M, et al
    Trust in governments, public health institutions, and other information sources as determinants of COVID-19 vaccine uptake behavior in Japan.
    Vaccine. 2024 May 6:S0264-410X(24)00520-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  500. JEARANAIWITAYAKUL T, Sunintaboon P, Kittiayuwat A, Limthongkul J, et al
    Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development.
    Vaccine. 2024 May 6:S0264-410X(24)00519-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  501. SOE P, Wong H, Naus M, Muller MP, et al
    mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network.
    Vaccine. 2024 May 6:S0264-410X(24)00535-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  502. SHI XC, Gruber JF, Ondari M, Lloyd PC, et al
    Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older.
    Vaccine. 2024 May 3:S0264-410X(24)00478-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  503. MAUREL M, Mazagatos C, Goerlitz L, Oroszi B, et al
    Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.
    Vaccine. 2024 May 3:S0264-410X(24)00497-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  504. BENEDICT KPOZEHOUEN E, Macintyre CR, Tan TC
    Determinants of uptake of influenza, zoster and pneumococcal vaccines in patients with cardiovascular diseases.
    Vaccine. 2024 May 3:S0264-410X(24)00445-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  505. HU H, Ma F, Gong L, Wang Y, et al
    Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults.
    Vaccine. 2024 May 3:S0264-410X(24)00495-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  506. ADINUGROHO I, Stafford T, Bentall RP
    The correlation between conspiracy mentality and vaccine intentions is moderated by social events: Evidence from longitudinal data during COVID-19 pandemic in the UK.
    Vaccine. 2024 May 3:S0264-410X(24)00510-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  507. CHRISTOU-ERGOS M, Bleicher K, Leask J
    Factors associated with vaccination intention and uptake over time in a sample of older Australians.
    Vaccine. 2024 May 3:S0264-410X(24)00508-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  508. BAGLIVO F, De Angelis L, Magri M, De Nicola I, et al
    The impact of COVID-19 vaccination campaign on pediatric vaccine uptake based on parents' attitudes towards mandatory and recommended vaccination in Southern Italy.
    Vaccine. 2024 May 3:S0264-410X(24)00513-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  509. MARINTHE G, Brown G, Cristea M, Kutlaca M, et al
    Predicting vaccination hesitancy: The role of basic needs satisfaction and institutional trust.
    Vaccine. 2024 May 3:S0264-410X(24)00507-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  510. EHRLICH KB, Lyle SM, Corallo KL, Lavner JA, et al
    Changes in depressive symptoms and antibody production following influenza vaccination in adolescents and adults.
    Vaccine. 2024 May 2:S0264-410X(24)00505-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    April 2024
  511. FLEARY SA, Shahn Z, Teasdale CA
    Effects of parental childhood cultural health environment on children's influenza and COVID-19 vaccination status.
    Vaccine. 2024 Apr 29:S0264-410X(24)00515-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  512. NIESSEN FA, Bruijning-Verhagen PCJL, Bonten MJM, Knol MJ, et al
    Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands by medical risk condition: A test-negative case-control study.
    Vaccine. 2024 Apr 29:S0264-410X(24)00432-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  513. GUDOORU K, Nguyen K, Le K, Sarabu V, et al
    Collective good and individual choice: Perceptions on COVID-19 vaccine mandate among COVID-19 vaccinated individuals.
    Vaccine. 2024 Apr 27:S0264-410X(24)00479-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  514. DORJEE K, Namdon T, Topgyal S, Gyatso U, et al
    Association between Covishield vaccine and menstrual disturbance. Findings from a cross-sectional study among participants of Zero TB cohort in India.
    Vaccine. 2024 Apr 27:S0264-410X(24)00500-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  515. LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
    Authors' reply: Excess mortality in Cyprus during the COVID-19 vaccination campaign.
    Vaccine. 2024 Apr 25:S0264-410X(24)00506-1. doi: 10.1016/j.vaccine.2024.
    PubMed    


  516. XIE Z, Stallings-Smith S, Patel S, Case S, et al
    COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population.
    Vaccine. 2024 Apr 25:S0264-410X(24)00509-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  517. PIASECKI AM, Hall DM, Zajac J, Miller SA, et al
    A programmatic update on COVID-19 vaccination in rural communities in the United States.
    Vaccine. 2024 Apr 25:S0264-410X(24)00469-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  518. FUJITA DM, da Silva Nali LH, da Costa RR, de Andrade Junior HF, et al
    Low vaccine coverage and varicella outbreaks in Brazil - 2019-2022.
    Vaccine. 2024 Apr 24:S0264-410X(24)00435-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  519. SELLIES AJ, Knol MJ, de Melker HE, Bruijning-Verhagen PCJL, et al
    Non-specific effects of the inactivated influenza vaccine. A test-negative study: The inactivated influenza vaccine and SARS-CoV-2 infections.
    Vaccine. 2024 Apr 23:S0264-410X(24)00468-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  520. SONG S, Madewell ZJ, Liu M, Miao Y, et al
    A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.
    Vaccine. 2024 Apr 22:S0264-410X(24)00476-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  521. MUSA S, Merdrignac L, Skocibusic S, Nedic R, et al
    BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study.
    Vaccine. 2024 Apr 20:S0264-410X(24)00471-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  522. LIEVRE G, Sicsic J, Galmiche S, Charmet T, et al
    Are the 7C psychological antecedents associated with COVID-19 vaccine behaviours beyond intentions? A cross-sectional study on at-least-one-dose and up-to-date vaccination status, and uptake speed among adults in France.
    Vaccine. 2024 Apr 19:S0264-410X(24)00438-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  523. INGRAO F, Ngabirano E, Rauw F, Dauphin G, et al
    Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.
    Vaccine. 2024 Apr 18:S0264-410X(24)00452-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  524. WON H, Kim JA, Jeong NY, Choi NK, et al
    Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly.
    Vaccine. 2024 Apr 18:S0264-410X(24)00400-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  525. RICKE IJ, Spaulding AB, Rajtar NN, Benton EM, et al
    Predictors of willingness to receive updated 2023-2024 COVID-19 booster vaccines among a convenience sample in Minnesota.
    Vaccine. 2024 Apr 18:S0264-410X(24)00480-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  526. ORANGZEB S, Desalegn A, Trinh NTH, Zhao J, et al
    COVID-19 vaccine uptake among children and adolescents in Norway: A comprehensive registry-based cohort study of over 800,000 individuals.
    Vaccine. 2024 Apr 18:S0264-410X(24)00464-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  527. TRINITE B, Durr E, Pons-Grifols A, O'Donnell G, et al
    VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
    Vaccine. 2024 Apr 18:S0264-410X(24)00473-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  528. VAN DER POL S, Zeevat F, Postma MJ, Boersma C, et al
    Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations.
    Vaccine. 2024 Apr 17:S0264-410X(24)00465-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  529. BEITARI S, Yi S, Sharma S, Yung R, et al
    Exploring COVID-19 vaccine uptake and hesitancy among vulnerable populations in inner city Vancouver, Canada: Insights into characteristics and clinical outcomes.
    Vaccine. 2024 Apr 17:S0264-410X(24)00477-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  530. PEREIRA ET, Iasulaitis S, Greco BC
    Analysis of causal relations between vaccine hesitancy for COVID-19 vaccines and ideological orientations in Brazil.
    Vaccine. 2024 Apr 16:S0264-410X(24)00436-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  531. LEE N, Hong Y, Kirkpatrick CE, Hu S, et al
    COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants.
    Vaccine. 2024 Apr 16:S0264-410X(24)00402-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  532. DEAL A, Crawshaw AF, Salloum M, Hayward SE, et al
    Understanding the views of adult migrants around catch-up vaccination for missed routine immunisations to define strategies to improve coverage: A UK in-depth interview study.
    Vaccine. 2024 Apr 16:S0264-410X(24)00406-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  533. GEE J, Shimabukuro TT, Su JR, Shay D, et al
    Overview of U.S. COVID-19 vaccine safety surveillance systems.
    Vaccine. 2024 Apr 16:S0264-410X(24)00224-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  534. MARTINEZ JL, Lemus N, Lai TY, Mishra M, et al
    The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex.
    Vaccine. 2024 Apr 15:S0264-410X(24)00451-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  535. MELNIKOW J, Padovani A, Zhang J, Miller M, et al
    Patient concerns and physician strategies for addressing COVID-19 vaccine hesitancy.
    Vaccine. 2024 Apr 15:S0264-410X(24)00437-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  536. WONG IOL, Wong C, Mak N, Dai A, et al
    Assessment of the impact of the vaccine pass policy on COVID-19 vaccine hesitancy and uptake among Chinese adults in Hong Kong.
    Vaccine. 2024 Apr 15:S0264-410X(24)00449-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  537. BAKER J, Aliabadi N, Munjal I, Jiang Q, et al
    Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Vaccine. 2024 Apr 13:S0264-410X(24)00387-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  538. SUKIK L, Chemaitelly H, Ayoub HH, Coyle P, et al
    Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.
    Vaccine. 2024 Apr 13:S0264-410X(24)00440-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  539. NOLAN MB, Chrenka E, Walker P, Steiner A, et al
    COVID-19 vaccine uptake among non-US-born populations in the United States, 2020-2022.
    Vaccine. 2024 Apr 11:S0264-410X(24)00443-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  540. KAINTH MK, Sembajwe GN, Ahn H, Qian M, et al
    Despite mandated primary series, health care personnel still hesitant about COVID-19 vaccine and immunizing children.
    Vaccine. 2024 Apr 11:S0264-410X(24)00442-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  541. LEE JS, Choi H, Shin SH, Hwang MJ, et al
    Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents.
    Vaccine. 2024 Apr 11:S0264-410X(24)00446-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  542. PITTS PJ, Poland GA
    Addressing vaccine hesitancy: Learning from the successes and failures of the COVID-19 pandemic.
    Vaccine. 2024 Apr 10:S0264-410X(24)00396-7. doi: 10.1016/j.vaccine.2024.
    PubMed    


  543. AKMATOVA R, Ebama MS, Temirbekov S, Alymkulova V, et al
    A comparative analysis of knowledge, attitude, and practice (KAP) towards influenza and influenza vaccination among healthcare workers in Kyrgyzstan prior to and during the COVID-19 pandemic.
    Vaccine. 2024 Apr 9:S0264-410X(24)00420-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  544. THAI H, Audet EC, Koestner R
    Motivation for COVID-19 Vaccination: Applying a Self-Determination Theory Perspective to a Global Health Crisis.
    Vaccine. 2024 Apr 9:S0264-410X(24)00439-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available



  545. Immunization agenda 2030: A global strategy to leave no one behind.
    Vaccine. 2024;42 Suppl 1:S5-S14.
    PubMed    


  546. ZHU J, Cole CB, Fihman J, Adjagba A, et al
    Opportunities to accelerate immunization progress in middle-income countries.
    Vaccine. 2024;42 Suppl 1:S98-S106.
    PubMed     Abstract available


  547. BLANC DC, Grundy J, Sodha SV, O'Connell TS, et al
    Immunization programs to support primary health care and achieve universal health coverage.
    Vaccine. 2024;42 Suppl 1:S38-S42.
    PubMed     Abstract available


  548. SAXENIAN H, Alkenbrack S, Freitas Attaran M, Barcarolo J, et al
    Sustainable financing for Immunization Agenda 2030.
    Vaccine. 2024;42 Suppl 1:S73-S81.
    PubMed     Abstract available


  549. CERNUSCHI T, Malvolti S, Hall S, Debruyne L, et al
    The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Vaccine. 2024;42 Suppl 1:S64-S72.
    PubMed     Abstract available


  550. KONERU A, Wells K, Amanda Carnes C, Drumhiller K, et al
    A survey of state and local practices encouraging pediatric COVID-19 vaccination of children ages 6 months through 11 years.
    Vaccine. 2024 Apr 8:S0264-410X(24)00369-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  551. CHARD AN, Machingaidze C, Loayza S, Gharpure R, et al
    Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018.
    Vaccine. 2024 Apr 6:S0264-410X(24)00419-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  552. ARCHER H, McCoy SI, Sears D, Kwan A, et al
    Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a California state Prison, May 2021.
    Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  553. SCHULTZE A, Martin I, Messina D, Bots S, et al
    A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases.
    Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  554. BAUM HE, Thirard R, Halliday A, Baos S, et al
    Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
    Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  555. NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al
    Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial.
    Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  556. WU CY, Kao SE, Tseng YC, Hou JT, et al
    Pilot-scale production of a highly efficacious and stable monoglycosylated influenza split virus vaccine.
    Vaccine. 2024;42:2220-2228.
    PubMed     Abstract available


  557. LASRADO N, Rossler A, Rowe M, Collier AY, et al
    Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
    Vaccine. 2024;42:2117-2121.
    PubMed     Abstract available


    March 2024
  558. GONG JD, Barnboym E, O'Mara M, Gurevich N, et al
    Self-reported determinants of COVID-19 vaccine acceptance among persons with and without autoimmune disease.
    Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  559. MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al
    Effectiveness of COVID-19 vaccination against school absenteeism in children and adolescents hospitalized with COVID-19.
    Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  560. HUF SW, Grailey K, Crespo RF, Woldmann L, et al
    Testing the impact of differing behavioural science informed text message content in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical trial.
    Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  561. DALEY MF, Reifler LM, Shoup JA, Glanz JM, et al
    Influenza vaccination accuracy among adults: Self-report compared with electronic health record data.
    Vaccine. 2024 Mar 25:S0264-410X(24)00339-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  562. BIEGUS J, Szenborn L, Zymlinski R, Zakliczynski M, et al
    The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure.
    Vaccine. 2024 Mar 25:S0264-410X(24)00366-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  563. VOLKMANN AM, Goldin S, McMurren B, Gapare C, et al
    Leveraging seasonal influenza health worker vaccination programmes for COVID-19 vaccine Introduction: A global qualitative analysis.
    Vaccine. 2024 Mar 25:S0264-410X(23)01490-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  564. DAHL BA, Tritter B, Butryn D, Dahlke M, et al
    Global VAX: A U.S. contribution to global COVID-19 vaccination efforts, 2021-2023.
    Vaccine. 2024 Mar 23:S0264-410X(24)00359-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  565. MORGAN G, Casalino S, Chowdhary S, Frangione E, et al
    COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00317-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  566. CONDIE J, Northstone K, Major-Smith D, Halstead I, et al
    Exploring associations between the Big Five personality traits and cognitive ability with COVID-19 vaccination hesitancy and uptake among mothers and offspring in a UK prospective cohort study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00305-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  567. KLUWER B, Gleditsch R, Rydland KM, Mamelund SE, et al
    Higher educational attainment associated with higher confidence in influenza vaccination in Norway.
    Vaccine. 2024 Mar 21:S0264-410X(24)00338-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  568. PRICE O, Dietze P, Maher L, Dore GJ, et al
    High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs.
    Vaccine. 2024 Mar 21:S0264-410X(24)00337-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  569. MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al
    Differences in social media use by COVID-19 vaccination status.
    Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  570. SASI A, Dandotiya J, Kaushal J, Ganguly S, et al
    Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  571. HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al
    Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
    Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  572. KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al
    Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity.
    Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  573. LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al
    Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.
    Vaccine. 2024;42:2004-2010.
    PubMed     Abstract available


  574. LANG JC, Kura K, Garba SM, Elbasha EH, et al
    Comparison of a static cohort model and dynamic transmission model for respiratory syncytial virus intervention programs for infants in England and Wales.
    Vaccine. 2024;42:1918-1927.
    PubMed     Abstract available


  575. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al
    CHO cells for virus-like particle and subunit vaccine manufacturing.
    Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  576. CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al
    COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
    Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  577. FIX J, Christopher Mast T, Smith K, Baker N, et al
    Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
    Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  578. COTTON SA, Subramanian A, Hughes TD, Huang Y, et al
    The effect of SARS-COV-2 variant on non-respiratory features and mortality among vaccinated and non-fully vaccinated patients.
    Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  579. CAMERON DB, Grage L, Van Wyck R, Edwards A, et al
    Identifying trusted local sources and predicting behavior change pathways according to COVID-19 vaccination status: Results of a 2022 statewide survey of Alaskan adults.
    Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  580. EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al
    Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: Findings from a multi-wave study.
    Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  581. MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al
    The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial.
    Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  582. RUSS S, Myers C, Licherdell E, Bowden A, et al
    Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
    Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  583. SHIJIA YAN A, Jay Sehgal N
    Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S.
    Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  584. MORO PL, Carlock G, Fifadara N, Habenicht T, et al
    Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  585. LUISI M, Geana MV, Pei J
    Pandemic antecedents - Exploring predictivity and relationships between COVID-19 vaccine uptake and influenza, shingles, and HPV vaccination.
    Vaccine. 2024 Mar 8:S0264-410X(24)00275-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  586. ST-LOUIS P, Martin C, Khatri V, Bourgault S, et al
    Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice.
    Vaccine. 2024 Mar 8:S0264-410X(24)00222-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  587. SU YW, Qiu YZ, Wang YH, Xu Y, et al
    Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
    Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available



  588. Expression of Concern: "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine [33/1], 1 January 2015, Pages 108-116].
    Vaccine. 2024;42:1851.
    PubMed    


  589. MENG L, Harris L, Shaw L, Lymon H, et al
    Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged >/= 12 years, United States, August 2021-October 2
    Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  590. KARRAS J, Harrison M, Steffens M, Abdi I, et al
    "COVID is a huge jigsaw puzzle that I am trying to make sense of myself": Exploring the perceptions towards the COVID-19 vaccine communication strategy in Australia amongst unvaccinated Australian adults.
    Vaccine. 2024 Mar 6:S0264-410X(24)00276-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  591. WONG WHS, Leung DL, Yip KM, So HK, et al
    Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less than 3 years old during Omicron wave in Hong Kong.
    Vaccine. 2024 Mar 6:S0264-410X(24)00226-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  592. RAETHKE M, van Hunsel F, Luxi N, Lieber T, et al
    Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
    Vaccine. 2024 Mar 6:S0264-410X(24)00273-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  593. CHEN D, Cowling BJ, Ainslie KEC, Lin Y, et al
    Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong.
    Vaccine. 2024 Mar 5:S0264-410X(24)00252-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  594. YASHAR-GERSHMAN SG, Rosenberg AT, Sawhney M, Fernanda Machicao M, et al
    Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care.
    Vaccine. 2024 Mar 1:S0264-410X(24)00228-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    February 2024
  595. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
    Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  596. KOHLI M, Maschio M, Lee A, Igarashi A, et al
    Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine.
    Vaccine. 2024 Feb 29:S0264-410X(24)00117-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  597. CHATHAM-STEPHENS K, Carter RJ, Duggar C, Woodworth KR, et al
    An overview of the COVID-19 pediatric vaccine program - The U.S. experience vaccinating children ages 6 months through 17 years.
    Vaccine. 2024 Feb 29:S0264-410X(24)00166-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  598. GUO J, Chen X, Guo Y, Liu M, et al
    Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies.
    Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  599. MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
    Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
    Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  600. YANG XY, Liu T, Jiang SC, Zhang ZW, et al
    Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells.
    Vaccine. 2024;42:1259-1267.
    PubMed     Abstract available


  601. JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
    Intensification of integrated immunization services to recover routine vaccination coverage and bring COVID-19 vaccine to the population of Iraq in 2022.
    Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  602. KRISTINSDOTTIR I, Haraldsson A, Thors V
    Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of influenza in pregnant women and their infants.
    Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  603. MUNDO ORTIZ A, Nasri B
    Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model.
    Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  604. NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al
    The association between influenza vaccination uptake and influenza and pneumonia-associated deaths in the United States.
    Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  605. MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against hospitalizations associated with influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November 2023.
    Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  606. SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
    Audiovestibular adverse events following COVID-19 vaccinations.
    Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  607. XU S, Sy LS, Hong V, Farrington P, et al
    Mortality risk after COVID-19 vaccination: A self-controlled case series study.
    Vaccine. 2024 Feb 21:S0264-410X(24)00191-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  608. SHOUKAT A, Bawden CE, Rost G, LeBlanc JJ, et al
    Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2024 Feb 16:S0264-410X(24)00200-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  609. CHERRY N, Adisesh A, Burstyn I, Charlton C, et al
    Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study.
    Vaccine. 2024;42:1168-1178.
    PubMed     Abstract available


  610. JIN F, Qiu Y, Wu Z, Wang YH, et al
    Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
    Vaccine. 2024 Feb 15:S0264-410X(24)00124-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  611. MZIOU E, Hchaichi A, Letaief H, Dhaouadi S, et al
    Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021.
    Vaccine. 2024 Feb 15:S0264-410X(24)00174-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  612. ROCKSON ADJEI M, Longsignikuu A, Saeed Iddris I, Nang Suuri T, et al
    Trend of measles-rubella vaccination coverage and impact on measles epidemiology in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.
    Vaccine. 2024 Feb 15:S0264-410X(24)00170-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  613. KIM HK, Park SK, Choe SA, Gwak ES, et al
    Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study.
    Vaccine. 2024 Feb 15:S0264-410X(24)00168-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  614. KUTER BJ, Brien K, Anderson S, Bass SB, et al
    COVID-19 vaccine perspectives and uptake among university students three years into the pandemic.
    Vaccine. 2024 Feb 15:S0264-410X(24)00162-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  615. OKOLI GN, Righolt CH, Zhang G, Van Caeseele P, et al
    A population-based, province-wide, record-linkage interrupted time series analysis of impact of the universal seasonal influenza vaccination policy on seasonal influenza vaccine uptake among 5-64-year-olds in the province of Manitoba, Canada.
    Vaccine. 2024 Feb 14:S0264-410X(24)00104-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  616. BATHEJA A, Balkrishnan R
    Rhode Island as a model for promoting flu vaccination in the United States.
    Vaccine. 2024 Feb 14:S0264-410X(24)00161-0. doi: 10.1016/j.vaccine.2024.
    PubMed    


  617. KLASSEN AC, Lee G, Chiang S, Murray R, et al
    Did the COVID-19 experience change U.S. parents' attitudes towards HPV vaccination? Results from a national survey.
    Vaccine. 2024 Feb 14:S0264-410X(24)00142-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  618. DUGGAR C, Santoli JM, Noblit C, Moore LB, et al
    U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 - May 2023.
    Vaccine. 2024 Feb 14:S0264-410X(24)00167-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  619. DONATO F, Pilotto A, Foca E, Tresoldi M, et al
    The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection.
    Vaccine. 2024 Feb 13:S0264-410X(24)00147-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  620. HEARN EB, Kehinde G, Sambamoorthi U
    Food insecurity and COVID-19 vaccine hesitancy among adults in the United States (US).
    Vaccine. 2024 Feb 13:S0264-410X(24)00102-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  621. AMDISEN L, Pedersen L, Abildgaard N, Benn CS, et al
    The coverage of influenza vaccination and predictors of influenza non-vaccination in Danish cancer patients: A nationwide register-based cohort study.
    Vaccine. 2024 Feb 12:S0264-410X(24)00155-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  622. VALENTIN J, Ingrao F, Rauw F, Lambrecht B, et al
    Protection conferred by an H5 DNA vaccine against highly pathogenic avian influenza in chickens: The effect of vaccination schedules.
    Vaccine. 2024 Feb 12:S0264-410X(23)01422-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  623. MORGAN HJ, Clothier HJ, Sepulveda Kattan G, Boyd JH, et al
    Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis.
    Vaccine. 2024 Feb 12:S0264-410X(24)00126-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  624. FAKSOVA K, Walsh D, Jiang Y, Griffin J, et al
    COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Vaccine. 2024 Feb 12:S0264-410X(24)00127-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  625. WHITAKER HJ, Hassell K, Hoschler K, Power L, et al
    Influenza vaccination during the 2021/22 season: A data-linkage test-negative case-control study of effectiveness against influenza requiring emergency care in England and serological analysis of primary care patients.
    Vaccine. 2024 Feb 10:S0264-410X(24)00150-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  626. LIJESKIC O, Bauman N, Markovic M, Srbljanovic J, et al
    SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Vaccine. 2024 Feb 10:S0264-410X(24)00110-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  627. WEI J, Tan TC, Moa AM, MacIntyre CR, et al
    Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst Australian adults.
    Vaccine. 2024 Feb 9:S0264-410X(24)00154-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  628. BUEKENS P, Berrueta M, Ciapponi A, Bardach A, et al
    Safe in pregnancy: A global living systematic review and meta-analysis of COVID-19 vaccines in pregnancy.
    Vaccine. 2024 Feb 9:S0264-410X(24)00158-0. doi: 10.1016/j.vaccine.2024.
    PubMed    


  629. MARKOWITZ LE, Hopkins RH Jr, Broder KR, Lee GM, et al
    COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic.
    Vaccine. 2024 Feb 9:S0264-410X(23)01505-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  630. WADAPURKAR R, Singh S, Singh A
    Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine.
    Vaccine. 2024 Feb 8:S0264-410X(24)00111-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  631. RANDELL M, Sheel M, Dynes M, Li M, et al
    Influence of the COVID-19 pandemic on caregiver beliefs and experiences of routine childhood immunisation in Indonesia.
    Vaccine. 2024;42:812-818.
    PubMed     Abstract available


  632. KOLANDAI K, Milne B, von Randow M, Bullen C, et al
    Public opinion on global COVID-19 vaccine procurement and distribution policies: A nationally representative survey in Aotearoa New Zealand 2022.
    Vaccine. 2024 Feb 6:S0264-410X(24)00115-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  633. MAEDA M, Murata F, Fukuda H
    The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.
    Vaccine. 2024 Feb 5:S0264-410X(24)00106-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  634. MIYAMOTO S, Suzuki T
    Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
    Vaccine. 2024 Feb 2:S0264-410X(24)00112-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  635. RIVERS P, Porter C, LeClair LB, Jeddy Z, et al
    Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study.
    Vaccine. 2024 Feb 2:S0264-410X(24)00010-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  636. BENNETT JC, Luiten KG, O'Hanlon J, Han PD, et al
    Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
    Vaccine. 2024 Feb 1:S0264-410X(24)00103-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  637. DATTA S, Vattiato G, Maclaren OJ, Hua N, et al
    The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study.
    Vaccine. 2024 Feb 1:S0264-410X(24)00128-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    January 2024
  638. SOOD S, Matar MM, Kim J, Kinsella M, et al
    Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer.
    Vaccine. 2024 Jan 31:S0264-410X(24)00077-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  639. HUANG Y, Shi H, Forgacs D, Ross TM, et al
    Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection.
    Vaccine. 2024 Jan 30:S0264-410X(23)01543-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  640. JI Y, Sui X, Miao W, Wang C, et al
    Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
    Vaccine. 2024 Jan 30:S0264-410X(24)00097-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  641. SHAPIRO BEN DAVID S, Baruch Gez S, Adler L, Kovatch R, et al
    Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.
    Vaccine. 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  642. BALSELLS E, Vicente M, Reyes S, Figueroa M, et al
    Impact of the 'Health on Wheels' (HoW) strategy on COVID-19 vaccination coverage in hard-to-reach communities in Alta Verapaz, Guatemala, 2022.
    Vaccine. 2024 Jan 27:S0264-410X(24)00033-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  643. OKPANI AI, Adu P, Paetkau T, Lockhart K, et al
    Are COVID-19 vaccination mandates for healthcare workers effective? A systematic review of the impact of mandates on increasing vaccination, alleviating staff shortages and decreasing staff illness.
    Vaccine. 2024 Jan 27:S0264-410X(24)00052-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  644. FILIPAS DK, Labban M, Beatrici E, Stone BV, et al
    Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
    Vaccine. 2024;42:441-447.
    PubMed     Abstract available


  645. TAKALANI A, Robinson M, Jonas P, Bodenstein A, et al
    Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
    Vaccine. 2024 Jan 25:S0264-410X(24)00078-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  646. RUSS S, Bennett N, van Wijngaarden E, Hill E, et al
    Influence of Community Determinants on Barriers and Facilitators to COVID-19 Vaccine Uptake: Regional Stakeholders' Perspectives.
    Vaccine. 2024 Jan 24:S0264-410X(24)00051-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  647. LIU R, Fan Y, Patel A, Liu H, et al
    The association between influenza vaccination, cardiovascular mortality and hospitalization: A living systematic review and prospective meta-analysis.
    Vaccine. 2024 Jan 23:S0264-410X(24)00053-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  648. RATTAY K, Thierry JM, Yeargin-Allsopp M, Griffin-Blake S, et al
    Lessons learned: COVID-19 vaccinations and people with disabilities.
    Vaccine. 2024 Jan 23:S0264-410X(24)00028-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  649. ABAD N, Bonner KE, Kolis J, Brookmeyer KA, et al
    Strengthening COVID-19 vaccine confidence & demand during the US COVID-19 emergency response.
    Vaccine. 2024 Jan 23:S0264-410X(24)00029-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  650. HAMAD SAIED M, van Straalen JW, de Roock S, Verduyn Lunel FM, et al
    Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
    Vaccine. 2024 Jan 22:S0264-410X(24)00059-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  651. PAL R, Ferrari MG, Honda-Okubo Y, Wattay L, et al
    Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
    Vaccine. 2024 Jan 22:S0264-410X(24)00034-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  652. GEINITZ H, Silberberger E, Spiegl K, Feichtinger J, et al
    SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients.
    Vaccine. 2024 Jan 20:S0264-410X(24)00004-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  653. HILL PL, Morstead T, Pfund GN, Burrow AL, et al
    Examining changes in sense of purpose before, during, and after COVID-19 vaccination.
    Vaccine. 2024 Jan 20:S0264-410X(24)00027-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  654. MITCHELL MM, Klott A, Scholtes J, Braden BB, et al
    Mixed-methods examination of attitudes and behaviors related to COVID-19 vaccines among parents of children with autism and autistic adults.
    Vaccine. 2024 Jan 19:S0264-410X(24)00013-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  655. HICKEN A, Jones P, Menon A, Rozek LS, et al
    Can endorsement by religious leaders move the needle on vaccine hesitancy?
    Vaccine. 2024 Jan 18:S0264-410X(24)00006-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  656. MEMEDOVICH A, Orr T, Hollis A, Salmon C, et al
    Social network risk factors and COVID-19 vaccination: A cross-sectional survey study.
    Vaccine. 2024 Jan 18:S0264-410X(24)00005-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  657. GRIMA AA, Kwong JC, Richard L, Reid J, et al
    The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
    Vaccine. 2024 Jan 17:S0264-410X(24)00023-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  658. LEMMER Y, Chapman R, Abolnik C, Smith T, et al
    Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.
    Vaccine. 2024 Jan 17:S0264-410X(24)00036-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  659. FIEBELKORN AP, Adelsberg S, Anthony R, Ashenafi S, et al
    The role of funded partnerships in working towards decreasing COVID-19 vaccination disparities, United States, March 2021-December 2022.
    Vaccine. 2024 Jan 17:S0264-410X(23)01507-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  660. FAN J, Song Y, Cong S, Millman AJ, et al
    Assessing interventions to encourage primary care health workers to recommend influenza vaccination and the impact on vaccination uptake for persons with Non-Communicable diseases in China.
    Vaccine. 2024 Jan 16:S0264-410X(24)00011-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  661. HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Warner ND, et al
    Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine.
    Vaccine. 2024 Jan 16:S0264-410X(24)00032-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  662. KING ML
    How manufacturing won or lost the COVID-19 vaccine race.
    Vaccine. 2024 Jan 15:S0264-410X(23)01477-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  663. MCADAM E, Hayashi K, Barker B, Reddon H, et al
    COVID-19 vaccination among young people who use drugs in Vancouver, Canada.
    Vaccine. 2024 Jan 14:S0264-410X(24)00009-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  664. NAUTA J
    Estimand for non-inferiority influenza vaccine immunogenicity trials.
    Vaccine. 2024 Jan 13:S0264-410X(24)00014-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  665. RATISHVILI T, Quach HQ, Haralambieva IH, Suryawanshi YR, et al
    A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides.
    Vaccine. 2024;42:162-174.
    PubMed     Abstract available


  666. VAN ROEKEL C, Labuschagne L, Pijpers J, van Roon A, et al
    Factors associated with COVID-19 autumn 2022 booster uptake in the Netherlands among older adults aged >/= 60 years and younger adults with chronic conditions.
    Vaccine. 2024;42:146-155.
    PubMed     Abstract available


  667. PARK SI, Park S, Lee K, Kwak HW, et al
    Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
    Vaccine. 2024;42:69-74.
    PubMed     Abstract available


  668. REN S, Chen Q, Zhang Y, Yi L, et al
    Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
    Vaccine. 2024;42:352-361.
    PubMed     Abstract available


  669. GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al
    Assessing the relationship between existing childhood, adolescent and adult immunization programmes and national COVID-19 vaccination capacities in 2021.
    Vaccine. 2024 Jan 11:S0264-410X(23)01484-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  670. QURESHI NS, Miller LG, Judge SP, Tran NDT, et al
    Characterizing predictors of COVID-19 vaccine refusal in an urban southern California jail population.
    Vaccine. 2024 Jan 9:S0264-410X(24)00017-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  671. HINSON-ENSLIN AM, Espinoza LE
    The mental health symptoms of individuals with sensory disabilities and the reasons that lead to COVID-19 vaccine refusal and hesitancy.
    Vaccine. 2024 Jan 9:S0264-410X(24)00012-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  672. SHARP M, Lozano P, Southworth A, Peters A, et al
    Mixed methods approach to understanding COVID-19 vaccine hesitancy among immigrants in the Chicago.
    Vaccine. 2024 Jan 9:S0264-410X(23)01508-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  673. STELETOU E, Giannouchos T, Dimitriou G, Karatza A, et al
    Parental concerns and vaccine hesitancy against COVID-19 vaccination for children in Greece: A cross-sectional survey.
    Vaccine. 2024 Jan 6:S0264-410X(24)00003-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  674. STONE ND, Parker Fiebelkorn A, Guo A, Mothershed E, et al
    Challenges and opportunities during the COVID-19 vaccination efforts in long-term care.
    Vaccine. 2024 Jan 5:S0264-410X(23)01510-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  675. KRANZLER EC, Ihongbe TO, Marshall MC, Denison B, et al
    Racial and ethnic differences in COVID-19 vaccine readiness among adults in the United States, January 2021-April 2023.
    Vaccine. 2024 Jan 4:S0264-410X(23)01537-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  676. BUHL C, Jacobsen R, Almarsdottir AB, Abtahi S, et al
    Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states.
    Vaccine. 2024 Jan 4:S0264-410X(23)01511-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  677. CHARPIGNON ML, Gupta S, Shahnaz Majumder M
    Massachusetts companion program bolsters COVID-19 vaccine rates among seniors.
    Vaccine. 2024 Jan 3:S0264-410X(23)01494-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  678. DAVIDSON AM, Burns S, White LA, Perlman M, et al
    "I shall not poison my child with your human experiment": Investigating predictors of parents' hesitancy about vaccinating younger children (<12) in Canada.
    Vaccine. 2024 Jan 2:S0264-410X(23)01519-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  679. AGASSE E, Rodriguez GF, Vilarino V, Galli JH, et al
    Social determinants of health and vaccine uptake in pregnancy: Disparities in a diverse, predominately foreign-born population.
    Vaccine. 2024 Jan 2:S0264-410X(23)01515-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  680. VASHI MD, Watkins M
    Missed opportunities: Reducing zero dose children amongthe urban poor after COVID, Mumbai India, 2022.
    Vaccine. 2024;42:59-63.
    PubMed     Abstract available


    December 2023
  681. RUBIO-CASILLAS A, Rodriguez-Quintero CM, Redwan EM, Gupta MN, et al
    Do vaccines increase or decrease susceptibility to diseases other than those they protect against?
    Vaccine. 2023 Dec 28:S0264-410X(23)01506-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  682. BARZEN G, Rieber F, Stangl K, Hahn K, et al
    mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis.
    Vaccine. 2023 Dec 28:S0264-410X(23)01487-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  683. OLIVER SE, Wallace M, Twentyman E, Moulia DL, et al
    Development of COVID-19 vaccine policy - United States, 2020-2023.
    Vaccine. 2023 Dec 28:S0264-410X(23)01466-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  684. GHARPURE R, Akumu AO, Dawa J, Gobin S, et al
    Costs of seasonal influenza vaccine delivery in a pediatric demonstration project for children aged 6-23 months - Nakuru and Mombasa Counties, Kenya, 2019-2021.
    Vaccine. 2023 Dec 27:S0264-410X(23)01475-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  685. FONSECA HAR, Zimerman A, Monfardini F, Guimaraes HP, et al
    In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial.
    Vaccine. 2023 Dec 27:S0264-410X(23)01531-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  686. SHENTON P, Schrader S, Smith J, Alafaci A, et al
    Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study.
    Vaccine. 2023 Dec 27:S0264-410X(23)01516-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  687. SURTEES TC, Granade CJ, Wells C, Banks M, et al
    CDC COVID-19 vaccination program: Healthcare provider compliance with COVID-19 vaccine requirements and recommendations.
    Vaccine. 2023 Dec 27:S0264-410X(23)01467-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  688. NGUYEN KH, Coy KC, Black CL, Scanlon P, et al
    Comparison of adult hesitancy towards COVID-19 vaccines and vaccines in general in the USA.
    Vaccine. 2023 Dec 23:S0264-410X(23)01488-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  689. SEPPALA E, Dahl J, Veneti L, Rydland KM, et al
    Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023.
    Vaccine. 2023 Dec 22:S0264-410X(23)01496-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  690. KACHKO A, Selvaraj P, Liu S, Kim J, et al
    Vaccine-associated respiratory pathology correlates with viral clearance and protective immunity after immunization with self-amplifying RNA expressing the spike (S) protein of SARS-CoV-2 in mouse models.
    Vaccine. 2023 Dec 22:S0264-410X(23)01498-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  691. LO E, Brousseau N, Defay F, Fortin E, et al
    Neighborhood-level vaccine impact on COVID-19 infection and hospital admission in Quebec, Canada, during the Delta and early Omicron periods.
    Vaccine. 2023 Dec 22:S0264-410X(23)01489-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  692. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
    Vaccine. 2023 Dec 20:S0264-410X(23)01482-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  693. LINK-GELLES R, Britton A, Fleming-Dutra KE
    Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions.
    Vaccine. 2023 Dec 20:S0264-410X(23)01435-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  694. WOLFF M, Charpentier P, Canals A, Vial C, et al
    Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
    Vaccine. 2023 Dec 19:S0264-410X(23)01481-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  695. MIRIERI H, Nasimiyu C, Dawa J, Mburu C, et al
    Resilience of routine childhood immunization services in two counties in Kenya in the face of the COVID-19 pandemic.
    Vaccine. 2023;41:7695-7704.
    PubMed     Abstract available


  696. STUMPF J, Anders L, Siepmann T, Schwobel J, et al
    9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients.
    Vaccine. 2023 Dec 18:S0264-410X(23)01479-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  697. ARASHIRO T, Miwa M, Nakagawa H, Takamatsu J, et al
    COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study).
    Vaccine. 2023 Dec 18:S0264-410X(23)01480-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  698. DAWA J, Jalang'o R, Mirieri H, Kalani R, et al
    Comparing performance of year-round and campaign-mode influenza vaccination strategies among children aged 6-23 months in Kenya: 2019-2021.
    Vaccine. 2023 Dec 16:S0264-410X(23)01380-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  699. JACKSON LA, Stapleton JT, Walter EB, Chen WH, et al
    Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01434-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  700. JIANG W, Lu C, Yan X, Tucker JD, et al
    Vaccine confidence mediates the association between a pro-social pay-it-forward intervention and improved influenza vaccine uptake in China: A mediation analysis.
    Vaccine. 2023 Dec 15:S0264-410X(23)01392-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  701. ZHAN XY, Chen Y, Zhang X, Shi Q, et al
    Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination.
    Vaccine. 2023 Dec 15:S0264-410X(23)01465-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  702. BAJRACHARYA D, Jansen RJ
    Observations of COVID-19 vaccine coverage and vaccine hesitancy on COVID-19 outbreak: An American ecological study.
    Vaccine. 2023 Dec 15:S0264-410X(23)01441-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  703. BURNS KE, Dube E, Godinho Nascimento H, Meyer SB, et al
    Examining vaccine hesitancy among a diverse sample of Canadian adults.
    Vaccine. 2023 Dec 15:S0264-410X(23)01476-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  704. DONG C, Ma Y, Zhu W, Wang Y, et al
    Influenza immune imprinting synergizes PEI-HA/CpG nanoparticle vaccine protection against heterosubtypic infection in mice.
    Vaccine. 2023 Dec 14:S0264-410X(23)01485-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  705. FERRONI E, Gennaro N, Maifredi G, Leoni O, et al
    Access to SARS-CoV-2 vaccination in immigrants in Italy, by geographical area of origin.
    Vaccine. 2023 Dec 13:S0264-410X(23)01387-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  706. CAO Z, Yu R, Yuan Q, Ji W, et al
    Impact of the COVID-19 pandemic on routine vaccination coverage under varying prevalence Conditions: A cohort study in Beijing, China.
    Vaccine. 2023 Dec 13:S0264-410X(23)01447-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  707. SCHARF LG, Adeniyi K, Augustini E, Boyd D, et al
    Monitoring and reporting the US COVID-19 vaccination effort.
    Vaccine. 2023 Dec 13:S0264-410X(23)01438-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  708. O'NEIL SS, Pendl-Robinson EL, Carosella EA, Sullivan BD, et al
    The importance of community-specific survey data in understanding behavioral and social drivers of COVID-19 vaccination: Lessons learned from urban neighborhoods in four United States cities.
    Vaccine. 2023 Dec 12:S0264-410X(23)01450-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  709. OPRIESSNIG T, Gauger PC, Filippsen Favaro P, Rawal G, et al
    An experimental universal swine influenza a virus (IAV) vaccine candidate based on the M2 ectodomain (M2e) peptide does not provide protection against H1N1 IAV challenge in pigs.
    Vaccine. 2023 Dec 11:S0264-410X(23)01445-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  710. LYTRAS T, Di Gregorio AAA, Apostolopoulos D, Naziris D, et al
    Effectiveness of COVID-19 vaccine mandates in raising vaccination rates among the elderly and general population in Europe: Controlled interrupted time series analysis.
    Vaccine. 2023 Dec 11:S0264-410X(23)01472-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  711. AKMATOVA R, Dzhangaziev B, Ebama MS, Otorbaeva D, et al
    Knowledge, attitudes, and practices (KAP) towards seasonal influenza and influenza vaccine among pregnant women in Kyrgyzstan: A cross-sectional study.
    Vaccine. 2023 Dec 9:S0264-410X(23)01453-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  712. MESIDOR M, Liu Y, Talbot D, Skowronski DM, et al
    Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review.
    Vaccine. 2023 Dec 9:S0264-410X(23)01446-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  713. SUI Y, Andersen H, Li J, Hoang T, et al
    SARS-CoV-2 mucosal vaccine protects against clinical disease with sex bias in efficacy.
    Vaccine. 2023 Dec 8:S0264-410X(23)01426-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  714. DI CHIARA C, Cantarutti A, Raffaella Petrara M, Bonfante F, et al
    Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5-11 years old children with prior COVID-19.
    Vaccine. 2023 Dec 8:S0264-410X(23)01439-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  715. CHENG DR, Reimer H, Le D, Crawford NW, et al
    Analyzing an immunization resource website: User browsing trends.
    Vaccine. 2023;41:7498-7502.
    PubMed     Abstract available


  716. YU Y, Zhang X, Lau MMC, Lau JTF, et al
    The intention to get COVID-19 booster vaccination and its association with cognitive and emotional factors: A survey of Chinese COVID-19 infected people in Hong Kong.
    Vaccine. 2023 Dec 7:S0264-410X(23)01448-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  717. GRAMACHO W, Turgeon M, Santos Mundim P, Pereira I, et al
    Why did Brazil fail to vaccinate children against COVID-19 during the pandemic? An assessment of attitudinal and behavioral determinants.
    Vaccine. 2023 Dec 6:S0264-410X(23)01432-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  718. CANEVARI JT, Cheng AC, Wu L, Rowe SL, et al
    The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: A data linkage study.
    Vaccine. 2023 Dec 5:S0264-410X(23)01393-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  719. MADNI SA, Sharma AJ, Zauche LH, Waters AV, et al
    CDC COVID-19 Vaccine Pregnancy Registry: Design, data collection, response rates, and cohort description.
    Vaccine. 2023 Dec 5:S0264-410X(23)01423-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  720. PRASERT K, Praphasiri P, Lerdsamran H, Nakphook S, et al
    Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial.
    Vaccine. 2023 Dec 1:S0264-410X(23)01396-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  721. GASHTI AB, Agbayani G, Hrapovic S, Nassoury N, et al
    Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components.
    Vaccine. 2023 Dec 1:S0264-410X(23)01394-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    November 2023
  722. WANG Y, Hu Y, Ma Y, Li P, et al
    RBD class 1 and 2 antibody epitopes elicit around 70% neutralizing capacity against SARS-CoV-2 virus following boosting with inactivated virus vaccine.
    Vaccine. 2023 Nov 27:S0264-410X(23)01381-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  723. NISHIYAMA T, Miyamatsu Y, Park H, Nakamura N, et al
    Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history.
    Vaccine. 2023 Nov 25:S0264-410X(23)01384-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  724. DUCASA N, Benencio P, Mauro E, Anders M, et al
    Evaluation of the humoral response to the third dose of SARS-COV-2 vaccines in liver transplant recipients.
    Vaccine. 2023 Nov 24:S0264-410X(23)01383-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  725. PAYNE AB, Ciesla AA, Rowley EAK, Weber ZA, et al
    Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design.
    Vaccine. 2023 Nov 23:S0264-410X(23)01337-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  726. FITZPATRICK MC, Laufer RS, Baral R, Driscoll AJ, et al
    Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022.
    Vaccine. 2023;41:7047-7059.
    PubMed     Abstract available


  727. WANG B, McDonough J, Chen G, Ong JJ, et al
    Sociodemographic factors and attitudes associated with Australian parental acceptance of paediatric COVID-19 vaccination.
    Vaccine. 2023 Nov 22:S0264-410X(23)01336-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  728. NEELY SR, Hao F
    Breakthrough COVID-19 infections and perceived vaccine effectiveness.
    Vaccine. 2023 Nov 22:S0264-410X(23)01365-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  729. ZURCHER SJ, Signorell A, Lechot-Huser A, Aebi C, et al
    Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
    Vaccine. 2023;41:7226-7233.
    PubMed     Abstract available


  730. ECONOMIDOU EC, Soteriades ES
    Excess mortality in Cyprus during the COVID-19 vaccination campaign.
    Vaccine. 2023 Nov 22:S0264-410X(23)01361-0. doi: 10.1016/j.vaccine.2023.
    PubMed    


  731. LAW AW, Judy J, Atwell JE, Willis S, et al
    Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States: Implications for maternal RSV vaccine uptake in the future.
    Vaccine. 2023 Nov 21:S0264-410X(23)01307-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  732. NAUGLE D, Tibbels N, Dosso A, Benie W, et al
    "I'd do it for my baby": Lessons learned from qualitative research on COVID-19 vaccination among pregnant women in Cote d'Ivoire.
    Vaccine. 2023 Nov 19:S0264-410X(23)01333-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  733. HAEDER SF
    Assessing parental intention to vaccinate against COVID-19, influenza, and RSV in the United States in late 2023.
    Vaccine. 2023 Nov 15:S0264-410X(23)01303-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  734. AMITAI N, Wertheimer R, Prais D, Wertheimer KO, et al
    Influenza vaccination in children with pulmonary disease during the COVID-19 pandemic.
    Vaccine. 2023 Nov 15:S0264-410X(23)01338-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  735. CHOI Y, Park S, Lee J, Kim Y, et al
    Who gets COVID-19 booster vaccination? Trust in public health institutions and promotion strategies post-pandemic in the Republic of Korea.
    Vaccine. 2023 Nov 15:S0264-410X(23)01294-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  736. SARAFIAN JT, Eucker SA, Gillman M, DeLaroche AM, et al
    Impact of a hypothetical COVID-19 vaccine mandate on parental likelihood to vaccinate children: Exploring school-related concerns and vaccination decision-making.
    Vaccine. 2023 Nov 14:S0264-410X(23)01334-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  737. PLUMB ID, Briggs Hagen M, Wiegand R, Dumyati G, et al
    Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
    Vaccine. 2023 Nov 14:S0264-410X(23)01287-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  738. GUBERNOT D, Menis M, Whitaker B
    Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics.
    Vaccine. 2023;41:6922-6929.
    PubMed     Abstract available


  739. LASRADO N, Collier AY, Hachmann NP, Miller J, et al
    Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
    Vaccine. 2023;41:6904-6909.
    PubMed     Abstract available


  740. GOTO T, Chong Y, Tani N, Susai N, et al
    Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
    Vaccine. 2023;41:7019-7025.
    PubMed     Abstract available


  741. CUBIZOLLES C, Barjat T, Chauleur C, Bruel S, et al
    Evaluation of intentions to get vaccinated against influenza, COVID 19, pertussis and to get a future vaccine against respiratory syncytial virus in pregnant women.
    Vaccine. 2023 Nov 12:S0264-410X(23)01280-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  742. JIANG X, Wang J, Li C, Yeoh EK, et al
    Impact of the surge of COVID-19 Omicron outbreak on the intention of seasonal influenza vaccination in Hong Kong: A cross-sectional study.
    Vaccine. 2023 Nov 11:S0264-410X(23)01304-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  743. GRABENSTEIN JD, Ferrara P, Mantovani LG, McGovern I, et al
    Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of adjuvanted influenza vaccine.
    Vaccine. 2023 Nov 10:S0264-410X(23)01302-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  744. HERZIG VAN WEES S, Stalgren M, Viberg N, Puranen B, et al
    "Who is Anders Tegnell?" Unanswered questions hamper COVID-19 vaccine uptake: A qualitative study among ethnic minorities in Sweden.
    Vaccine. 2023 Nov 10:S0264-410X(23)01328-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  745. BRUXVOORT KJ, Sy LS, Hong V, Lewin B, et al
    Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system.
    Vaccine. 2023 Nov 10:S0264-410X(23)01324-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  746. DUDLEY MZ, Schwartz B, Brewer J, Kan L, et al
    COVID-19 vaccination attitudes, values, intentions: US parents for their children, September 2021.
    Vaccine. 2023 Nov 9:S0264-410X(23)01295-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  747. ANDERSON EC, Blair PS, Finn A, Ingram J, et al
    Maternal vaccination provision in NHS maternity trusts across England.
    Vaccine. 2023 Nov 9:S0264-410X(23)01284-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  748. YANG C, Zheng Z, Zheng P, Chen J, et al
    Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for both pregnant women and neonates.
    Vaccine. 2023 Nov 8:S0264-410X(23)01322-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  749. INOUE Y, Li Y, Yamamoto S, Fukunaga A, et al
    The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study.
    Vaccine. 2023 Nov 7:S0264-410X(23)01220-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  750. SPACKMAN E, Suarez DL, Lee CW, Pantin-Jackwood MJ, et al
    Efficacy of inactivated and RNA particle vaccines against a North American Clade 2.3.4.4b H5 highly pathogenic avian influenza virus in chickens.
    Vaccine. 2023 Nov 4:S0264-410X(23)01285-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  751. HANSEN LG, Larsen LE, Rasmussen TB, Miar Y, et al
    Investigation of the SARS-CoV-2 post-vaccination antibody response in Canadian farmed mink.
    Vaccine. 2023 Nov 4:S0264-410X(23)01288-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  752. JONES G, Perry M, Bailey R, Arumugam S, et al
    Dimensions of equality in uptake of COVID-19 vaccination in Wales, UK: A multivariable linked data population analysis.
    Vaccine. 2023 Nov 4:S0264-410X(23)01279-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  753. AKHTAR Z, Gotberg M, Erlinge D, Christiansen EH, et al
    Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial.
    Vaccine. 2023 Nov 2:S0264-410X(23)01211-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  754. CHEN GL, Yu XY, Luo LP, Zhang F, et al
    Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
    Vaccine. 2023 Nov 2:S0264-410X(23)01278-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  755. BOLOTIN S, Osman S, Halperin S, Severini A, et al
    Immunity of Canadians and risk of epidemics workshop - Conference report.
    Vaccine. 2023;41:6775-6781.
    PubMed     Abstract available


  756. DO LAH, Le NTN, Mahmud S, Mulholland K, et al
    Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
    Vaccine. 2023;41:6782-6790.
    PubMed     Abstract available


  757. ALIZADEH M, Raj S, Shojadoost B, Matsuyama-Kato A, et al
    In ovo administration of retinoic acid enhances cell-mediated immune responses against an inactivated H9N2 avian influenza virus vaccine.
    Vaccine. 2023 Nov 1:S0264-410X(23)01261-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  758. JAMES WG, Stanberry LR, LaRussa PS, Grodman MD, et al
    Vaccines and global health: COVID-19 vaccine development, strategy, and implementation symposium - Summary of the meeting at Vagelos College of Physicians and Surgeons (February 22-26, 2021, New York).
    Vaccine. 2023 Nov 1:S0264-410X(23)01254-9. doi: 10.1016/j.vaccine.2023.
    PubMed    


    October 2023
  759. RAMSAY JA, Jones M, Vande More AM, Hunt SL, et al
    A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study).
    Vaccine. 2023 Oct 28:S0264-410X(23)01250-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  760. SALLOUM M, Paviotti A, Bastiaens H, Van Geertruyden JP, et al
    The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023.
    Vaccine. 2023 Oct 28:S0264-410X(23)01259-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  761. LIU Y, Sanchez-Ovando S, Carolan L, Dowson L, et al
    Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines.
    Vaccine. 2023 Oct 28:S0264-410X(23)01217-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  762. NYAMBAYO PPM, Gold MS, Mehta UC, Clarke S, et al
    Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
    Vaccine. 2023;41:6700-6709.
    PubMed     Abstract available


  763. TANI N, Ikematsu H, Goto T, Kondo S, et al
    Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers.
    Vaccine. 2023;41:6672-6678.
    PubMed     Abstract available


  764. WALLIAR T, Khan B, Newstead S, Al-Assadi G, et al
    "Fighting the pandemic!" Western Australian pharmacists' perspectives on COVID-19 vaccines: A qualitative study.
    Vaccine. 2023 Oct 25:S0264-410X(23)01243-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  765. ANASTASSOPOULOU C, Boufidou F, Hatziantoniou S, Vasileiou K, et al
    Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01214-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  766. CENAT JM, Moshirian Farahi SMM, Broussard C, Dalexis RD, et al
    The state of COVID-19 vaccine confidence and need in Black individuals in Canada: Understanding the role of sociodemographic factors, health literacy, conspiracy theories, traumatic stressors and racial discrimination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01246-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  767. KITIKOON P, Knetter SM, Mogler MA, Morgan CL, et al
    Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01175-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  768. FLOR N, Garcia MI, Molineri A, Bottasso O, et al
    Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01221-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  769. BRESEE J, Koh M, Chadwick C, Jit M, et al
    The need and ongoing efforts to understand the full value of improved influenza vaccines.
    Vaccine. 2023 Oct 21:S0264-410X(23)01245-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  770. WANGCHUK S, Prabhakaran AO, Dhakal GP, Zangmo C, et al
    Introducing seasonal influenza vaccine in Bhutan: Country experience and achievements.
    Vaccine. 2023 Oct 20:S0264-410X(23)01255-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  771. IRVING SA, Groom HC, Belongia EA, Crane B, et al
    Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons.
    Vaccine. 2023 Oct 20:S0264-410X(23)01206-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  772. TUNIS M, Deeks S, Harrison R, Quach C, et al
    Canada's National Advisory Committee on immunization: Adaptations and challenges during the COVID-19 pandemic.
    Vaccine. 2023;41:6538-6547.
    PubMed     Abstract available


  773. MORI Y, Uchida N, Wake A, Miyawaki K, et al
    Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
    Vaccine. 2023 Oct 20:S0264-410X(23)01022-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  774. HART R, Feygin Y, Kluthe T, Quinn KG, et al
    Emergency departments: An underutilized resource to address pediatric influenza vaccine coverage.
    Vaccine. 2023 Oct 19:S0264-410X(23)01222-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  775. MCCLYMONT E, Atkinson A, Albert A, Av-Gay G, et al
    Reactogenicity, pregnancy outcomes, and SARS-CoV-2 infection following COVID-19 vaccination during pregnancy in Canada: A national prospective cohort study.
    Vaccine. 2023 Oct 19:S0264-410X(23)01215-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  776. HONDA-OKUBO Y, Bowen R, Barker M, Bielefeldt-Ohmann H, et al
    Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.
    Vaccine. 2023 Oct 18:S0264-410X(23)01190-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  777. RIEFOLO F, Castillo-Cano B, Martin-Perez M, Messina D, et al
    Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.
    Vaccine. 2023 Oct 17:S0264-410X(23)01181-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  778. HAEDER SF
    U.S. public support and opposition to vaccination mandates in K-12 education in light of the COVID-19 pandemic.
    Vaccine. 2023 Oct 17:S0264-410X(23)01188-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  779. YANG H, Wang Z, Zhang Y, Xu M, et al
    Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 Omicron subvariant BF.7 among outpatients in Beijing, China.
    Vaccine. 2023 Oct 17:S0264-410X(23)01219-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  780. PLATENBURG PPLI, Deschamps F, Jung J, Leonard C, et al
    Carbohydrate fatty acid monosulphate ester is a potent adjuvant for low-dose seasonal influenza vaccines.
    Vaccine. 2023 Oct 16:S0264-410X(23)01189-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  781. LOPEZ-GOMEZ A, Pelaez-Prestel HF, Juarez I
    Approaches to evaluate the specific immune responses to SARS-CoV-2.
    Vaccine. 2023;41:6434-6443.
    PubMed     Abstract available


  782. MOSCA S, Lin Q, Stokes R, Bharucha T, et al
    Innovative method for rapid detection of falsified COVID-19 vaccines through unopened vials using handheld Spatially Offset Raman Spectroscopy (SORS).
    Vaccine. 2023 Oct 13:S0264-410X(23)01182-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  783. ARASHIRO T, Arima Y, Kuramochi J, Muraoka H, et al
    Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan.
    Vaccine. 2023 Oct 13:S0264-410X(23)01194-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  784. PARK H, Jang MS, Choi JA, Kim W, et al
    Nonclinical safety assessment and immunogenicity of rVSVInd(GML)-mspSGtc vaccine for SARS-CoV-2 in rabbits.
    Vaccine. 2023 Oct 9:S0264-410X(23)01178-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  785. MO C, Li X, Wu Q, Fan Y, et al
    SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses.
    Vaccine. 2023 Oct 9:S0264-410X(23)01156-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  786. SATHE N, Shaikh S, Bhavsar M, Parte L, et al
    Safety, immunogenicity and efficacy of Relcovax(R), a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
    Vaccine. 2023 Oct 8:S0264-410X(23)01176-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  787. LOPEZ-ZAMBRANO MA, Pita CC, Escribano MF, Galan Melendez IM, et al
    Factors associated to influenza vaccination among hospital's healthcare workers in the Autonomous Community of Madrid, Spain 2021-2022.
    Vaccine. 2023 Oct 6:S0264-410X(23)01117-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  788. PROCTER TD, Ogasawara H, Spruin S, Wijayasri S, et al
    Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector COVID-19 vaccination in Canada.
    Vaccine. 2023 Oct 6:S0264-410X(23)01159-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  789. OZAWA S, Schuh HB, Nakamura T, Yemeke TT, et al
    How to increase and maintain high immunization coverage: Vaccination Demand Resilience (VDR) framework.
    Vaccine. 2023 Oct 3:S0264-410X(23)01097-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  790. ZACHRESON C, Tobin R, Szanyi J, Walker C, et al
    Individual variation in vaccine immune response can produce bimodal distributions of protection.
    Vaccine. 2023 Oct 2:S0264-410X(23)01095-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    September 2023
  791. OKOLI GN, Righolt CH, Zhang G, Alessi-Severini S, et al
    Impact of the universal seasonal influenza vaccination policy in the province of Manitoba, Canada: A population-based, province-wide record-linkage study.
    Vaccine. 2023 Sep 29:S0264-410X(23)01133-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  792. DIONNE M, Sauvageau C, Kiely M, Rathwell M, et al
    "The problem is not lack of information": A qualitative study of parents and school nurses' perceptions of barriers and potential solutions for HPV vaccination in schools.
    Vaccine. 2023 Sep 28:S0264-410X(23)01140-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  793. HARBOE ZB, Hald A, Ekenberg C, Ete Wareham N, et al
    Implementation of a vaccination clinic for adult solid organ transplant candidates: A single-center experience.
    Vaccine. 2023 Sep 27:S0264-410X(23)01106-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  794. LAVELL AHA, Schramade AE, Sikkens JJ, van der Straten K, et al
    25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune response following SARS-CoV-2 mRNA vaccinations.
    Vaccine. 2023 Sep 27:S0264-410X(23)00957-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  795. SHEN X, Hao Y, Wang S, Li D, et al
    Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
    Vaccine. 2023 Sep 26:S0264-410X(23)01100-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  796. CASSARINO N, Ahnger-Pier KK, Wurcel A
    Trends in COVID-19 and influenza vaccine ordering and distribution in Massachusetts jails.
    Vaccine. 2023 Sep 25:S0264-410X(23)01115-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  797. SANA S, Merkelbach I, Magnee T, Kollmann J, et al
    Identifying barriers to vaccination intention at walk-in vaccination facilities in deprived neighbourhoods: A cross-sectional survey.
    Vaccine. 2023 Sep 25:S0264-410X(23)01038-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  798. GOLOVKINA MI, Ertz SC, Lechnir SS, Hayney MS, et al
    Providing influenza vaccines at endoscopy visits increases influenza vaccine uptake.
    Vaccine. 2023 Sep 23:S0264-410X(23)01108-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  799. RAISER F, Davis M, Adelglass J, Cai MR, et al
    Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
    Vaccine. 2023;41:5965-5973.
    PubMed     Abstract available


  800. HAO F, Shao W
    Social network, political climate, income inequality, and Americans uptake of monovalent COVID-19 booster.
    Vaccine. 2023;41:6077-6082.
    PubMed     Abstract available


  801. NGAMCHALIEW P, Kaewkuea N, Nonthasorn N, Vonnasrichan T, et al
    Acceptance of COVID-19 vaccination and vaccine confidence levels in Thailand: A cross-sectional study.
    Vaccine. 2023 Sep 22:S0264-410X(23)01088-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  802. HOMAIRA N, He WQ, McRae J, Macartney K, et al
    Coverage and predictors of influenza and pertussis vaccination during pregnancy: a whole of population-based study.
    Vaccine. 2023 Sep 21:S0264-410X(23)01062-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  803. FU Y, Wu K, Wang Z, Yang H, et al
    Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.
    Vaccine. 2023 Sep 21:S0264-410X(23)01025-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  804. WILKINSON B, Patel KS, Smith K, Walker R, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 vir
    Vaccine. 2023 Sep 20:S0264-410X(23)00871-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  805. ALHARBI HS
    Review: Factors influencing parents' decisions to vaccinate children against COVID-19.
    Vaccine. 2023 Sep 19:S0264-410X(23)01090-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  806. HAN C, Zhao ZZ, Chan P, Li F, et al
    A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population.
    Vaccine. 2023 Sep 17:S0264-410X(23)01056-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  807. NELSON CB, Brady BL, Richards M, Lew CR, et al
    Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US).
    Vaccine. 2023;41:5820-5824.
    PubMed     Abstract available


  808. SHAVER N, Katz M, Darko Asamoah G, Linkins LA, et al
    Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness.
    Vaccine. 2023 Sep 15:S0264-410X(23)01065-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  809. IRALA S, Hamid S, Penayo E, Michel F, et al
    COVID-19 vaccine effectiveness against hospitalizations in Paraguay, May 2021-April 2022: A test-negative design.
    Vaccine. 2023 Sep 14:S0264-410X(23)01069-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  810. SURYAWANSHI YR
    An overview of protein-based SARS-CoV-2 vaccines.
    Vaccine. 2023 Sep 10:S0264-410X(23)01067-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  811. POTT H, Andrew MK, Shaffelburg Z, Nichols MK, et al
    Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canad
    Vaccine. 2023 Sep 9:S0264-410X(23)01026-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  812. YU J, Sreenivasan C, Sheng Z, Zhai SL, et al
    A recombinant chimeric influenza virus vaccine expressing the consensus H3 hemagglutinin elicits broad hemagglutination inhibition antibodies against divergent swine H3N2 influenza viruses.
    Vaccine. 2023 Sep 7:S0264-410X(23)01060-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  813. MONTEIRO HS, Lima Neto AS, Kahn R, Sousa GS, et al
    Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study.
    Vaccine. 2023;41:5742-5751.
    PubMed     Abstract available


  814. PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
    Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
    Vaccine. 2023 Sep 5:S0264-410X(23)01028-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  815. YUE PHR, Lau HPB, Ng SM, Chan LWC, et al
    When to be vaccinated? What to consider? Modelling decision-making and time preference for COVID-19 vaccine through a conjoint experiment.
    Vaccine. 2023 Sep 5:S0264-410X(23)01024-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  816. PHILLIPS A, Jiang Y, Walsh D, Andrews N, et al
    Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis.
    Vaccine. 2023 Sep 5:S0264-410X(23)01045-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  817. ALSAIF F, Twigg M, Scott S, Blyth A, et al
    A systematic review of barriers and enablers associated with uptake of influenza vaccine among care home staff.
    Vaccine. 2023 Sep 4:S0264-410X(23)01048-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  818. CLAESSENS T, Krouwer S, Vandebosch H, Poels K, et al
    Pathways to informed choices: The impact of freedom of choice and two-sided messages on psychological reactance and vaccination intentions among individuals who express concerns.
    Vaccine. 2023 Sep 3:S0264-410X(23)00948-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  819. WILLIS DE, Moore R, Andersen JA, Li J, et al
    Correlates of COVID-19 vaccine coverage in Arkansas: Results from a weighted random sample survey.
    Vaccine. 2023 Sep 1:S0264-410X(23)01039-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  820. PORRAS-RAMIREZ A, Sanchez-Paris R, Lopez-Devia W, Moreno-Perilla Z, et al
    Confirmed cases of COVID-19 after vaccination against COVID in health personnel in Bogota, Colombia.
    Vaccine. 2023 Sep 1:S0264-410X(23)00924-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    August 2023
  821. SAKALA IG, Honda-Okubo Y, Petrovsky N
    Developmental and reproductive safety of Advax-CpG55.2 adjuvanted COVID-19 and influenza vaccines in mice.
    Vaccine. 2023 Aug 31:S0264-410X(23)01007-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  822. GRILLS LA, Wagner AL
    The impact of the COVID-19 pandemic on parental vaccine hesitancy: A cross-sectional survey.
    Vaccine. 2023 Aug 31:S0264-410X(23)00977-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  823. DUDLEY HM, O'Mara M, Auma A, Gong J, et al
    Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine.
    Vaccine. 2023 Aug 31:S0264-410X(23)00965-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  824. REGAN AK, Fell DB, Wise LA, Vazquez-Benitez G, et al
    Challenges & opportunities for the epidemiological evaluation of the effects of COVID-19 vaccination on reproduction and pregnancy.
    Vaccine. 2023 Aug 31:S0264-410X(23)00964-7. doi: 10.1016/j.vaccine.2023.
    PubMed    


  825. PHIRIYASART F, Aimyong N, Jirapongsuwan A, Roseh N, et al
    COVID-19 vaccine hesitancy among older adult Thai Muslim people: A case-control study.
    Vaccine. 2023 Aug 27:S0264-410X(23)00994-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  826. YANG J, Li B, Yang D, Wu J, et al
    The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
    Vaccine. 2023 Aug 26:S0264-410X(23)01017-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  827. JANSSEN ERC, van Montfoort AZ, Hollman F, Lambers Heerspink FO, et al
    The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers.
    Vaccine. 2023 Aug 25:S0264-410X(23)00975-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  828. CHIBA S, Halfmann PJ, Iida S, Hirata Y, et al
    Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
    Vaccine. 2023 Aug 25:S0264-410X(23)01008-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  829. CHEN IR, Wang GJ, Hsueh PR, Chou CH, et al
    Immune responses and safety of COVID-19 vaccination in atypical hemolytic uremic syndrome patients in Taiwan.
    Vaccine. 2023 Aug 25:S0264-410X(23)00952-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  830. WATERLOW NR, Procter SR, van Leeuwen E, Radhakrishnan S, et al
    The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis.
    Vaccine. 2023 Aug 24:S0264-410X(23)00963-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  831. MOHAMMED IS, Widome R, Searle KM
    COVID-19 vaccine decision-making among Black women: A qualitative study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00920-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  832. DENG L, Tapper K, Thosar D, Goeman E, et al
    Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination: An Australian retrospective cohort study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00956-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  833. GOULD S, Wrzesinski C, Stebbings R, Segal L, et al
    Report from an ICT 2022 workshop on toxicology for Covid19 vaccines: Industry, regulatory and CRO perspectives.
    Vaccine. 2023 Aug 24:S0264-410X(23)00972-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  834. STRUYF F, Hardt K, Van Rampelbergh R, Shukarev G, et al
    Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.
    Vaccine. 2023;41:5351-5359.
    PubMed     Abstract available


  835. KUMRU OS, Sanyal M, Friedland N, Hickey JM, et al
    Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.
    Vaccine. 2023 Aug 22:S0264-410X(23)00969-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  836. SU Y, Guo Z, Gu X, Sun S, et al
    Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China.
    Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  837. YAO T, Guo Y, Xu X, Zhang X, et al
    Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population.
    Vaccine. 2023 Aug 19:S0264-410X(23)00974-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  838. KENIGSBERG TA, Goddard K, Hanson KE, Lewis N, et al
    Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines.
    Vaccine. 2023 Aug 18:S0264-410X(23)00955-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  839. CHAIWONG W, Takheaw N, Pata S, Laopajon W, et al
    Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease.
    Vaccine. 2023 Aug 18:S0264-410X(23)00966-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  840. PALACHE A, Billingsley JK, MacLaren K, Morgan L, et al
    Lessons learned from the COVID-19 pandemic for improved influenza control.
    Vaccine. 2023 Aug 17:S0264-410X(23)00960-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  841. MORRISON K, Cullen L, James AB, Chua V, et al
    Predictors of incomplete COVID-19 vaccine schedule among adults in Scotland: Two retrospective cohort analyses of the primary schedule and third dose.
    Vaccine. 2023 Aug 17:S0264-410X(23)00916-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  842. ZUR M, Shelef L, Glassberg E, Fink N, et al
    Are intelligent people more likely to get vaccinated? The association between COVID-19 vaccine adherence and cognitive profiles.
    Vaccine. 2023 Aug 15:S0264-410X(23)00951-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  843. SARNA M, Gebremedhin A, Richmond P, Levy A, et al
    Determining the true incidence of seasonal respiratory syncytial virus-confirmed hospitalizations in preterm and term infants in Western Australia.
    Vaccine. 2023;41:5216-5220.
    PubMed     Abstract available


  844. TOYAMA K, Eto T, Takazawa K, Shimizu S, et al
    DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
    Vaccine. 2023 Aug 14:S0264-410X(23)00824-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  845. WITTAWATMONGKOL O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, et al
    Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
    Vaccine. 2023 Aug 14:S0264-410X(23)00953-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  846. BERTHELEMY C, Bouche P, Lamiral Z, Boivin JM, et al
    Parental acceptability of vaccinating young children against influenza and COVID-19.
    Vaccine. 2023 Aug 12:S0264-410X(23)00929-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  847. HONDA-OKUBO Y, Bart Tarbet E, Hurst BL, Petrovsky N, et al
    An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection.
    Vaccine. 2023 Aug 9:S0264-410X(23)00941-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  848. BAGLIVO F, Magri M, De Angelis L, Aprile V, et al
    Performance comparison between heterologous and homologous COVID19 vaccine schedules on Omicron variant incidence: A real-world retrospective cohort study in Southern Italy.
    Vaccine. 2023 Aug 9:S0264-410X(23)00886-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  849. MAC S, Shi S, Millson B, Tehrani A, et al
    Burden of illness associated with Respiratory Syncytial Virus (RSV)-related hospitalizations among adults in Ontario, Canada: A retrospective population-based study.
    Vaccine. 2023;41:5141-5149.
    PubMed     Abstract available


  850. CHICOYE A, Crepey P, Nguyen VH, Marquez-Pelaez S, et al
    Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe.
    Vaccine. 2023 Aug 5:S0264-410X(23)00919-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  851. SIMMS AJ, King KD, Tsui N, Edwards SA, et al
    COVID-19 vaccine behaviour among citizens of the Metis Nation of Ontario: A qualitative study.
    Vaccine. 2023 Aug 5:S0264-410X(23)00891-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  852. VERJOVSKY M, Barreto MP, Carmo I, Coutinho B, et al
    Political quarrel overshadows vaccination advocacy: How the vaccine debate on Brazilian Twitter was framed by anti-vaxxers during Bolsonaro administration.
    Vaccine. 2023 Aug 5:S0264-410X(23)00921-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  853. CAMPBELL J, Kaur A, Gamino D, Benoit E, et al
    Individual and structural determinants of COVID-19 vaccine uptake in a marginalized community in the United States.
    Vaccine. 2023 Aug 5:S0264-410X(23)00923-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  854. MOSCARA L, Venerito V, Martinelli A, Di Lorenzo A, et al
    Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00874-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  855. XU S, Yu H, Cheng X, Wu J, et al
    Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves' disease: An observational cohort study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00884-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  856. AUVIGNE V, Tamandjou Tchuem CR, Schaeffer J, Vaux S, et al
    Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France.
    Vaccine. 2023 Aug 2:S0264-410X(23)00917-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  857. MO J, Spackman E, Swayne DE
    Prediction of highly pathogenic avian influenza vaccine efficacy in chickens by comparison of in vitro and in vivo data: A meta-analysis and systematic review.
    Vaccine. 2023 Aug 1:S0264-410X(23)00922-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    July 2023
  858. HONDA-OKUBO Y, Sakala IG, Andre G, Tarbet EB, et al
    An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice.
    Vaccine. 2023 Jul 31:S0264-410X(23)00892-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  859. WALLACE M, Rosenblum HG, Moulia DL, Broder KR, et al
    A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States.
    Vaccine. 2023 Jul 30:S0264-410X(23)00868-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  860. LIU B, Stepien S, Qian J, Gidding H, et al
    Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection.
    Vaccine. 2023 Jul 29:S0264-410X(23)00881-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  861. AMANI A, Njoh AA, Atuhebwe P, Ndoula S, et al
    Beyond the numbers: An in-depth look at Cameroon's fifth national COVID-19 vaccination campaign through geographical and gender lenses.
    Vaccine. 2023 Jul 29:S0264-410X(23)00905-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  862. GREEN-MCKENZIE J, Shofer FS, Kruse G, Momplaisir F, et al
    COVID-19 vaccine uptake before and after a vaccine mandate at a major academic hospital: Trends by race/ethnicity and level of patient contact.
    Vaccine. 2023 Jul 28:S0264-410X(23)00853-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  863. LAVENDER B, Hooker C, Frampton C, Williams M, et al
    Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naive New Zealand cohort.
    Vaccine. 2023 Jul 27:S0264-410X(23)00882-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  864. ROSA RG, Falavigna M, Manfio JL, de Araujo CLP, et al
    BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study.
    Vaccine. 2023 Jul 26:S0264-410X(23)00869-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  865. KIM DH, Lee J, Youk S, Jeong JH, et al
    Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection.
    Vaccine. 2023;41:4787-4797.
    PubMed     Abstract available


  866. TAMADA Y, Takeuchi K, Kusama T, Maeda M, et al
    Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative study from the VENUS study.
    Vaccine. 2023 Jul 22:S0264-410X(23)00856-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  867. GHAZY RM, Ibrahim SA, Taha SHN, Elshabrawy A, et al
    Attitudes of parents towards influenza vaccine in the Eastern Mediterranean Region: A multilevel analysis.
    Vaccine. 2023 Jul 20:S0264-410X(23)00808-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  868. ARAUJO-CHAVERON L, Sicsic J, Moffroid H, Diaz Luevano C, et al
    Impact of a COVID-19 certificate requirement on vaccine uptake pattern and intention for future vaccination. A cross-sectional study among French adults.
    Vaccine. 2023 Jul 20:S0264-410X(23)00805-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  869. KIM YA, Mousavi K, Yazdi A, Zwierzyna M, et al
    Computational design of mRNA vaccines.
    Vaccine. 2023 Jul 20:S0264-410X(23)00836-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  870. KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al
    Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.
    Vaccine. 2023 Jul 19:S0264-410X(23)00823-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  871. PISL V, Vevera J
    COVID-19 vaccine uptake in mental healthcare users: Czech nationwide register study.
    Vaccine. 2023 Jul 19:S0264-410X(23)00840-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  872. ZIMMERMAN RK, Patricia Nowalk M, Dauer K, Clarke L, et al
    Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design.
    Vaccine. 2023 Jul 18:S0264-410X(23)00741-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  873. SABAT I, Neumann-Bohme S, Barros PP, Torbica A, et al
    Vaccine hesitancy comes in waves: Longitudinal evidence on willingness to vaccinate against COVID-19 from seven European countries.
    Vaccine. 2023 Jul 15:S0264-410X(23)00829-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  874. MOROS A, Prenafeta A, Barreiro A, Perozo E, et al
    Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.
    Vaccine. 2023 Jul 15:S0264-410X(23)00820-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  875. CLOUSTON SAP, Hanes DW, Link BG
    Social inequalities and the early provision and dispersal of COVID-19 vaccinations in the United States: A population trends study.
    Vaccine. 2023 Jul 15:S0264-410X(23)00833-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  876. TALOTTA R
    COVID-19 mRNA vaccines as hypothetical epigenetic players: Results from an in silico analysis, considerations and perspectives.
    Vaccine. 2023 Jul 13:S0264-410X(23)00819-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  877. ALABANZA C, Gavrilov V, Scott T, Yang RS, et al
    Quantitation of strain-specific hemagglutinin trimers in mosaic quadrivalent influenza nanoparticle vaccine by ELISA.
    Vaccine. 2023 Jul 12:S0264-410X(23)00821-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  878. BEYERS KCL, Rbeihat MNM, S Vasconcelos D, Pasmans D, et al
    Preclinical evaluation of performance, safety and usability of VAX-ID(R), a novel intradermal injection device.
    Vaccine. 2023;41:4609-4615.
    PubMed     Abstract available


  879. AGRAWAL P, Damania D, Cseh A, Grab J, et al
    Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Vaccine. 2023 Jul 12:S0264-410X(23)00822-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  880. MINCHIN J, Harris GH, Baumann S, Smith ER, et al
    Exclusion of pregnant people from emergency vaccine clinical trials: A systematic review of clinical trial protocols and reporting from 2009 to 2019.
    Vaccine. 2023 Jul 11:S0264-410X(23)00776-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  881. WILLIS DE, Reece S, Gurel-Headley M, Selig JP, et al
    Social processes, practical issues, and COVID-19 vaccination among hesitant adults.
    Vaccine. 2023 Jul 7:S0264-410X(23)00809-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  882. FLEMING JA, Baral R, Higgins D, Khan S, et al
    Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
    Vaccine. 2023 Jul 6:S0264-410X(22)01212-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  883. ZHANG X, Shen P, Liu J, Ji X, et al
    Evaluating the effectiveness and cost-effectiveness of free influenza vaccination policy for older adults in Yinzhou, China: Study protocol of a real-world analyses.
    Vaccine. 2023 Jul 5:S0264-410X(23)00790-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  884. WAGNER A, Juvalta S, Speranza C, Suggs LS, et al
    Let's talk about COVID-19 vaccination: Relevance of conversations about COVID-19 vaccination and information sources on vaccination intention in Switzerland.
    Vaccine. 2023 Jul 5:S0264-410X(23)00807-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  885. LE H, de Klerk N, Blyth CC, Gidding H, et al
    Non-specific benefit of seasonal influenza vaccine on respiratory syncytial virus-hospitalisations in children: An instrumental variable approach using population-based data.
    Vaccine. 2023 Jul 3:S0264-410X(23)00788-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  886. PATEL UC, Schultz T, Schmidt J
    Veteran influenza vaccination acceptance rates after completion of the COVID-19 vaccination series among historical influenza vaccine refusers.
    Vaccine. 2023 Jul 3:S0264-410X(23)00803-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  887. ROSHCHINA Y, Rozhkova K, Roshchin S
    Between nudges and mandates: The drivers of COVID-19 vaccination intentions and subsequent uptake in Russia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00756-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  888. TUCKERMAN J, Kaufman J, Overmars I, Holland P, et al
    Barriers to COVID-19 vaccination of migrant populations: A qualitative interview study of immunisation providers in Victoria, Australia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00804-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  889. TROGSTAD L, Laake I, Robertson AH, Mjaaland S, et al
    Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination.
    Vaccine. 2023 Jul 3:S0264-410X(23)00801-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    June 2023
  890. LIU Z, Pang C, Deng Y, Guo C, et al
    Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults.
    Vaccine. 2023 Jun 30:S0264-410X(23)00616-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  891. SHINJOH M, Furuichi M, Tsuzuki S, Iqbal A, et al
    Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized children in 2022/23 season in Japan - The first season of co-circulation of influenza and COVID-19.
    Vaccine. 2023 Jun 30:S0264-410X(23)00785-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  892. LIU Y, Zhang A, Wang Y, Yang J, et al
    Immunogenicity and protective effects of recombinant bivalent COVID-19 vaccine in mice and rhesus macaques.
    Vaccine. 2023 Jun 30:S0264-410X(23)00789-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  893. KU JH, Sy LS, Qian L, Ackerson BK, et al
    Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study.
    Vaccine. 2023;41:4212-4219.
    PubMed     Abstract available


  894. VAN DER BOOR SC, Schmitz-de Vries ETJ, Smits D, Scholl JHG, et al
    Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
    Vaccine. 2023;41:4319-4326.
    PubMed     Abstract available


  895. ALVES K, Plested JS, Galbiati S, Chau G, et al
    Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
    Vaccine. 2023;41:4280-4286.
    PubMed     Abstract available


  896. ISHIKAWA K, Nascimento MC, Asano M, Hirata H, et al
    One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.
    Vaccine. 2023;41:4199-4205.
    PubMed     Abstract available


  897. LEE KS, Rader NA, Miller-Stump OA, Cooper M, et al
    Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Vaccine. 2023 Jun 28:S0264-410X(23)00783-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  898. SHENG Y, Li Z, Lin X, Ma Y, et al
    The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
    Vaccine. 2023 Jun 28:S0264-410X(23)00759-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  899. DOMNICH A, Orsi A, Ogliastro M, Trombetta CS, et al
    Influenza vaccine effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season.
    Vaccine. 2023 Jun 27:S0264-410X(23)00775-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  900. KIM S, Ko M, Heo Y, Lee YK, et al
    Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
    Vaccine. 2023 Jun 27:S0264-410X(23)00780-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  901. BARRIENTOS M, Vasquez-Lavin F, Rosales C, Bratti L, et al
    Understanding the role of personal experiences and contextual variables in shaping risk reduction preferences.
    Vaccine. 2023;41:4092-4105.
    PubMed     Abstract available


  902. TORP HANSEN K, Kusk Povlsen F, Hammer Bech B, Nygaard Hansen S, et al
    Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens.
    Vaccine. 2023 Jun 23:S0264-410X(23)00758-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  903. TURLEY CB, Tables L, Fuller T, Sanders LJ, et al
    Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
    Vaccine. 2023 Jun 23:S0264-410X(23)00755-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  904. SALEH SN, McDonald SA, Basit MA, Kumar S, et al
    Public perception of COVID-19 vaccines through analysis of Twitter content and users.
    Vaccine. 2023 Jun 23:S0264-410X(23)00743-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  905. HOWARD MC
    Integrating the person-centered approach with the study of vaccine hesitancy: Applying latent profile analysis to identify vaccine hesitancy subpopulations and assess their relations with correlates and vaccination outcomes.
    Vaccine. 2023 Jun 23:S0264-410X(23)00742-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  906. CHAUDHARY A, Madhavan R, Babji S, Raju R, et al
    Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
    Vaccine. 2023 Jun 23:S0264-410X(23)00744-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  907. AUGUSTYNIAK A, Szymanski T, Porzucek F, Mieloch AA, et al
    A cohort study reveals different dynamics of SARS-CoV-2-specific antibody formation after Comirnaty and Vaxzevria vaccination.
    Vaccine. 2023 Jun 21:S0264-410X(23)00665-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  908. LUANGASANATIP N, Painter C, Pan-Ngum W, Saralamba S, et al
    How to model the impact of vaccines for policymaking when the characteristics are uncertain: A case study in Thailand prior to the vaccine rollout during the COVID-19 pandemic.
    Vaccine. 2023 Jun 20:S0264-410X(23)00740-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  909. CHEN X, Lin Y, Yue S, Yang Y, et al
    PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness.
    Vaccine. 2023 Jun 20:S0264-410X(23)00737-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  910. EKIMOV A, Arunachalam AB, Blake T, Bodle J, et al
    Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine.
    Vaccine. 2023 Jun 19:S0264-410X(23)00726-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  911. HONDA-OKUBO Y, Li L, Andre G, Leong KH, et al
    An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
    Vaccine. 2023 Jun 19:S0264-410X(23)00748-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  912. UDA K, Okubo Y, Tsuge M, Tsukahara H, et al
    Impacts of routine varicella vaccination program and COVID-19 pandemic on varicella and herpes zoster incidence and health resource use among children in Japan.
    Vaccine. 2023 Jun 19:S0264-410X(23)00739-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  913. TZENG R, Huang FY, Lee J
    Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation.
    Vaccine. 2023 Jun 19:S0264-410X(23)00745-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  914. MASOUD D, Pierz A, Rauh L, Cruz AK, et al
    Vaccine Trust Gauge: Mixed methods research to measure and understand vaccine trust.
    Vaccine. 2023 Jun 17:S0264-410X(23)00690-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  915. DOYON-PLOURDE P, Przepiorkowski J, Young K, Zhao L, et al
    Intraseasonal waning immunity of seasonal influenza vaccine - A systematic review and meta-analysis.
    Vaccine. 2023 Jun 16:S0264-410X(23)00713-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  916. DUNN DT, Gilson R, McCormack S, McCoy LE, et al
    Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trials.
    Vaccine. 2023 Jun 16:S0264-410X(23)00712-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  917. BISWAS RK, Afiaz A, Huq S, Farzana M, et al
    Public opinion on COVID-19 vaccine prioritization in Bangladesh: Who gets the vaccine and whom do you leave out?
    Vaccine. 2023 Jun 16:S0264-410X(23)00725-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  918. NISHIYAMA A, Adachi Y, Tonouchi K, Moriyama S, et al
    Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
    Vaccine. 2023 Jun 15:S0264-410X(23)00685-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  919. PIGNATTI P, Ramirez GA, Russo M, Marraccini P, et al
    Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients.
    Vaccine. 2023 Jun 15:S0264-410X(23)00714-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  920. MUANGNOICHAROEN S, Wiangcharoen R, Nanthapisal S, Kamolratakul S, et al
    Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Vaccine. 2023 Jun 15:S0264-410X(23)00718-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  921. KENIGSBERG TA, Hanson KE, Klein NP, Zerbo O, et al
    Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink.
    Vaccine. 2023 Jun 15:S0264-410X(23)00717-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  922. PUTHANAKIT T, Chokephaibulkit K, Chaithongwongwatthana S, Bhat N, et al
    A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.
    Vaccine. 2023 Jun 15:S0264-410X(23)00657-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  923. SHOAIBI A, Lloyd PC, Wong HL, Clarke TC, et al
    Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
    Vaccine. 2023 Jun 14:S0264-410X(23)00682-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  924. CIEMINS EL, Gillen A, Tallam M
    RSV: A vaccine is coming, time to educate providers.
    Vaccine. 2023 Jun 14:S0264-410X(23)00695-3. doi: 10.1016/j.vaccine.2023.
    PubMed    


  925. SAADATIAN-ELAHI M, Henaff L, Elias C, Nunes MC, et al
    Patient influenza vaccination reduces the risk of hospital-acquired influenza: An incident test negative-case control study in Lyon university hospital, France (2004-2020).
    Vaccine. 2023 Jun 13:S0264-410X(23)00621-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  926. SALMANTON-GARCIA J, Wipfler P, Valle-Simon P, Merakou C, et al
    VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe.
    Vaccine. 2023;41:3915-3922.
    PubMed     Abstract available


  927. WOO EJ, Gee J, Marquez P, Baggs J, et al
    Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
    Vaccine. 2023 Jun 13:S0264-410X(23)00687-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  928. MUNOZ FM, Posavad CM, Richardson BA, Badell ML, et al
    COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
    Vaccine. 2023 Jun 13:S0264-410X(23)00698-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  929. WATESKA AR, Nowalk MP, Lin CJ, Harrison LH, et al
    Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
    Vaccine. 2023 Jun 12:S0264-410X(23)00669-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  930. MA D, Tian S, Qin Q, Yu Y, et al
    Construction of an inhalable recombinant M2e-FP-expressing Bacillus subtilis spores-based vaccine and evaluation of its protection efficacy against influenza in a mouse model.
    Vaccine. 2023 Jun 10:S0264-410X(23)00655-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  931. MADRAN B, Kayi I, Beser A, Ergonul O, et al
    Uptake of COVID-19 vaccines among healthcare workers and the effect of nudging interventions: A mixed methods study.
    Vaccine. 2023 Jun 9:S0264-410X(23)00688-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  932. UI M, Hirama T, Akiba M, Honda M, et al
    Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
    Vaccine. 2023 Jun 9:S0264-410X(23)00663-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  933. MARTINEZ MR, Gao J, Wan H, Kang H, et al
    Inactivated influenza virions are a flexible vaccine platform for eliciting protective antibody responses against neuraminidase.
    Vaccine. 2023 Jun 8:S0264-410X(23)00629-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  934. NOGAREDA F, Gharpure R, Contreras M, Velandia M, et al
    Seasonal influenza vaccination in the Americas: Progress and challenges during the COVID-19 pandemic.
    Vaccine. 2023 Jun 8:S0264-410X(23)00689-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  935. DE GIER B, van Asten L, Boere TM, van Roon A, et al
    Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022.
    Vaccine. 2023 Jun 8:S0264-410X(23)00660-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  936. ROY A, Polazzi S, Ploin D, Gillet Y, et al
    The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs.
    Vaccine. 2023;41:3796-3800.
    PubMed     Abstract available


  937. SHAW RJ, Doyle AJ, Millen EA, Stowe J, et al
    Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria.
    Vaccine. 2023 Jun 7:S0264-410X(23)00662-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  938. KATO H, Hozawa T, Fukushima W, Nobusawa E, et al
    Influenza vaccine viruses and the development of seasonal vaccines: A Japanese perspective.
    Vaccine. 2023 Jun 6:S0264-410X(23)00640-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  939. KIM DELUCA E, Gebremariam A, Rose A, Biggerstaff M, et al
    Cost-effectiveness of routine annual influenza vaccination by age and risk status.
    Vaccine. 2023 Jun 6:S0264-410X(23)00495-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  940. KIM WJ, Roberts CC, Song JY, Yoon JG, et al
    Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
    Vaccine. 2023 Jun 6:S0264-410X(23)00683-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  941. PELLETIER C, Labbe F, Bettinger JA, Curran J, et al
    From high hopes to disenchantment: A qualitative analysis of editorial cartoons on COVID-19 vaccines in Canadian newspapers.
    Vaccine. 2023 Jun 6:S0264-410X(23)00658-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  942. ELDER E, Bangalore Revanna C, Johansson C, Wallin RPA, et al
    Protective immunity induced by an inhaled SARS-CoV-2 subunit vaccine.
    Vaccine. 2023 Jun 6:S0264-410X(23)00684-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  943. MAKANUT S, Wangteeraprasert A, Jitpewngam W, Ngoenkam J, et al
    Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
    Vaccine. 2023 Jun 5:S0264-410X(23)00666-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  944. WESSELINK AK, Lovett SM, Weinberg J, Geller RJ, et al
    COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study.
    Vaccine. 2023 Jun 5:S0264-410X(23)00681-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  945. KOZMA GT, Meszaros T, Berenyi P, Facsko R, et al
    Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG.
    Vaccine. 2023 Jun 5:S0264-410X(23)00667-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  946. ERGUN T, Hosgoren Tekin S, Apti Sengun O, Akin Cakici O, et al
    Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
    Vaccine. 2023 Jun 3:S0264-410X(23)00615-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  947. FEDDEMA JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM, et al
    Upscaling vaccine manufacturing capacity - Kkey bottlenecks and lessons learned.
    Vaccine. 2023 Jun 3:S0264-410X(23)00554-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    May 2023
  948. WANG LJ, Tsai CS, Chou WJ, Li CJ, et al
    Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study.
    Vaccine. 2023 May 29:S0264-410X(23)00628-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  949. ARROSPIDE A, Sagardui MG, Larizgoitia I, Iturralde A, et al
    Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort study.
    Vaccine. 2023 May 29:S0264-410X(23)00622-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  950. HU S, Xiong C, Zhao Y, Yuan X, et al
    Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant.
    Vaccine. 2023 May 29:S0264-410X(23)00617-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  951. MILLER ER, Moro PL, Shimabukuro TT, Carlock G, et al
    COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office.
    Vaccine. 2023 May 24:S0264-410X(23)00613-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  952. HORI D, Keneda Y, Ozaki A, Tabuchi T, et al
    Sexual orientation was associated with intention to be vaccinated with a smallpox vaccine against mpox: A cross-sectional preliminary survey in Japan.
    Vaccine. 2023 May 24:S0264-410X(23)00611-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  953. NUGENT C, Abul Y, White EM, Shehadeh F, et al
    Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers.
    Vaccine. 2023;41:3403-3409.
    PubMed     Abstract available


  954. JOUDEH AI, Lutf AQ, Mahdi S, Tran G, et al
    Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.
    Vaccine. 2023 May 22:S0264-410X(23)00609-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  955. ALICANDRO G, Orena BS, Rosazza C, Cariani L, et al
    Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis.
    Vaccine. 2023 May 22:S0264-410X(23)00590-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  956. GHAZNAVI C, Eguchi A, Suu Lwin K, Yoneoka D, et al
    Estimating global changes in routine childhood vaccination coverage during the COVID-19 pandemic, 2020-2021.
    Vaccine. 2023 May 22:S0264-410X(23)00583-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  957. GUO BQ, Li HB, Yang LQ
    Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12-17 years.
    Vaccine. 2023 May 22:S0264-410X(23)00610-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  958. BOLSEWICZ KT, Steffens MS, King C, Abdi I, et al
    A qualitative study on COVID-19 pandemic impacts on parental attitudes and intentions for routine adolescent vaccinations: The role of trust.
    Vaccine. 2023 May 22:S0264-410X(23)00586-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  959. EGER J, Kaplan LC, Sternberg H
    How to reduce vaccination hesitancy? The relevance of evidence and its communicator.
    Vaccine. 2023 May 22:S0264-410X(23)00298-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  960. EMBI PJ, Levy ME, Patel P, DeSilva MB, et al
    Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021.
    Vaccine. 2023 May 22:S0264-410X(23)00588-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  961. BOING AF, Boing AC, Barberia L, Borges ME, et al
    Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: A multilevel study of 2021-2022 data.
    Vaccine. 2023 May 17:S0264-410X(23)00569-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  962. ZHOU ZH, Cortese MM, Fang JL, Wood R, et al
    Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
    Vaccine. 2023 May 16:S0264-410X(23)00568-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  963. BLACK SB, Chandler RE, Edwards KM, Sturkenboom MCJM, et al
    Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future.
    Vaccine. 2023 May 15:S0264-410X(23)00468-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  964. LIMAYE RJ, Singh P, Paul A, Fesshaye B, et al
    COVID-19 vaccine decision-making among pregnant and lactating women in Bangladesh.
    Vaccine. 2023 May 15:S0264-410X(23)00551-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  965. SURIE D, Bonnell LN, DeCuir J, Gaglani M, et al
    Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022.
    Vaccine. 2023 May 15:S0264-410X(23)00567-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  966. GEORGE TK, Nair NP, Singh AK, Dilesh Kumar A, et al
    Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach.
    Vaccine. 2023 May 12:S0264-410X(23)00486-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  967. KEHAGIA E, Papakyriakopoulou P, Valsami G
    Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.
    Vaccine. 2023 May 11:S0264-410X(23)00529-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  968. ROBERTS-MCCARTHY E, Buck PO, Smith-Ray RL, Van de Velde N, et al
    Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic.
    Vaccine. 2023 May 11:S0264-410X(23)00383-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  969. LANGLETE P, Tesli M, Veneti L, Starrfelt J, et al
    Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022.
    Vaccine. 2023 May 10:S0264-410X(23)00549-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  970. SMITH K, Hegazy K, Cai MR, McKnight I, et al
    Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
    Vaccine. 2023 May 10:S0264-410X(23)00543-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  971. VAN IERSEL SCJL, McDonald SA, de Gier B, Knol MJ, et al
    Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022.
    Vaccine. 2023 May 10:S0264-410X(23)00545-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  972. RUBIN THOMPSON LJ, Grubo M, Veller M, Badenhorst RH, et al
    Building global vaccine manufacturing capacity: Spotlight on Africa.
    Vaccine. 2023 May 10:S0264-410X(23)00527-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  973. CHIAVENNA C, Leone LP, Melegaro A, Rotesi T, et al
    Personal risk or societal benefit? Investigating adults' support for COVID-19 childhood vaccination.
    Vaccine. 2023 May 9:S0264-410X(23)00544-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  974. KURIYAMA K, Murakami K, Masuda T, Sugiura K, et al
    Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
    Vaccine. 2023 May 8:S0264-410X(23)00519-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  975. SUTTON WJH, Branham PJ, Williamson YM, Cooper HC, et al
    Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using isotope dilution mass spectrometry.
    Vaccine. 2023 May 8:S0264-410X(23)00458-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  976. BORDALO FERREIRA F, Rafael MA, Coimbra L, Boavida N, et al
    Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
    Vaccine. 2023 May 8:S0264-410X(23)00530-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  977. FITZ-PATRICK D, Young M, Yacisin K, McElwee K, et al
    Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults >/=65 years old.
    Vaccine. 2023 May 8:S0264-410X(23)00520-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  978. KPOZEHOUEN EB, Heywood AE, Menzies R, Seale H, et al
    Informing the design of a whole of life immunisation register for Australia.
    Vaccine. 2023;41:3011-3018.
    PubMed     Abstract available


  979. RODRIGUEZ DM, Major CG, Sanchez-Gonzalez L, Jones E, et al
    Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico.
    Vaccine. 2023 May 5:S0264-410X(23)00516-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  980. KU JH, Sy LS, Qian L, Ackerson BK, et al
    Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study.
    Vaccine. 2023 May 3:S0264-410X(23)00498-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  981. FUKUNAGA R, Kaplan ZE, Rodriguez T, Hagan L, et al
    Attitudes towards COVID-19 vaccination among incarcerated persons in the Federal Bureau of Prisons, June-July 2021.
    Vaccine. 2023 May 2:S0264-410X(23)00512-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  982. LEFFERTS B, Bruden D, Plumb ID, Hodges E, et al
    Effectiveness of the COVID-19 vaccines on preventing symptomatic SARS-CoV-2 infections and hospitalizations in Southwestern Alaska, January-December 2021.
    Vaccine. 2023 May 1:S0264-410X(23)00496-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  983. MESINA FZ, Sapinoso FAD, De Castro JAV, Vaswani PPM, et al
    Hematologic adverse events reported after COVID-19 vaccination in the Philippines: A national database study.
    Vaccine. 2023 May 1:S0264-410X(23)00490-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  984. HUSSAINI L, Labberton AS, Winje BA, Kraft KB, et al
    COVID-19 vaccination rates among adolescents (12-17 years) by immigrant background and sociodemographic factors: A nationwide registry study in Norway.
    Vaccine. 2023 May 1:S0264-410X(23)00514-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  985. KUHLBRANDT C, McGowan CR, Stuart R, Grenfell P, et al
    COVID-19 vaccination decisions among Gypsy, Roma, and Traveller communities: A qualitative study moving beyond "vaccine hesitancy".
    Vaccine. 2023 May 1:S0264-410X(23)00515-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    April 2023
  986. MARCHESE AM, Zhou X, Kinol J, Underwood E, et al
    NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.
    Vaccine. 2023 Apr 29:S0264-410X(23)00467-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  987. VANNI T, da Graca Salomao M, Viscondi JYK, Braga PE, et al
    A randomized, double-blind, non-inferiority trial comparing the immunogenicity and safety of two seasonal inactivated influenza vaccines in adults.
    Vaccine. 2023 Apr 28:S0264-410X(23)00464-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  988. KOEN AL, Izu A, Baillie V, Kwatra G, et al
    Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
    Vaccine. 2023 Apr 27:S0264-410X(23)00483-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  989. KIM C, Aminawung JA, Brinkley-Rubinstein L, Wang EA, et al
    COVID-19 vaccine deliberation in individuals directly impacted by incarceration.
    Vaccine. 2023 Apr 26:S0264-410X(23)00492-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  990. ALSUHEBANY N, Alowais SA, Aldairem A, Almohareb SN, et al
    Identifying gaps in vaccination perception after mandating the COVID-19 vaccine in Saudi Arabia.
    Vaccine. 2023 Apr 26:S0264-410X(23)00481-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  991. LU X, Masuda S, Horlad H, Katoh T, et al
    Safety and adverse effects of the coronavirus disease 2019 vaccine among the general Japanese adult population.
    Vaccine. 2023 Apr 26:S0264-410X(23)00469-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  992. KIM SJ, Kwon SL, Lee JY, Oh J, et al
    Why school is crucial to increase vaccination coverage for children: Evaluation of school vaccination check program in South Korea 2021-2022.
    Vaccine. 2023 Apr 25:S0264-410X(23)00430-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  993. JIANG M, Vaisanen E, Kolehmainen P, Huttunen M, et al
    COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.
    Vaccine. 2023 Apr 25:S0264-410X(23)00463-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  994. WALTER D, Ophir Y, Ye H
    Conspiracies, misinformation and resistance to public health measures during COVID-19 in white nationalist online communication.
    Vaccine. 2023;41:2868-2877.
    PubMed     Abstract available


  995. TAMANDJOU C, Auvigne V, Schaeffer J, Vaux S, et al
    Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France.
    Vaccine. 2023;41:2754-2760.
    PubMed     Abstract available


  996. MA L, Brecher M, Soufal A, Gaiotto T, et al
    Structural interrogation of a trimeric prefusion RSV fusion protein vaccine candidate by a camelid nanobody.
    Vaccine. 2023 Apr 19:S0264-410X(23)00413-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  997. BAO Y, He L, Miao B, Zhong Z, et al
    BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.
    Vaccine. 2023 Apr 19:S0264-410X(23)00377-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  998. PILLSBURY A, Phillips A, Deng L, Quinn H, et al
    Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
    Vaccine. 2023 Apr 18:S0264-410X(23)00441-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  999. MAO Z, Li X, Dacosta-Urbieta A, Billard MN, et al
    Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe.
    Vaccine. 2023;41:2707-2715.
    PubMed     Abstract available


  1000. HOUTSMA C, Raines AM, Reggio A, Rushing LK, et al
    COVID-19 vaccine distribution: A high reliability organization approach.
    Vaccine. 2023 Apr 17:S0264-410X(23)00423-1. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1001. GORDON SF, Lam J, Vasquez JT, Cercone R, et al
    A tailored COVID-19 vaccination pathway for children 5-11 years in Victoria, Australia.
    Vaccine. 2023 Apr 17:S0264-410X(23)00424-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1002. LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Biela M, et al
    COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS).
    Vaccine. 2023 Apr 14:S0264-410X(23)00427-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1003. FREITAG TL, Fagerlund R, Karam NL, Leppanen VM, et al
    Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Vaccine. 2023 Apr 14:S0264-410X(23)00403-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1004. ANDRAUD M, Herve S, Gorin S, Barbier N, et al
    Evaluation of early single dose vaccination on swine influenza A virus transmission in piglets: From experimental data to mechanistic modelling.
    Vaccine. 2023 Apr 13:S0264-410X(23)00401-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1005. ESTEPHAN L, Lin YC, Lin YT, Chen YH, et al
    Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
    Vaccine. 2023 Apr 12:S0264-410X(23)00421-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1006. UEMURA K, Ono S, Michihata N, Yamana H, et al
    Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data.
    Vaccine. 2023 Apr 10:S0264-410X(23)00373-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1007. RATHORE APS, St John AL
    Promises and challenges of mucosal COVID-19 vaccines.
    Vaccine. 2023 Apr 10:S0264-410X(23)00396-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1008. HARRIS C, Cottrell S, Perry M, Meaden R, et al
    A pilot intervention to improve uptake and equality of childhood influenza vaccination in an area of Wales, through the introduction of a mixed delivery model including nursery school immunisation sessions.
    Vaccine. 2023 Apr 8:S0264-410X(23)00382-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1009. LEIGH HOBBS J, Paul LA, Buchan SA, Harris T, et al
    Methodological changes implemented over time to support accurate and timely COVID-19 vaccine coverage estimates: Ontario, Canada.
    Vaccine. 2023 Apr 7:S0264-410X(23)00389-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1010. HARRIS JN, Mauro CM, Morgan TL, de Roche A, et al
    Factors impacting parental uptake of COVID-19 vaccination for U.S. Children ages 5-17.
    Vaccine. 2023 Apr 7:S0264-410X(23)00384-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1011. ALMAHASIS SO, Fox B, Ha D, Qian J, et al
    Pharmacy-based immunization in rural USA during the COVID-19 pandemic: A survey of community pharmacists from five southeastern states.
    Vaccine. 2023;41:2503-2513.
    PubMed     Abstract available


  1012. SMITS PD, Gratzl S, Simonov M, Nachimuthu SK, et al
    Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities.
    Vaccine. 2023;41:2447-2455.
    PubMed     Abstract available


  1013. GOLD MS, Amarasinghe A, Greenhawt M, Kelso JM, et al
    Anaphylaxis: Revision of the Brighton collaboration case definition.
    Vaccine. 2023;41:2605-2614.
    PubMed     Abstract available


  1014. BURKHOLDER B, Wadood Z, Kassem AM, Ehrhardt D, et al
    The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.
    Vaccine. 2023;41 Suppl 1:A2-A11.
    PubMed     Abstract available


  1015. KALKOWSKA DA, Pallansch MA, Wassilak SGF, Cochi SL, et al
    Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Vaccine. 2023;41 Suppl 1:A136-A141.
    PubMed     Abstract available


  1016. KALKOWSKA DA, Voorman A, Pallansch MA, Wassilak SGF, et al
    The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
    Vaccine. 2023;41 Suppl 1:A12-A18.
    PubMed     Abstract available


  1017. PAYNE JR, Bose S, Kubiak RW, Nolen LD, et al
    Evaluation of mortality risk after COVID-19 vaccination, Utah 2021.
    Vaccine. 2023 Apr 5:S0264-410X(23)00380-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1018. BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
    Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022.
    Vaccine. 2023 Apr 5:S0264-410X(23)00376-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1019. KIM H, Cho HK, Kang YM, Sagong M, et al
    Protective efficacy of a bivalent H5 influenza vaccine candidate against both clades 2.3.2.1 and 2.3.4.4 high pathogenic avian influenza viruses in SPF chickens.
    Vaccine. 2023 Apr 4:S0264-410X(23)00311-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1020. PRADA E, Langbecker A, Catalan-Matamoros D
    Public discourse and debate about vaccines in the midst of the covid-19 pandemic: A qualitative content analysis of Twitter.
    Vaccine. 2023 Apr 4:S0264-410X(23)00375-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1021. FRODLUND M, Nived P, Chatzidionysiou A, Sodergren A, et al
    The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
    Vaccine. 2023 Apr 4:S0264-410X(23)00372-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1022. TOSHKOV D
    What accounts for the variation in COVID-19 vaccine hesitancy in Eastern, Southern and Western Europe?
    Vaccine. 2023 Apr 4:S0264-410X(23)00314-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1023. ALI Y, Piche-Renaud PP, Karimi-Shahrbabak E, Farrar DS, et al
    Pediatricians' perceptions, practices, and barriers regarding COVID-19 vaccine for children: A cross-sectional survey in Ontario, Canada.
    Vaccine. 2023 Apr 3:S0264-410X(23)00335-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1024. URQUIDI C, Santelices E, Lagomarcino AJ, Teresa Valenzuela M, et al
    The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study.
    Vaccine. 2023 Apr 3:S0264-410X(23)00354-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1025. MAQUILING A, Jeevakanthan A, Ho Mi Fane B
    The effect of vaccine mandate announcements on vaccine uptake in Canada: An interrupted time series analysis.
    Vaccine. 2023 Apr 3:S0264-410X(23)00334-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1026. CRIADO MF, Kassa A, Bertran K, Kwon JH, et al
    Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses.
    Vaccine. 2023 Apr 1:S0264-410X(23)00349-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1027. LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
    Lack of association between vaccination rates and excess mortality in Cyprus during the COVID-19 pandemic.
    Vaccine. 2023 Apr 1:S0264-410X(23)00316-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    March 2023
  1028. XU S, Zhang B, Yao J, Ruan W, et al
    A new H9 influenza virus mRNA vaccine elicits robust protective immunity against infection.
    Vaccine. 2023 Mar 31:S0264-410X(23)00343-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1029. DATAR RS, Fette LM, Hinkelman AN, Hammershaimb EA, et al
    Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective study.
    Vaccine. 2023 Mar 31:S0264-410X(23)00352-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1030. HU Y, Wang Y, Shao T, Tang W, et al
    Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
    Vaccine. 2023 Mar 30:S0264-410X(23)00350-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1031. FUKUDA H, Maeda M, Murata F
    Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study.
    Vaccine. 2023 Mar 29:S0264-410X(23)00353-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1032. SU WJ, Arnold Chan K, Chuang JH, Wang TA, et al
    Acute reactions after a homologous primary COVID-19 vaccination series: Analysis of Taiwan V-Watch data.
    Vaccine. 2023 Mar 28:S0264-410X(23)00336-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1033. SANTI LAURINI G, Montanaro N, Broccoli M, Bonaldo G, et al
    Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
    Vaccine. 2023 Mar 28:S0264-410X(23)00348-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1034. GIDENGIL CA, Parker AM, Markowitz LE, Gedlinske AM, et al
    Health care provider knowledge around shared clinical decision-making regarding HPV vaccination of adults aged 27-45 years in the United States.
    Vaccine. 2023 Mar 27:S0264-410X(23)00186-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1035. HU B, Yang W, Bouanchaud P, Chongo Y, et al
    Determinants of COVID-19 vaccine acceptance in Mozambique: The role of institutional trust.
    Vaccine. 2023 Mar 27:S0264-410X(23)00347-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1036. KANG SW, Park H, Yeun Kim J, Bae JY, et al
    Comparison of culture-competent virus shedding duration of SARS-CoV-2 Omicron variant in regard to vaccination status: A prospective cohort study.
    Vaccine. 2023 Mar 27:S0264-410X(23)00339-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1037. CESUR F, Atasever Z, Ozoran Y
    Impact of vitamin D3 supplementation on COVID-19 vaccine response and immunoglobulin G antibodies in deficient women: A randomized controlled trial.
    Vaccine. 2023 Mar 27:S0264-410X(23)00341-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1038. DUGOVICH AM, Cox TH, Weeda ER, Garner SS, et al
    First hepatitis B vaccine uptake in neonates prior to and during the COVID-19 pandemic.
    Vaccine. 2023 Mar 27:S0264-410X(23)00333-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1039. PANNUS P, Depickere S, Kemlin D, Georges D, et al
    Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naive nursing home residents and healthy adults.
    Vaccine. 2023 Mar 27:S0264-410X(23)00340-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1040. CIAPPONI A, Berrueta M, P K Parker E, Bardach A, et al
    Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.
    Vaccine. 2023 Mar 27:S0264-410X(23)00332-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1041. VAN KESSEL R, Forman R, Milstein R, Mastylak A, et al
    Divergent COVID-19 vaccine policies: Policy mapping of ten European countries.
    Vaccine. 2023 Mar 22:S0264-410X(23)00320-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1042. YANG J, Huo X, Jiang Q, Liao Y, et al
    Preclinical safety evaluation of intradermal SARS-CoV-2 inactivated vaccine (Vero cells) administration in macaques.
    Vaccine. 2023 Mar 21:S0264-410X(23)00317-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1043. PHOOLCHAROEN W, Shanmugaraj B, Khorattanakulchai N, Sunyakumthorn P, et al
    Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
    Vaccine. 2023 Mar 21:S0264-410X(23)00312-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1044. SATO R
    Vaccine hesitancy against COVID-19 vaccine over time in Nigeria.
    Vaccine. 2023 Mar 21:S0264-410X(23)00313-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1045. ATMAR RL, Bernstein DI, Winokur P, Frey SE, et al
    Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial.
    Vaccine. 2023 Mar 18:S0264-410X(23)00285-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1046. SHEN AK, Browne S, Srivastava T, Kornides ML, et al
    Trusted messengers and trusted messages: The role for community-based organizations in promoting COVID-19 and routine immunizations.
    Vaccine. 2023;41:1994-2002.
    PubMed     Abstract available


  1047. PEREZ MA, Hsiao HM, Chen X, Kunkel A, et al
    Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C).
    Vaccine. 2023 Mar 15:S0264-410X(23)00283-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1048. LIN JH, Huang YT, Yu JC, Chan KA, et al
    Mediation and instrumental variable analyses for vaccine-induced antibody titer against influenza B.
    Vaccine. 2023 Mar 14:S0264-410X(23)00261-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1049. LAMUDA PA, Azar A, Taylor BG, Balawajder EF, et al
    Latent class analysis of medical mistrust and COVID-19 vaccine hesitancy among adults in the United States just prior to FDA emergency use authorization.
    Vaccine. 2023 Mar 13:S0264-410X(23)00263-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1050. KELLY D, O'Donnell K, Marron L, Dwyer R, et al
    Immunocompromise among vaccinated versus unvaccinated COVID-19 cases admitted to critical care in Ireland, July to October 2021.
    Vaccine. 2023 Mar 13:S0264-410X(23)00258-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1051. KWAK HW, Park HJ, Jung SY, Oh EY, et al
    Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants.
    Vaccine. 2023;41:1892-1901.
    PubMed     Abstract available


  1052. LIU YC, Munoz FM, Izurieta HS, Tamborska AA, et al
    Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2023;41:1902-1910.
    PubMed     Abstract available


  1053. SRIVASTAV A, Lu PJ, Amaya A, Dever JA, et al
    Prevalence of influenza-specific vaccination hesitancy among adults in the United States, 2018.
    Vaccine. 2023 Mar 10:S0264-410X(23)00255-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1054. SANCHEZ L, Nakama T, Nagai H, Matsuoka O, et al
    Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults >/= 60 years of age: Results from a phase III, randomized clinical trial.
    Vaccine. 2023 Mar 9:S0264-410X(23)00225-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1055. PLUMB ID, Fette LM, Tjaden AH, Feldstein L, et al
    Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
    Vaccine. 2023 Mar 9:S0264-410X(23)00253-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1056. IKEWAKI N, Kurosawa G, Levy GA, Preethy S, et al
    Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management.
    Vaccine. 2023 Mar 8:S0264-410X(23)00252-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1057. HART RJ, Baumer-Mouradian S, Bone JN, Olson P, et al
    Factors associated with US caregivers' uptake of pediatric COVID-19 vaccine by race and ethnicity.
    Vaccine. 2023 Mar 6:S0264-410X(23)00242-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1058. BAEK YJ, Kim WJ, Ko JH, Lee YJ, et al
    A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
    Vaccine. 2023;41:1694-1702.
    PubMed     Abstract available


  1059. GRIGNOLIO CORSINI A, Zagarella RM, Adamo M, Caporale C, et al
    From COVID-19 vaccine candidates to compulsory vaccination: The attitudes of Italian citizens in the key 7-month of vaccination campaign.
    Vaccine. 2023 Mar 3:S0264-410X(23)00243-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1060. ESTEPHAN L, Liu LT, Lien CE, Smith ER, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
    Vaccine. 2023 Mar 3:S0264-410X(23)00245-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1061. XIE S, Monteiro K, Gjelsvik A
    The association between maternal influenza vaccination during pregnancy and adverse birth outcomes in the United States: Pregnancy risk Assessment Monitoring System (PRAMS).
    Vaccine. 2023 Mar 2:S0264-410X(23)00228-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1062. LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Olbromski MJ, et al
    COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study.
    Vaccine. 2023 Mar 2:S0264-410X(23)00227-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1063. HURSTAK EE, Paasche-Orlow MK, Hahn EA, Henault LE, et al
    The mediating effect of health literacy on COVID-19 vaccine confidence among a diverse sample of urban adults in Boston and Chicago.
    Vaccine. 2023 Mar 2:S0264-410X(23)00202-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1064. GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
    Willingness to vaccinate children against COVID-19 declined during the pandemic.
    Vaccine. 2023 Mar 2:S0264-410X(23)00223-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1065. NA L, Banks S, Wang PP
    Racial and ethnic disparities in COVID-19 vaccine uptake: A mediation framework.
    Vaccine. 2023 Mar 1:S0264-410X(23)00241-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    February 2023
  1066. MALTEZOU HC, Hatziantoniou S, Theodoridou K, Vasileiou K, et al
    Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.
    Vaccine. 2023 Feb 27:S0264-410X(23)00221-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1067. TAMANDJOU TCHUEM CR, Auvigne V, Vaux S, Montagnat C, et al
    Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Vaccine. 2023 Feb 27:S0264-410X(23)00216-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1068. O'KENNEDY MM, Abolnik C, Smith T, Motlou T, et al
    Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
    Vaccine. 2023 Feb 27:S0264-410X(23)00185-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1069. ITAMOCHI M, Yazawa S, Inasaki N, Saga Y, et al
    Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Vaccine. 2023 Feb 27:S0264-410X(23)00222-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1070. GETANEH AM, Li X, Mao Z, Johannesen CK, et al
    Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
    Vaccine. 2023;41:1623-1631.
    PubMed     Abstract available


  1071. FEITSMA EA, Janssen YF, Boersma HH, van Sleen Y, et al
    A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
    Vaccine. 2023 Feb 23:S0264-410X(23)00200-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1072. KABIR SULAIMAN S, Sale Musa M, Isma'il Tsiga-Ahmed F, Muhammad Dayyab F, et al
    COVID-19 vaccine hesitancy among people living with HIV in a low-resource setting: A multi-center study of prevalence, correlates and reasons.
    Vaccine. 2023 Feb 23:S0264-410X(23)00199-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1073. CANNON K, Cardona JF, Yacisin K, Thompson A, et al
    Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
    Vaccine. 2023 Feb 22:S0264-410X(22)01459-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1074. MOORE KA, Leighton T, Ostrowsky JT, Anderson CJ, et al
    A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy.
    Vaccine. 2023 Feb 21:S0264-410X(23)00167-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1075. ZHANG H, Chen L, Huang Z, Li D, et al
    The effects of parent's health literacy and health beliefs on vaccine hesitancy.
    Vaccine. 2023 Feb 21:S0264-410X(23)00161-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1076. HAMBURG M, Poland GA
    The time is now for committed and comprehensive action to attain more broadly protective coronavirus vaccines: The coronavirus vaccines R&D roadmap.
    Vaccine. 2023 Feb 21:S0264-410X(23)00196-2. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1077. MOTTA M, Callaghan T, Lunz-Trujillo K, Lockman A, et al
    Erroneous Consonance. How inaccurate beliefs about physician opinion influence COVID-19 vaccine hesitancy.
    Vaccine. 2023 Feb 20:S0264-410X(23)00195-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1078. GEOGHEGAN S, Acosta F, Stephens LC, Gillan H, et al
    Maternity care provider acceptance of a future Group B Streptococcus vaccine - A qualitative study in three countries.
    Vaccine. 2023 Feb 18:S0264-410X(23)00172-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1079. FORD A, Hwang A, Mo AX, Baqar S, et al
    Meeting Summary: Global Vaccine and Immunization Research Forum, 2021.
    Vaccine. 2023 Feb 18:S0264-410X(23)00163-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1080. DUDLEY MZ, Gerber JE, Budigan Ni H, Blunt M, et al
    Vaccinomics: A scoping review.
    Vaccine. 2023 Feb 18:S0264-410X(23)00135-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1081. RANADE D, Jena R, Patil K, Dogar V, et al
    A novel high throughput plate-based method for 2-PE quantification in novel multidose vaccines (R21 malaria, Covishield and Covovax) and combination vaccines (Hexavalent).
    Vaccine. 2023 Feb 17:S0264-410X(23)00174-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1082. PARODI A, Martini M
    History of vaccine and immunization: Vaccine-hesitancy discussion in Germany in XIX century.
    Vaccine. 2023 Feb 17:S0264-410X(23)00164-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1083. MEYER C, Goffe L, Antonopoulou V, Graham F, et al
    Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England.
    Vaccine. 2023 Feb 17:S0264-410X(23)00182-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1084. MORAIS A, Morais J, Felix M, Neto Z, et al
    Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020.
    Vaccine. 2023 Feb 17:S0264-410X(23)00170-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1085. ZIMMERMANN BM, Paul KT, Araujo ER, Buyx A, et al
    The social and socio-political embeddedness of COVID-19 vaccination decision-making: A five-country qualitative interview study from Europe.
    Vaccine. 2023 Feb 16:S0264-410X(23)00139-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1086. CAMPMAN SL, van Rossem G, Boyd A, Coyer L, et al
    Intent to vaccinate against SARS-CoV-2 and its determinants across six ethnic groups living in Amsterdam, the Netherlands: A cross-sectional analysis of the HELIUS study.
    Vaccine. 2023 Feb 13:S0264-410X(23)00165-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1087. BARNES K, Faasse K, Colagiuri B
    The impact of side effect framing on COVID-19 booster vaccine intentions in an Australian sample.
    Vaccine. 2023 Feb 13:S0264-410X(23)00158-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1088. SAELEE R, Chandra Murthy N, Patel Murthy B, Zell E, et al
    Minority Health Social Vulnerability Index and COVID-19 vaccination coverage - The United States, December 14, 2020-January 31, 2022.
    Vaccine. 2023 Feb 13:S0264-410X(23)00157-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1089. WANKHEDE D, Grover S, Hofman P
    Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis.
    Vaccine. 2023 Feb 13:S0264-410X(23)00115-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1090. AFREH OK, Angwaawie P, Attivor E, Boateng LA, et al
    Examining confidence and hesitancy towards COVID-19 vaccines: A cross-sectional survey using in-person data collection in rural Ghana.
    Vaccine. 2023 Feb 13:S0264-410X(23)00159-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1091. DE VRIES M, Claassen L, Lambooij MS, Timen A, et al
    Did the temporary suspension of Vaxzveria vaccinations influence COVID-19 vaccination intentions, vaccination perceptions and trust in the vaccination campaign? A repeated survey study in the Netherlands.
    Vaccine. 2023 Feb 10:S0264-410X(23)00138-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1092. HOSAIN R, Aquino P, Baccarini C, Smolenov I, et al
    Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.
    Vaccine. 2023 Feb 10:S0264-410X(23)00144-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1093. SHEN AK, Browne S, Srivastava T, Kornides ML, et al
    Persuading the "Movable Middle": Characteristics of effective messages to promote routine and COVID-19 vaccinations for adults and children - The impact of COVID-19 on beliefs and attitudes.
    Vaccine. 2023 Feb 9:S0264-410X(23)00141-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1094. SILVA VASCONCELOS G, da Conceicao Rodrigues Fernandes M, Cardoso Matsui T, Claudia Dos Santos Luciano M, et al
    Persistent SARS-COV-2 infection in vaccinated individual with three doses of COVID-19 vaccine.
    Vaccine. 2023 Feb 9:S0264-410X(23)00145-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1095. BUNTINX E, Brochado L, Borja-Tabora C, Yu CY, et al
    Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naive and exposed individuals in a phase 2/3, double-blind, randomized study.
    Vaccine. 2023 Feb 9:S0264-410X(23)00143-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1096. FEIKIN DR, Higdon MM, Andrews N, Collie S, et al
    Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
    Vaccine. 2023 Feb 9:S0264-410X(23)00146-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1097. BUGHIN J, Cincera M, Peters K, Reykowska D, et al
    Make it or break it: On-time vaccination intent at the time of Covid-19.
    Vaccine. 2023 Feb 8:S0264-410X(23)00140-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1098. WATANABE A, Iwagami M, Yasuhara J, Takagi H, et al
    Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis.
    Vaccine. 2023 Feb 8:S0264-410X(23)00134-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1099. FELL DB, Torok E, Sprague AE, Regan AK, et al
    Temporal trends and determinants of COVID-19 vaccine coverage and series initiation during pregnancy in Ontario, Canada, December 2020 to December 2021: A population-based retrospective cohort study.
    Vaccine. 2023 Feb 3:S0264-410X(23)00114-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1100. HASSAN RAZA S, Yousaf M, Zaman U, Waheed Khan S, et al
    Unlocking infodemics and mysteries in COVID-19 vaccine hesitancy: Nexus of conspiracy beliefs, digital informational support, psychological Well-being, and religious fatalism.
    Vaccine. 2023 Feb 3:S0264-410X(23)00079-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1101. LI R, Liu H, Fairley CK, Ong JJ, et al
    mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.
    Vaccine. 2023 Feb 3:S0264-410X(23)00126-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1102. MALTEZOU HC, Basoulis D, Bonelis K, Gamaletsou MN, et al
    Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece.
    Vaccine. 2023 Feb 2:S0264-410X(23)00109-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1103. HAMADA H, Futamura M, Ito H, Yamamoto R, et al
    Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study.
    Vaccine. 2023 Feb 1:S0264-410X(23)00082-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1104. JOHNSON R, Djaafara B, Haw D, Doohan P, et al
    The societal value of SARS-CoV-2 booster vaccination in Indonesia.
    Vaccine. 2023 Feb 1:S0264-410X(23)00110-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1105. ANDREJKO KL, Myers JF, Fukui N, Nelson L, et al
    Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: A registry-linkage study.
    Vaccine. 2023 Feb 1:S0264-410X(23)00108-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    January 2023
  1106. UWAMINO Y, Yokoyama T, Sato Y, Shibata A, et al
    Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine.
    Vaccine. 2023 Jan 31:S0264-410X(23)00081-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1107. GRESSENS SB, Wiedemann A, Dechenaud M, Dupuis J, et al
    Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies.
    Vaccine. 2023 Jan 30:S0264-410X(23)00095-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1108. HARBIN A, Laventhal N, Navin M
    Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19.
    Vaccine. 2023 Jan 27:S0264-410X(23)00087-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1109. GROSSMAN-GIRON A, Tzur Bitan D, Shemesh S, Mayer Y, et al
    COVID-19 vaccine hesitancy scale and its association with actual COVID-19 vaccine uptake in Israel.
    Vaccine. 2023 Jan 23:S0264-410X(23)00065-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1110. MALLAH SI, Alawadhi A, Jawad J, Wasif P, et al
    Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Vaccine. 2023 Jan 23:S0264-410X(23)00053-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1111. STRATHDEE SA, Abramovitz D, Vera CF, Artamonova I, et al
    Predictors of COVID-19 vaccine uptake among people who inject drugs.
    Vaccine. 2023 Jan 23:S0264-410X(23)00063-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1112. KALRA S, Kalra D, Grafova I, Rubin JS, et al
    Association of death or illness from COVID-19 among family and friends on vaccine uptake within four months of the Emergency Use Authorization. Findings from a national survey in the United States.
    Vaccine. 2023 Jan 13:S0264-410X(23)00035-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1113. TSUCHIYA Y, Tamura H, Fujii K, Numaguchi H, et al
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan.
    Vaccine. 2023 Jan 5:S0264-410X(23)00006-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1114. FORD JS, Rouleau SG, Wagner JL, Adams CB, et al
    Assessment of a COVID-19 vaccination protocol for unhoused patients in the emergency department.
    Vaccine. 2023 Jan 2:S0264-410X(22)01598-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


    December 2022
  1115. SONOYAMA T, Iwata S, Shinkai M, Iwata-Yoshikawa N, et al
    Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
    Vaccine. 2022 Dec 16:S0264-410X(22)01540-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1116. OLAYINKA F, Sauer M, Menning L, Summers D, et al
    Building and sustaining public and political commitment to the value of vaccination: Recommendations for the Immunization Agenda 2030 (Strategic Priority Area 2).
    Vaccine. 2022 Dec 15:S0264-410X(22)01451-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1117. SALVATORE PP, Lee CC, Sleweon S, McCormick DW, et al
    Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021.
    Vaccine. 2022 Dec 13:S0264-410X(22)01458-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1118. HALL PA, Meng G, Boudreau C, Hudson A, et al
    Social cognitive predictors of vaccination status, uptake and mitigation behaviors in the Canadian COVID-19 Experiences survey.
    Vaccine. 2022 Dec 12:S0264-410X(22)01526-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1119. WALLACE AS, Ryman TK, Privor-Dumm L, Morgan C, et al
    Leaving no one behind: Defining and implementing an integrated life course approach to vaccination across the next decade as part of the immunization Agenda 2030.
    Vaccine. 2022 Dec 8:S0264-410X(22)01452-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


    November 2022
  1120. MCCORMICK DW, Hagan LM, Salvatore PP, Magleby R, et al
    SARS-CoV-2 viral shedding in vaccinated and unvaccinated persons: A case series.
    Vaccine. 2022 Nov 18:S0264-410X(22)01428-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


    October 2022
  1121. HALL PA, Meng G, Sakib MN, Quah ACK, et al
    Do the vaccinated perform less distancing, mask wearing and hand hygiene? A test of the risk compensation hypothesis in a representative sample during the COVID-19 pandemic.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01289.
    PubMed     Abstract available


  1122. HUDSON A, Hall PA, Hitchman SC, Meng G, et al
    Cognitive predictors of COVID-19 mitigation behaviors in vaccinated and unvaccinated general population members.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01242.
    PubMed     Abstract available


    March 2022
  1123. SNIDER CJ, Boualam L, Tallis G, Takashima Y, et al
    Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021.
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00145.
    PubMed     Abstract available


    October 2021
  1124. BOZORGI A, Fahimnia B
    Micro array patch (MAP) for the delivery of thermostable vaccines in Australia: A cost/benefit analysis.
    Vaccine. 2021;39:6166-6173.
    PubMed     Abstract available


  1125. BOZORGI A, Fahimnia B
    Transforming the vaccine supply chain in Australia: Opportunities and challenges.
    Vaccine. 2021;39:6157-6165.
    PubMed     Abstract available


    September 2021
  1126. MOLODECKY NA, Jafari H, Safdar RM, Ahmed JA, et al
    Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01228.
    PubMed     Abstract available


  1127. LIU D, Leung K, Jit M, Wu JT, et al
    Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities.
    Vaccine. 2021;39:5490-5498.
    PubMed     Abstract available


  1128. KOHL-HECKL WK, Schroter M, Dobos G, Cramer H, et al
    Complementary medicine use and flu vaccination - A nationally representative survey of US adults.
    Vaccine. 2021;39:5635-5640.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.